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ABSTRACT	OF	THE	DISSERTATION		Development	and	Application	of	a	Computational	Force	Field	for	the	Study	of	Structure,	Function	and	Motion	of	Enzymes	in	the	Acetate	and	Non-ribosomal	Peptide	Pathways			By		Andrew	Joseph	Schaub		Doctor	of	Philosophy	in	Chemistry				University	of	California,	Irvine,	2018		Professor	Shiou-Chuan	Tsai,	Chair				Enzymes	 in	 the	 acetate	 and	 non-ribosomal	 peptide	 pathways	 generate	 chemically	diverse	and	complex	bioactive	molecules,	with	the	intermediates	being	chauffeured	between	catalytic	partners	via	 a	 carrier	protein.	Recent	efforts	have	been	made	 to	engineer	 these	systems	 to	 expand	 their	 product	 diversity.	 A	 major	 stumbling	 block	 is	 our	 poor	understanding	of	the	transient	protein-protein	and	protein-substrate	interactions	between	the	carrier	protein	and	its	many	catalytic	partner	domains.	The	innate	reactivity	of	pathway	intermediates	has	obfuscated	our	mechanistic	understanding	of	 these	 interactions	during	the	 biosynthesis	 of	 these	 natural	 products,	 ultimately	 impeding	 the	 engineering	 of	 these	systems	for	the	generation	of	“unnatural”	natural	products.	Molecular	dynamics	can	be	used	to	provide	models	of	these	key	interactions	that	are	difficult	to	capture	experimentally,	providing	the	potential	to	expand	the	diversity	in	these	systems.	Current	force	fields	support	basic	biochemical	building	blocks,	and	specialized	force	fields	 support	 post-translational	 modifications	 and	 non-canonical	 amino	 acids,	 yet	 none	currently	exist	that	are	capable	of	modeling	bound	intermediates	from	these	systems.	
xii		
The	objective	of	this	dissertation	is	to	address	this	gap	in	knowledge	and	available	technology	and	to	present	the	description	of	the	development	of	a	force	field	that	can	be	used	with	MD	 and	 other	 computational	 techniques	 to	 provide	models	 of	 these	 experimentally	intractable	transient	interactions.	This	objective	will	be	divided	into	three	aims.	Aim	1:	The	development	and	validation	of	a	force	field	for	use	in	investigations	and	engineering	 efforts	 involving	 these	 pathways.	 A	 fragmentation	 approach	 was	 used,	providing	a	degree	of	modularity	to	the	force	field	while	at	the	same	time	reducing	the	size,	complexity	and	degrees	of	 freedom	during	the	 charge	 fitting	and	parameterization	steps.		Tutorials	and	a	web	interface	were	also	developed	to	provide	end	users	access	to	this	tool.	Aim	 2:	 The	 application	 of	 the	 force	 field	 towards	 understanding	 dynamics	 and	interactions	in	these	pathways.	Regulation	of	the	transient	protein-protein	interactions	and	discrete	steps	in	fatty	acid	biosynthesis	remain	poorly	understood.	MD	was	able	to	show	that	specific	interactions	with	its	partner	are	either	strengthened	or	weakened	depending	on	the	loaded	state	 of	 the	 carrier	 protein.	 The	 force	 field	was	 also	 used	 to	model	 a	 plant-based	polyketide	 synthase	 at	 different	 pHs,	 resulting	 in	 the	 identification	 of	 an	 allosterically	modulated	pH	sensor	on	the	surface	of	the	polyketide	synthase.		Aim	3:	The	application	of	 the	 force	 field	 in	engineering	efforts	 in	 these	systems	to	produce	 biofuels.	MD	 simulations	were	 employed	 to	 provide	 a	 deeper	 understanding	 of	protein-substrate	 interactions	 in	 a	 reductase	 domain	 from	 a	 non-ribosomal	 peptide	megasynthase.	 This	 led	 to	 a	 deeper	 understanding	 of	 this	 domain,	 and	 further	 identified	residues	critical	for	structure	integrity	and	substrate	binding,	leading	to	a	rationally	altered	variant	with	improved	activity	toward	highly	reduced	substrates.	
 1	
CHAPTER	1	
	
Introduction	
1.1 Natural	products	For	thousands	of	years,	natural	products	have	captivated	the	curiosity	of	humans,	and	have	 been	 intertwined	 into	 our	 culture,	 with	 early	 applications	 to	 religious	 ceremonies,	mysticism,	and	witchcraft.1	In	addition,	some	have	been	revered	for	their	healing	properties	and	the	source	of	oldest	known	medications,	with	substances	found	naturally	occurring	in	plants,	bacteria	and	fungi.	An	important	distinction	needs	to	be	made	between	biochemistry	and	 natural	 product	 chemistry.	 Traditionally,	 biochemistry	 encompasses	 primary	metabolism,	which	would	include	the	biosynthesis	of	nucleic	acids,	carbohydrates,	proteins,	fats,	and	sugars.	The	primary	metabolism	is	ubiquitous	across	all	species.	 In	comparison,	natural	 product	 chemistry	 encompasses	 secondary	 metabolism,	 in	 which	 the	 natural	products,	 or	 secondary	 metabolites,	 may	 only	 be	 synthesized	 during	 certain	 cellular	processes	 or	 by	 certain	 organisms.	 The	 field	 received	 international	 recognition	 in	 2015,	when	Drs.	Youyou	Tu,	William	Campbell	and	Satoshi	Omura	were	awarded	the	Nobel	Prize	in	Physiology	and	Medicine	for	their	discoveries	of	two	natural	products,	artemisinin	and	avermectin.2	 On	 a	 broader	 scale,	 the	 field	 of	 pharmacognosy	 evaluates	 these	 naturally	occurring	medicinal	drugs	using	evidence-based	science.3	This	field	contains	many	areas	of	research,	including	host	cultivation,	assay	development,	analytical	chemistry,	clinical	studies,	cell	 biology,	 genetics,	 marine	 chemistry,	 ethnobotany,	 heterologous	 gene	 expression,	enzymatic	structural	studies,	and	organic	synthesis,	to	name	a	few.3	The	 primary	 focus	 of	 this	 thesis	 is	 molecular	 dynamic	 (MD)	 simulations	 of	 natural	product-biosynthesizing	enzymes.	In	2013,	the	Nobel	Prize	in	Chemistry	was	awarded	to	Drs.	
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Martin	 Karplus,	 Michael	 Levitt	 and	 Arieh	Warshel,	 for	 their	 contributions	 in	 theoretical	chemistry	that	opens	up	a	brand-new	field	for	the	simulations	of	macromolecules.4	While	there	are	other	computational	biology	techniques	such	as	bioinformatics	and	genomics,	they	are	not	the	focus	of	this	thesis,	and	these	two	topics	are	covered	in	depth	in	other	outstanding	reviews.5-8	 Computational	 structural	 biology	 in	 natural	 product	 research	 includes	 the	development	and	application	of	computational	techniques	to	provide	much-needed	insight	to	engineer	these	enzymes	 in	order	to	generate	new	“unnatural”	natural	products,	which	would	be	invaluable	for	the	identification	of	new	pharmaceuticals	and	industrially-relevant	compounds	 such	as	biofuels.	 Improved	computational	methods	obtained	 from	 this	 thesis	will	make	significant	impacts	by	bridging	a	major	knowledge	gap	in	our	understanding	of	the	protein	dynamics	involved	in	the	biosynthesis	of	these	natural	products.	While	natural	product	compounds	may	initially	look	very	complex,	the	majority	of	them	are	actually	made	up	of	basic	building	blocks,	and	a	cursory	logical	inspection	can	often	be	used	 to	determine	 the	 logical	 assembly	of	 these	 compounds.	The	 focus	of	 this	 thesis	will	primarily	 be	 the	 natural	 products	 constructed	 from	 amino	 acids,	 or	 two-carbon	 units	supplied	by	Coenzyme	A	derivatives.	These	classes	of	natural	products	include	fatty	acids,	polyketides	 and	 non-ribosomal	 peptides,	 and	 have	 been	 utilized	 as	 antibiotics,	immunosuppresants,	 cholesterol-lowering	drugs,	 antitumoral	 agents,	 and	biofuels.9	Other	classes	of	 natural	 products	 include	 terpenoids,	 alkaloids,	 and	 phenylpropanoids,	 and	 are	summarized	 in	 other	 excellent	 reviews.10-14	 Fatty	 acids,	 polyketides	 and	 non-ribosomal	peptides	are	medically	and	industrially	useful	compounds	that	are	assembled	incrementally	through	 the	 addition	 of	 extender	 units	 to	 an	 initial	 starter	 unit	 by	 fatty	 acid	
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Figure	 1-1.	 Examples	 of	 natural	 products	 from	 the	 acetate	 and	 non-ribosomal	 peptide	pathways.	 These	 compounds	 can	 be	 classified	 as	 fatty	 acids,	 polyketides,	 non-ribosomal	peptides,	or	a	hybrid	of	any	of	these	categories.	
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synthases	 (FAS),	 polyketide	 synthases	 (PKS)	 and	 non-ribosomal	 peptide	 synthetases	(NRPS).15-17	These	natural	products	have	great	diversity	in	their	structures	and	bioactivities	(Fig.	 1).18-19	 A	 previous	 review	 by	 Zhang	 and	 Rock	 on	 the	 application	 of	 computational	methods	towards	the	exploration	of	diversity	and	structure	in	FASs	reviews	this	subfield	up	to	2003.20	This	chapter	attempts	to	summarize	the	progress	up	to	2017,	and	also	includes	polyketides	and	non-ribosomal	peptides.	To	the	best	of	our	knowledge,	this	chapter	is	the	first	 attempt	 to	 comprehensively	 review	 the	 development	 and	 application	 of	 biophysical	computational	 techniques	 towards	 understanding	 the	 enzymes	 in	 the	 acetate	 and	 non-ribosomal	peptide	pathways.			
1.2 Enzymatic	machinery	The	biosynthesis	of	fatty	acids,	polyketides	(PKs),	and	non-ribosomal	peptides	(NRPs)	is	typically	 accomplished	 by	 large,	multi-domain	 enzyme	 complexes	 in	 eukaryotes,	 and	 by	discrete	mono-domain	enzymes	in	prokaryotes.	The	enzymes	are	called	fatty	acid	synthase	(FAS),	 polyketide	 synthase	 (PKS),	 and	 non-ribosomal	 peptide	 synthetase	 (NRPS),	respectively.	Their	 intermediate	products,	often	highly	reactive,	are	shuttled	between	the	catalytic	domains	via	carrier	proteins	(CPs)	in	a	well-choreographed	order	that	results	in	the	generation	 of	 final	 products	 with	 high	 fidelity.	 These	 “megasynthases”	 can	 generate	chemically	diverse	and	complex	bioactive	natural	products.	The	biosynthesis	is	most	often	mediated	 by	 an	 acyl	 carrier	 protein	 (ACP)	 in	 fatty	 acid	 and	 polyketide	 biosynthesis,	 or	peptidyl	carrier	protein	(PCP)	in	non-ribosomal	peptide	biosynthesis.	The	growing	chain	is	tethered	 to	a	post-translationally	modified	phosphopantetheine	 (PPant)	prosthetic	group	attached	 to	 a	 serine	 residue	 on	 the	 carrier	 protein	 (CP),	 and	 ultimately	 released	 by	 the	
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hydrolytic	cleavage	of	a	thioester	bond	to	generate	a	macrocycle	or	linear	chain.	The	valuable	compounds	 generated	 by	 these	 megasynthases	 are	 difficult	 to	 access	 through	 organic	synthesis	 because	 of	 their	 chemical	 complexity,	 innate	 reactivity,	 and	 multiple	stereocenters.21	Rather,	biosynthesis	of	fatty	acids,	polyketides,	and	non-ribosomal	peptides	using	FAS,	PKS	and	NRPS	offer	a	more	economic	and	efficient	way	to	obtain	these	natural	products.		
	
Figure	 1-2.	 Assembly	 line	 biosynthesis	 of	 a)	 non-ribosomal	 peptides	 in	 Type	 A	 NRPS	systems	and	b)	polyketides	in	Type	I	modular	PKS	systems.		 In	the	multi-modular	FASs,	PKSs,	and	NRPSs,	one	extender	unit	is	added	for	every	chain	extension,	and	it	is	sometimes	possible	to	predict	the	chemical	structure	of	the	final	product	based	on	the	sequence	of	gene	clusters.	There	exists	an	iterative	type	that	is	capable	of	using	the	 same	module	more	 than	 once	 for	multiple	 extensions,	 which	 adds	 an	 extra	 layer	 of	difficulty	in	chemical	structure	prediction.22	The	growing	substrate	is	guided	to	each	binding	partner	by	a	peptidyl	carrier	protein	(PCP)	in	NRPSs	and	by	an	acyl	carrier	protein	(ACP)	in	FASs	and	PKSs	(Fig.	1-2).	ACP	and	PCP	 are	 highly	 similar	 in	 structure.	 Both	 consist	 of	 a	 four-helix	 bundle,	 and	 a	 prosthetic	
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phosphopantetheine	group	is	post-translationally	attached	to	a	conserved	serine	residue	of	CP.			
1.2.1 Fatty	acid	synthase	(FAS)	The	biosynthesis	of	fatty	acids	occurs	through	the	condensation	of	acetyl	units.	This	was	shown	experimentally	by	Rittenberg	and	Bloch,	who	in	1945	labeled	acetate	with	13C	at	the	carbonyl	group	and	deuterium	in	the	methyl	group,	followed	by	the	detection	of	isotope	locations	in	the	products.23	They	also	proved	that	it	is	acetyl-CoA	that	serves	as	the	extender	unit	of	FAS.	Ten	years	later,	the	same	isotope	labeling	technique	was	applied	to	the	study	of	polyketides,	 with	 the	 generation	 of	 6-methylsalicylic	 acid,	 which	 showed	 a	 head-to-tail	addition	of	three	acetate	units.		In	1958,	Brady	did	a	simple	buffer	exchange	experiment,	in	which	he	replaced	a	bicarbonate	buffer	with	a	phosphate	buffer,	which	led	to	failure	in	the	original	radiolabeling	assay	and	revealed	the	necessity	of	bicarbonate	in	the	biosynthesis	of	fatty	acids.23	 	A	few	years	later,	Wakil	and	Brady	independently	showed	malonyl-CoA	as	a	needed	intermediate,	which	is	formed	from	the	ATP	dependent	carboxylation	of	acetyl-CoA	(Fig.	1-3).	The	exergonic	decarboxylation	of	malonyl-CoA	generates	a	resonance-stabilized	carbanion	on	acetyl-ACP,	which	 is	 able	 to	 function	as	a	nucleophile.24	These	experiments	paved	the	foundation	for	current	biosynthesis	studies	of	megasynthases.		
	
Figure	1-3.	Carbon-carbon	bond	formation	in	fatty	acid	biosynthesis	as	elucidated	by	Wakil	and	Brady.	
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	 All	 organisms	 need	 to	 synthesize	 fatty	 acids	 for	 cellular	membranes,	 and	 animals	store	 fatty	 acids	 as	 triglycerides	 for	 future	 energy	 demands.	 Nature	 has	 adopted	 two	solutions	for	this	high	demand	of	fatty	acids.	One	solution	employed	by	eukaryotes	and	some	bacteria	involves	linking	the	necessary	domains	covalently,	forming	a	“megasynthase”;	these	large	 polypeptides	 are	 known	 as	 type	 I	 FASs.23,	 25	 	 Another	 solution	 found	 in	 plants	 and	bacteria	is	to	synthesize	fatty	acids	by	use	of	functional	discrete	mono-domain	enzymes,	with	ACP	shuttling	the	growing	intermediates,	and	these	standalone	enzymes	are	known	as	type	II	FASs.			
1.2.1.1 Type	I	FAS	Two	comprehensive	reviews	on	type	I	FAS	systems	have	been	written	by	Smith	and	Maier.23,	26	Here,	we	briefly	described	the	structural	biology	relevant	to	this	thesis.		
1.2.1.1.1 Mammalian	Type	I	FAS	In	 2006,	 Maier	 et	 al.	 obtained	 an	 initial	 X-ray	 structure	 of	mammalian	 fatty	 acid	synthase	 from	 Sus	 scrofa	 at	 a	 resolution	 of	 4.5	 Å	 (PDB	 ID:	 2CF2),	 and	 the	 homodimeric	structure	 revealed	 that	 mammalian	 FAS	 adopts	 an	 overall	 X-shape.27	 The	 porcine	 FAS	(UniProtKB:	I3LC73)	shares	a	79%	sequence	identity	with	human	FAS	(UniProtKB:	P49327),	Furthermore,	the	structure	revealed	the	relatively	long	distances	between	catalytic	domains,	highlighting	the	flexibility	required	by	the	ACP	to	interact	with	its	many	partners.	In	2008,	Maier	et	al.	again	obtained	another	structure	of	the	porcine	mammalian	FAS	(Fig.	1-4),	at	an	improved	resolution	of	3.2	Å	(PDB	IDs:	2VZ8,	2VZ9)25	These	higher	quality	structures	of	the	
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wild	boar	FAS	revealed	a	central	axle,	by	which	the	ACP	is	able	to	rotate	around	as	it	swivels	to	its	many	partners	to	incrementally	increase	the	length	of	the	growing	fatty	acyl	chains.		
 
Figure	1-4.	The	homodimer	porcine	mammalian	FAS	(mFAS)	structure	determined	by	Maier	
et	al.	is	shown	above	in	“Connolly”	surface	representation.25,	28	This	figure	is	an	adaptation	of	an	original	present	in	the	original	work	by	Maier.	Domains	are	colored	for	clarity	and	include	the	 ketosynthase	 (KS),	 linker	 (LD),	 malonyl-acyl	 transferase	 (MAT),	 dehydratase	 (DH),	inactive	 methyltransferase	 (ΨME),	 inactive	 ketoreductase	 (ΨKR),	 enoylreductase	 (ER),	ketoreductase	(KR)	domains.	The	acyl	carrier	protein	(ACP)	and	thioesterase	(TE)	domains	are	 missing	 from	 the	 crystal	 structure.	 Shown	 below	 the	 crystal	 structure	 is	 the	 linear	organization	 of	 the	 domains	 on	 each	 of	 the	 monomer	 polypeptide	 chains,	 with	 colors	matching	the	cartoon	representation	above,	and	the	ACP	and	TE	domains	are	shown	in	white	with	dashed	lines	to	represent	that	they	are	missing.		Using	the	above	structural	information,	a	murine	type	I	FAS	was	shown	to	accept	non-native	substrates	by	Rittner	et	al.,	who	also	assigned	kinetic	constants	for	native	substrates	acetyl-CoA	and	malonyl-CoA,	and	used	these	for	comparison	purposes.29	The	authors	noted	
ER TEACPKRΨME ΨKRDHLD MATKS
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the	malonyl/acyltransferase	(MAT)	of	murine	FAS	might	serve	a	useful	tool	for	the	loading	of	un-natural	substrates	due	to	the	domain	separation	present	in	its	structure.	Furthermore,	the	 same	MAT,	 or	 a	 similar	MAT	 from	 other	 FAS/PKS	 systems	might	 provide	 access	 to	incorporation	of	different	starter	units.			The	 full-length	 structures	of	human	 fatty	acid	 synthase	 (hFAS)	have	 so	 far	eluded	structural	biologists.	It	is	known	that	the	thioesterase	(TE)	domain	in	hFAS	is	responsible	for	chain	length	selection,	and	two	crystal	structures	of	the	hFAS	thioesterase	(hFASTE)	domain	were	 reported	at	2.6	Å	and	1.48	Å,	 respectively.30-31	More	 recently,	 in	2015,	 scientists	 at	GlaxoSmithKline	 (GSK)	obtained	a	 structure	of	 a	hFAS	 tri-domain	 consisting	of	 the	ΨME,	ΨKR	and	KR	domains	with	a	length	of	660	residues	and	mass	of	71.8	kDa.32	The	tri-domain	showed	high	conservation	between	hFAS	and	porcine	FAS,	with	an	RMSD	of	0.44	Å	between	the	two	KR	domains,	and	an	RMSD	of	0.98	Å	between	the	Ψ	domains.	Hardwicke	et	al.	then	evaluated	the	effectiveness	of	the	tri-domain	as	catalysis	for	reduction.32	Unfortunately,	they	found	a	markedly	reduced	activity.	Therefore,	the	authors	caution	that	that	these	truncated	constructs	may	be	suitable	for	structural	studies,	but	probably	not	for	mechanistic	studies.			
1.2.1.1.2 Fungal	Type	I	FAS	Interestingly,	 in	 fungal	systems	all	of	 the	catalytic	domains	are	separated	between	two	multidomain	polypeptide	chains,	known	as	the	α	and	β	chains.	The	first	glimpse	of	this	type	 of	 structure	 was	 obtained	 in	 2006	 from	 the	 Ban	 lab,	 and	 was	 from	 the	 organism	
Thermomyces	lanuginosus	at	a	resolution	of	5	Å	(PDB	ID:	2CDH).33	The	following	year,	the	labs	of	Steitz	and	Ban	independently	solved	structures	of	the	yeast	type	I	FAS	at	relatively	high	resolutions	of	4.0	Å	and	3.1	Å	respectively	(PDB	IDs:	2PFF,	4V58,	4V59).34-35	The	fungal	
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FAS	structure	from	T.	lanuginosus	revealed	a	2.6	mDa	α6β6	heterododecameric	FAS,	which	is	contrast	to	the	540	kDa	homodimer	mFAS	described	previously.	The	α	chain	contains	the	acyltransferase	(AT),	ER,	DH	and	malonyl/palmitoyl	transferase	(MPT)	domains.	The	β	chain	contains	 the	ACP,	 KR,	 KS	 and	 phosphopantetheine	 transferase	 (PT)	 domains.	 Jenni	 et	 al.	described	the	fungal	FAS	structure	as	containing	three	parts,	a	central	wheel,	and	two	domes	which	enclose	the	reaction	chambers.33,	36	The	fungal	FAS	is	less	relevant	to	this	thesis	and	will	not	be	discussed	in	detail	here.		
1.2.1.1.3 Bacterial	Type	I	FAS		 While	Type	I	FASs	are	primarily	present	 in	eukaryotes,	a	 few	are	present	 in	some	bacterial	 species.	 Boehringer	 et	 al.	 and	 Ciccarelli	 et	 al.	 obtained	 cryo-em	 structures	 of	bacterial	type	I	FASs	at	7.5	Å	(PDB	ID:	4V8L)	for	Mycobacterium	smegmatis	and	17.5	Å	(PDB	IDs:	 	 4V8W,	 4V8V)	 for	 Mycobacterium	 tuberculosis.37-38	 These	 structures	 revealed	conservation	of	overall	domain	architecture	similar	architecture	to	 the	 fungal	FAS,	with	a	central	 wheel,	 and	 two	 domes	 enclosing	 the	 reaction	 chambers.	 These	 structures	 led	Boehringer	and	Ciccarelli	to	propose	two	possible	origins	for	these	bacterial	type	I	FASs.	The	first	possibility	is	simply	that	bacteria	adopted	these	type	I	FASs	through	an	early	horizontal	gene	 transfer,	 with	 the	 second	 possibility	 being	 that	 these	 type	 I	 FASs	 might	 actually	represent	 an	 ancient	minimal	 type	 I	 FAS,	 which	 fungi	were	 later	 able	 to	 refine	 through	evolution.	 Another	 interesting	 anomaly	 in	 these	 structures	 is	 the	 complete	 lack	 of	 linker	regions,	which	are	present	in	eukaryotic	FASs.	Currently	it	is	not	known	if	this	is	due	to	a	functional	purpose	or	is	simply	the	result	of	bacterial	genome	reduction.		
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1.2.1.2 Type	II	FAS	Although	Type	I	FAS	is	proposed	to	be	more	efficient	due	to	the	localized	nature	of	the	domains,	Type	II	FASs	display	a	greater	product	diversity.39	The	simplest	model	system	is	the	Type	II	FAS	in	E.	coli.	In	this	system,	the	acyl	carrier	protein	AcpP	has	to	interact	with	more	than	10	different	catalytic	partners,	and	it	does	so	with	high	efficiency	and	fidelity.39	The	final	products	generated	by	Type	II	FASs	are	long	fatty-acyl	chains.		Several	NMR	studies	have	been	carried	out	on	the	E.	coli	acyl	carrier	protein	(AcpP);	however,	because	of	the	transient	interactions	between	a	CP	and	its	enzyme	partner,	it	has	been	difficult	to	capture	AcpP-partner	domain	interactions.	Most	recently,	Nguyen	et	al.	from	our	group	reported	the	crystallographic,	NMR	and	MD	studies	of	a	 type	II	FAS	di-domain	complex	of	AcpP	and	a	dehydratase	(FabA)	from	E.	coli,	stabilized	via	a	mechanism-based	synthetic	 crosslinker	 (PDB	 ID:	 4KEH).40	 Further	 success	 was	 recently	 obtained	 when	 a	complex	crystal	structure	was	solved	of	the	ketosynthase	(FabB)	from	the	same	pathway	in	
E.	coli	that	is	covalently	bound	to	AcpP	using	a	different	mechanism-based	crosslinker	(PDB	ID:	5KOF),	as	detailed	in	Chapter	4.	In	addition,	Zhang	et	al.	reported	the	complex	structure	of	 another	 dehydratase	 (FabZ)	 from	 E.	 coli	 with	 holo-AcpP	 (PDB	 ID:	 4ZJB),	 providing	additional	details	on	the	differences	between	loaded	and	unloaded	ACP	variants.41	This	class	is	covered	more	in-depth	in	Chapter	4,	with	focus	on	the	role	allostery	plays	in	the	regulation	and	biosynthesis	of	fatty	acids	in	bacteria.		
	
1.2.2 Polyketide	synthase	(PKS)	Nature	 has	 co-opted	 the	 fatty	 acid	 biosynthetic	 assembly	 line	 strategy	 to	 produce	linear	and	macrocyclic	polyketide	natural	products	by	utilizing	additional	tailoring	domains	
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for	increased	chemical	diversity	and	biological	function.42	PKSs	can	be	categorized	into	three	types	depending	on	their	domain	organizations.	The	Type	I	PKSs	assemble	into	“modules,”	a	collection	of	enzymatic	domains	that	are	covalently	linked	together	on	the	same	polypeptide	chain.	 These	 Type	 I	 PKSs	 can	 either	 catalyze	 polyketide	 biosynthesis	 as	 multi-module	complexes,	or	as	a	single	iterative	module.43	The	Type	II	PKSs,	like	their	FAS	counter-parts,	are	 stand-alone	enzymes.	Type	 III	PKSs	are	also	stand-alone	enzymes,	but	one	domain	 is	capable	of	performing	chain	elongation,	cyclization	and	chain	release	independent	of	other	enzymes.	More	about	PKS	will	be	discussed	in	Chapter	5.		
1.2.3 Non-ribosomal	peptide	synthetase	(NRPS)	NRPSs	utilize	the	CP	machinery	as	well,	but	with	amino	acids	instead	of	acyl	groups	as	 the	building	blocks.	Nonribosomal	peptides	 (NRPs)	are	assembled	 in	an	assembly	 line	fashion	similar	to	polyketides	and	fatty	acids	as	described	previously.	Similarly,	the	NRPS	is	categorized	into	three	types.	The	Type	A	NRPS	is	also	modular,	but	it	uses	amino	acids	as	building	blocks	that	consist	of	over	400	varieties,	including	the	20	proteinogenic	amino	acids	(Fig.	 1-2a).44	 The	 large	 pool	 of	 starter	 and	 extender	 units	 from	which	 to	 build	NRPs	has	generated	 a	wide	 array	 of	 compounds,	 and	 includes	many	 antibiotics	 such	 as	 penicillins,	vancomycin,	 and	 cyclosporines.	 Efforts	 in	 synthetic	 biology	 have	 shown	 that	 further	expansion	of	the	NRP	products	generated	by	the	NRPSs	can	be	achieved	through	the	use	of	non-standard	starter	units	and	extender	units.45	More	about	NRPS	will	be	covered	in	Chapter	3.	 		
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1.2.4 Hybrids	A	 strategy	 employed	 by	 some	 organisms	 for	 the	 generation	 of	 complex	 natural	products	 is	 through	the	combination	of	different	 types	of	megasynthases,	resulting	 in	 the	generation	of	hybrids.	In	the	epothilone	biosynthetic	assembly,	an	initial	polyketide	scaffold	(generated	 by	 a	 PKS)	 is	 passed	 to	 a	 downstream	 NRPS,	 which	 then	 passes	 further	 to	downstream	 PKS.46-48	 A	 key	 requirement	 for	 these	 hybrids	 is	 the	 presence	 of	 docking	domains	that	are	able	to	recognize	the	correct	downstream	and	upstream	modules,	and	to	successfully	pass	the	intermediates.	Another	example	is	fujimycin,	an	immunosuppressant	that	 is	assembled	by	a	PKS	and	an	NRPS	using	an	assortment	of	substrates	 including	two	methoxymalonyl-acyl	 carrier	 proteins	 (-ACPs),	 an	 allylmalonyl-CoA,	 five	 methylmalonyl-CoAs,	two	malonyl-CoAs,	and	one	pipecolic	acid	molecule.49		
1.3 Computational	techniques	There	are	several	computational	techniques	available	to	researchers	in	pharmacognosy.	Common	 computational	 tools	 include	 bioinformatics,	 homology	 modeling,	 molecular	docking,	 and	 molecular	 dynamics.	 Below,	 we	 discuss	 current	 progress	 in	 megasynthase	studies	using	these	computational	techniques		
1.3.1 Bioinformatics	Traditionally,	 secondary	 metabolites	 were	 discovered	 through	 activity-guided	screens.	Advances	in	sequencing	and	genomics	have	provided	investigators	an	in	silico	way	of	identifying	secondary	metabolites	through	gene	cluster	analysis.50	The	genomic	data	also	contains	pathway	information,	vital	for	engineering	efforts	of	directed	biosynthesis.		
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There	are	several	prediction	tools	available	to	analyze	PKS	and	NRPS	gene	clusters,	which	have	been	summarized	in	reviews	by	Piel	and	Boddy,	and	include	SMURF,	AntiSMASH,	NaPDoS,	NP.searcher,	ClustScan,	CLUSEAN,	PKMiner,	and	NRPS-PKS.51-56	Another	excellent	resource	is	prediction	informatics	for	secondary	metabolites	(PRISM),	a	software	platform	with	a	web	component	which	can	aid	in	the	prediction	of	final	products	generated	from	PKS	and	NRPS	gene	clusters.57-58	Often	the	same	secondary	metabolite	is	produced	by	more	than	one	 species;	 therefore,	 these	 prediction	 tools	 provide	 investigators	 a	method	 to	 identify	novel	compounds.		From	 the	plethora	of	 genomic	and	metagenomic	data	available,	 one	 can	construct	phylogenetic	 trees	 of	 FAS,	 PKS	 and	 NRPS	 gene	 clusters.	 These	 trees	 can	 provide	 rich	information	about	the	evolutionary	history	of	natural	products.	In	a	recent	review	by	Jenke-Kodama	and	Dittman,	many	examples	were	discussed,	including	one	study	that	concludes	that	all	KS	domains	from	fungi	originated	from	one	common	source.59	In	2018,	Wood	et	al.	performed	an	extensive	phylogenetic	analysis	on	the	ACP	of	trans-acyltransferase	(trans-AT)	and	cis-acyltransferase	(cis-AT)	PKS	gene	clusters,	and	discovered	that	the	evolution	of	ACPs	is	coupled	with	downstream	ketosynthases	(KSs),	but	is	not	coupled	with	upstream	KSs.60	This	decoupling	 from	upstream	KSs	 is	probably	 influenced	by	downstream	modules	 that	ensure	 the	 correct	 intermediates	 are	 passed	 down,	 so	 that	 the	 final	 product	 can	 be	biosynthesized	 with	 high	 fidelity.	 	 In	 addition	 to	 the	 phylogenetic	 analysis,	 Wood	 et	 al.	generated	ACP	fingerprints	from	complex	structures	in	the	PDB	and	identified	helices	and	residues	important	for	docking	its	partner	enzymes.	The	application	of	ACP	fingerprint	data	generated	by	Wood	might	be	useful,	when	combined	with	molecular	dynamics,	to	predict	
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interface	residues	between	ACPs	and	partner	enzymes.	Similar	contact	predictions	utilizing	deep	learning	for	other	families	of	enzymes	have	been	used	with	relative	success.61-62		
1.3.2 Homology	modeling	In	 the	 absence	 of	 a	 structure	 from	 traditional	 structural	 biology	 methods,	 the	structures	 can	 be	 predicted	using	homology	modeling,	which	 gets	 its	 name	 from	using	 a	known	homolog	that	shares	the	same	evolutionary	origin	as	a	threading	template	to	make	a	predictive	model	of	the	target	protein.63	Popular	template-based	models	include	Rosetta	and	I-TASSER.64-67	In	addition	to	the	template-based	models,	in	the	absence	of	a	suitable	template,	
ab	 initio	 folding	methods	do	exist.	QUARK,	developed	by	 the	Zhang	 lab,	uses	an	ab	 initio	folding	approach	and	applies	a	 force	 field-based	method.68	Critical	Assessment	of	Protein	Structure	 Prediction	 (CASP)	 experiments	 are	 performed	 to	 evaluate	 current	 homology	modeling	techniques	via	blind	prediction	every	two	years.	This	bi-annual	competition	shows	methods	developers	key	areas	to	focus	on	for	future	developments.	In	addition,	there	is	also	a	dedicated	bi-annual	competition	focused	on	protein-protein	docking	modeling	known	as	the	Critical	Assessment	of	Predicted	Interactions	(CAPRI).69-71	HADDOCK	and	CLUSPRO	are	two	web	servers	which	have	consistently	done	well	in	CAPRI	competitions	in	the	past.70,	72-
77	An	entire	review	itself	could	be	written	on	homology	modeling	applications	in	the	acetate	and	non-ribosomal	peptide	pathways;	therefore,	in	the	interest	of	brevity,	key	examples	are	provided	in	the	next	few	sections.					
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1.3.2.1 FAS	As	mentioned	in	a	previous	section,	no	crystal	structure	is	available	of	human	FAS	(hFAS),	and	because	hFAS	is	associated	with	clinical	conditions	such	as	obesity,	diabetes	and	cancer,	a	structural	model	of	hFAS	is	much	needed.	An	apo	homology	model	was	generated	by	John	
et	al.	using	the	porcine	FAS	structure	as	the	threading	template.78	This	model	was	used	to	perform	docking,	and	the	quality	of	the	apo	and	ligand	bound	models	were	validated	using	short	20	ns	MD	simulations.		The	apo	structure	was	screened	with	a	ligand	database	from	the	National	Cancer	Institute	(NCI),	and	identified	NSC71039	as	a	potential	strong	binder.	The	 authors	 evaluated	 the	 efficacy	 of	 NSC71039	 in	 a	 FASN-expressing	 cancer	 line,	 thus	highlighting	the	effectiveness	of	molecular	modeling	approaches	in	drug	design,	as	well	as	the	versatility	of	homology	modeling	for	hFAS	structural	prediction.		Using	the	mammalian	FAS	(mFAS)	structure	solved	by	Maier	et	al.	as	a	template,	a	high-quality	homology	model	was	developed	by	Viegas	et	al.,	which	included	the	missing	TE	and	ACP	domains	not	present	in	the	reported	mFAS	structure.79	20.0	ns	MD	simulations	were	performed	with	and	without	the	TE	and	ACP	domains	to	evaluate	homology	model	quality,	and	the	model	including	the	TE	and	ACP	domains	showed	a	decrease	in	RMSD	over	time,	as	compared	to	the	model	missing	the	TE	and	ACP	domains.	The	validation	of	homology	models	by	 analyzing	 RMSD	 fluctuations	 over	 time	 obtained	 from	 MD	 simulations	 is	 a	 common	technique	in	modeling,	with	a	detailed	protocol	provided	by	Walker	et	al..80	Viegas	proposed	several	hydrophobic	residues	on	the	KS	surface,	including	Val261,	Phe263	and	Leu203	which,	in	combination	with	Leu2157,	Met2158,	Val2160	and	Val2176	on	ACP,	were	used	to	restrain	the	 ACP-KS	 interactions	 during	 the	 generation	 of	 full-length	 homology	 modeling.	
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Thoughtfully	 guided	 homology	 modeling	 can	 serve	 as	 the	 basis	 for	 biochemical	investigations	in	the	absence	of	an	experimentally	solved	structure.			
	
1.3.2.2 PKS	A	key	 focus	 in	 the	 study	of	 these	systems	 is	 the	elucidation	of	 the	protein-protein	interactions	between	CPs	and	their	partner	enzymes.	In	Type	II	PKS	systems,	similar	to	the	Type	II	FAS	systems,	the	CP	must	share	interfaces	with	its	various	partner	enzymes.	This	is	different	from	the	Type	I	systems,	where	the	CP	is	included	in	the	same	polypeptide,	and	a	single	“hot	spot”	of	CP	interacts	with	its	partners	may	not	be	as	necessary.	To	investigate	the	differences	between	Type	I	and	Type	II	PKSs,	Weissman	et	al.	in	2006	set	out	to	compare	and	contrast	recognition	regions	in	both	types	of	systems.81	A	homology	model	of	ACP4	from	6-deoxyerythronolide	B	synthase	(DEBS)	was	generated	and	used	to	 identify	helix	 II	as	 the	recognition	motif,	which	was	validated	through	mutagenesis	studies,	with	the	focus	on	the	interactions	of	ACP	with	its	partners,	the	phosphopantetheinyl	transferase	(PPTase)	and	TE.	In	a	 later	study,	Alekseyev	et	al.	obtained	a	solution	structure	of	one	ACP	from	DEBS	and	performed	homology	modeling	to	make	predictive	structures	of	the	other	five	ACPs	present	in	this	system.82		We	recently	obtained	a	crystal	structure	of	a	anthranilate:CoA	ligase	(AuaEII),	which	is	responsible	for	the	generation	of	an	uncommon	starter	unit	anthraniloyl-CoA	used	during	the	biosynthesis	of	aurachins,	a	class	of	quinoline	alkaloids.83	AuaE,	which	is	present	in	the	same	pathway,	 is	 responsible	 for	 transferring	the	anthraniloyl-CoA	onto	ACP,	 and	 shares	high	sequence	similarity	to	AuaEII.	In	the	absence	of	an	experimentally	derived	structure,	molecular	 dynamics	 guided	 homology	 modeling	 was	 used	 to	 develop	 high-quality	
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representations	of	AuaE	in	two	distinct	conformations.		Short	100	ns	simulations	were	used	to	 measure	 stability	 in	 the	 two	 original	 homology	 models,	 as	 well	 as	 refine	 sidechain	geometry.	The	MD-refined	models	provided	a	molecular	basis	for	hinge	movement	in	AuaE,	via	 stabilization	 of	 a	 salt	 bridge	 between	 Arg408	 and	 Asp410,	 while	 the	 same	 arginine	residue	 in	AuaEII	 is	unable	to	 form	this	salt	bridge	due	to	an	 interaction	with	a	hydroxyl	functional	group	on	the	anthraniloyl-AMP	ribose	ring.	This	study	showed	the	effectiveness	of	obtaining	additional	structural	and	functional	details	on	structures	through	higher	quality	MD-guided	homology	modeling	approaches.		
	
1.3.3 Docking	Traditionally,	 small-molecule	 docking	 approaches	 focus	 on	 non-covalent	 receptor	and	 ligand	 interactions.	 Enzymes	 in	 these	 pathways	 often	 covalently	 load	 their	intermediates	 on	 a	 post-translationally	 modified	 phosphopantetheine	 moiety,	 which	 is	attached	 to	 the	 CP	 domain.	 Therefore,	 covalent	 docking	 approaches	 (as	 opposed	 to	 non-covalent	docking)	may	be	needed.	A	 recent	 review	by	Scarpino	et	al.	 evaluated	 available	covalent	docking	tools,	including	AutoDock4,	CovDock,	FITTED,	GOLD,	ICM-Pro	and	MOE.84	The	six	tools	could	model	covalently	bound	ligands	with	40-70	%	success	rate,	with	a	lower-success	 rate	 for	 long	 and	 flexible	 ligands	 that	 are	 covalently	 bound.84-89	 The	phosphopantetheine	bound	intermediates	in	these	pathways	are	relatively	long	and	flexible;	therefore,	 we	 expect	 that	 its	 covalent	 docking	 will	 be	 a	 major	 issue	 that	 needs	 to	 be	addressed	 with	 careful	 consideration.	 Covalent	 docking	 was	 used	 by	 our	 lab	 to	 model	substrate	mimics,	 though	 the	 substrate	mimics	were	 compared	and	contrasted	 to	known	
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substrate	models	for	which	NMR	data	is	present	in	the	protein	data	bank	(PDB)	(detailed	in	Chapters	2-4).90		
	
1.3.4 Molecular	Dynamics	(MD)	Experimental	 techniques,	 including	 X-ray	 crystallography,	 NMR,	 FRET,	 and	 EM,	 are	powerful	tools	that	allow	us	to	visualize	biomolecules,	though	we’re	often	limited	to	specific	time	scales	and	the	ensemble	averages	of	the	target	proteins.	Starting	from	the	first	example,	sixty	years	ago,	Kendrew	et	al.	reported	the	first	crystal	structure	of	a	protein,	myoglobin	(PDB	 ID:	 1MBN).91	 	 These	 early	 crystallography	 experiments,	 while	 providing	 atomic-resolution	models,	instilled	in	us	a	static-view	of	proteins,	RNA	and	DNA.	Today,	researchers	show	the	importance	of	protein	dynamics	to	its	function,	and	a	static	picture	is	no	longer	satisfactory.	Although	protein	structures	solved	by	Nuclear	magnetic	resonance	(NMR)	can	capture	multiple	protein	conformations,	NMR	structures	cannot	resolve	dynamic	structures	in	the	femto-	and	picosecond	timescales.			To	circumvent	the	above	issues,	computational	structural	biologists	model	biomolecules	
in	 silico.	 Molecular	 behavior	 at	 the	 atomic	 level	 is	 described	 by	 the	 time-dependent	Schrödinger	equation	(1.1),	for	which	no	analytical	solution	exists	for	non-trivial	systems,	and	computationally	impracticable	even	on	today’s	fastest	computers.92		 𝑖ℏ 𝜕𝜕𝑡 |Ψ(𝐫, 𝑡)	⟩ = 𝐻/|Ψ(𝐫, 𝑡)⟩	 (1.1)	
	Using	 the	 Born-Oppenheimer	 approximation,	 the	 wave	 function	 of	 a	 molecule	 can	 be	described	in	terms	of	its	nuclear	and	electronic	components.	This	allows	us	to	treat	atoms	as	particles,	and	bonds	can	be	represented	as	springs,	thus	providing	a	framework	to	represent	
 20	
our	target	systems	classically.	In	MD	simulations,	we	can	obtain	particle	motion	as	a	function	of	time,	and	thus	resolve	time	regimes	far	beyond	traditional	structural	biology	techniques.	Because	MD	simulations	can	sample	different	time-scales,	we	can	gain	valuable	insight	into	protein-protein	 and	 protein-substrate	 interactions,	 as	 well	 as	 conformational	 changes.	Karplus	et	al.	classifies	simulations	into	three	main	types.93	The	purpose	of	the	first	type	is	to	sample	configuration	space,	and	this	is	used	in	X-ray	crystallography	refinement	through	annealing	protocols.	The	second	type	is	used	to	describe	systems	at	equilibrium,	with	the	goal	 of	 obtaining	 thermodynamic	 data.	 These	 first	 two	 types	 can	 also	 be	 accomplished	through	Monte	Carlo	simulations.	The	final	type	is	to	sample	protein	dynamics,	and	for	this	molecular	 dynamics	 (MD)	 is	 the	 only	 option.	 Investigators	 can	 perform	 a	 variety	 of	simulations	 and	 analyses	 using	 traditional	 MD	 programs	 such	 as	 AMBER,	 CHARMM,	GROMACS,	and	NAMD.94-98	The	frontier	area	is	MD	method	development,	which	is	a	result	of	demands	by	the	end-users	whose	needs	push	the	method	development	forward.		Modeling	 enzymes	 from	 the	 acetate	 and	 non-ribosomal	 peptide	 pathways	presents	 a	challenge,	 because	 traditional	 MD	 packages	 are	 unable	 to	 model	 the	 long-flexible	phosphopantetheine	 bound	 intermediates	 observed	 in	 these	 systems.	 Therefore,	 a	major	hurdle	 facing	 MD	 in	 these	 systems	 is	 the	 parameterization	 of	 electrostatic	 and	 bond	properties	 for	 the	 covalently-bound	 starter	 units,	 extender	 units,	 and	 intermediates.	 To	surmount	this	hurdle,	 I	developed	a	specialized	 forcefield	 for	use	 in	AMBER	to	probe	the	dynamics	of	 these	 systems	 (detailed	 in	Chapter	2).	The	development	of	 the	 force	 field	 is	based	on	previous	force	field	development	methods	and	is	available	for	free	to	the	molecular	dynamics	 and	 natural	product	 communities.	 It	 includes	 the	 forcefields	 of	 PPant-tethered	starter	units,	extender	units,	and	biosynthetic	intermediates.			
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1.3.4.1 FAS	Molecular	dynamics	(MD)	simulations	performed	by	Chen	et	al.	on	the	apo,	holo,	and	acyl	forms	on	the	Type	II	ACP	(AcpP)	from	E.	coli	revealed	two	substrate	binding	modes,	and	AcpP	 has	 an	 adjustable	 cavity	 to	 accommodate	 substrates	 of	 various	 lengths.17,	 99-100	Simulations	were	performed	in	which	the	loaded	phosphopantetheine	was	positioned	in	the	sequestered	 ACP	 cavity,	 or	 exposed	 to	 the	 solvent.99	 Different	 chain	 lengths	 were	 also	explored,	with	the	octanoyl-bound	intermediate	being	the	most	suited	for	substrate	binding	in	the	AcpP	cavity.	A	total	of	19	simulations	were	performed	and	sampled	up	to	50	ns.	Chen	suggests	from	his	computational	models	that	the	loop	between	the	second	and	third	helices	is	important	for	recognition	between	different	enzyme	partners	of	AcpP,	and	when	it’s	in	the	
apo-	 or	holo-	 forms,	 this	 loop	 region,	with	 highly	 acidic	 residues,	 fluctuates	 significantly.	Upon	loading	with	the	fatty	acid	“cargo”,	this	loop	region	has	an	increased	flexibility,	thus	allowing	this	electronegative	patch	of	ACP	to	interact	with	its	partner	via	the	“arginine-rich	groove”.		Medina	et	al.	performed	a	QM/MM	study	to	inspect	the	proposed	catalytic	mechanism	underlying	 reduction	 of	 β-ketoacyl	 to	 β-hydroxyacyl	 group	 via	 oxidation	 of	 a	 NADPH	cofactor	by	the	ketoreductase	(KR)	of	hFAS.101	Several	models	were	tested,	and	the	result	suggests	that	the	KR	reaction	proceeds	in	two	steps.	First,	the	β-carbon	of	the	acyl	substrate	is	subjected	to	nucleophilic	attack	by	the	NADPH	hydride,	and	the	proton	is	replenished	by	an	 asynchronous	 deprotonation	 of	 nearby	 Tyr2034.	 The	 model	 then	 predicts	 that	 the	reprotonation	of	Tyr2034	proceeds	by	the	deprotonation	of	NADP+	3’-OH	group,	which	is	
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coordinated	 with	 a	 neighboring	 Lys1995.	 This	 study	 showed	 that	 QM/MM	 studies	 can	provide	high	quality	models	to	probe	highly	reactive	intermediates.			
1.3.4.2 PKS	An	early	computational	study	performed	by	Yeates,	Tang	and	Houk	in	2014	explored	the	role	of	allostery	in	the	active	site	architecture	and	dynamics	of	a	PKS.102	Specifically,	they	investigated	 a	 lovastatin	 PKS	 (LovD)	 variant	 that	was	 1,000-fold	more	 efficient	 than	 the	wildtype.	Microsecond	MD	simulations	supported	that	 long-range	mutations	can	alter	 the	active	site	dynamics.	Furthermore,	MD	simulations	can	reproduce	a	conformational	change	of	the	active	site	channel,	as	was	observed	in	crystallographic	studies.	In	addition,	QM	studies	were	performed,	and	the	MD	simulations	matched	the	QM	geometrical	arrangements,	with	a	second-shell	 tyrosine	 constrained	 in	 an	 active	 conformation	 for	 the	 majority	 of	 the	simulation.		Interestingly,	several	conformations	were	reported	for	the	crystal	structures	of	LovD	variants.	The	MD	studies	performed	on	these	variants	also	showed	a	sampling	of	various	conformational	 states	due	 to	mutations.	Noteworthy	 from	 this	 study	was	 the	observation	that	when	the	ACP	was	bound	to	LovD,	there	was	a	stabilization	in	the	active	site	geometry	and	reduction	in	protein	dynamics.	This	suggests	that	the	PKS	has	an	inherent	flexibility,	and	that	crystal	packing	might	induce	modified	conformations	in	crystallographic	studies.102	The	authors	summarized	that	PKS	engineering	should	focus	not	only	on	the	active	site,	but	should	also	 should	 take	 into	 account	 the	 importance	 of	 protein-protein	 interactions	 and	 protein	dynamics.		
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Bravo-Rodriguez	et	al.	reported	the	potential	application	of	MD	towards	engineering	PKS	systems.	103	 	Specifically,	they	explored	the	potential	application	of	MD	to	incorporate	non-native	starter	and	extender	units.	An	MD	model	was	developed	for	an	acyltransferase	(AT5mon)	of	the	monensin	PKS.	The	model	was	used	to	engineer	the	active	site	in	AT5mon	for	incorporation	of	a	non-native	starter	unit	by	computationally	guided	predictions.	In	our	group,	Ellis	et	al.	developed	oxetane	substrate	mimics	for	Type	II	PKSs.	In	order	to	 evaluate	 the	 capability	 of	 the	 mimics	 replicating	 native	 substrate	 characteristics,	 MD	simulations	 and	 free	 energy	 calculations	 were	 performed	 on	 the	 native	 substrates	 and	oxetane	mimics.	The	binding	affinities	of	the	native	substrate	and	the	mimic	as	within	one	standard	deviation,	suggesting	that	 the	mimics	accurately	depict	 the	natural	substrates	 in	regards	to	binding.	Principal	component	analysis	(PCA)	was	also	used	to	evaluate	sampling	of	the	receptor	with	either	substrate	present,	showing	sufficient	overlap.104			
1.3.4.3 NRPS	Blouodoff	et	al.	 obtained	 the	 first	 crystal	 structure	of	 the	 condensation	domain	of	calcium-dependent	antibiotic	 (CDA)	 synthetase	 (CDA-C1)	 from	Streptomyces	 coelicolor.105	During	 the	 crystallographic	 studies,	 the	 team	 noted	 that	 the	 structures	 obtained	 were	different	from	previously	solved	condensation	domains.	Using	small	X-ray	angle	scattering	(SAXS),	 they	 noted	 that	 all	 of	 previously	 reported	 conformations	 were	 present	 in	 the	ensemble	 sampled	 from	 the	 SAXS	 experiment.	 To	 further	 investigate,	 they	 performed	targeted	 MD	 simulations,	 normal	 mode	 analyses	 (NMAs),	 and	 energy-minimized	 linear	interpolation.	 These	 three	 computational	 techniques	 reproduced	 the	 conformations	observed	 from	 different	 X-ray	 studies	 and	 suggested	 that	 there	 were	 no	 unfavorable	
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conformations	 for	 the	 condensation	 domains.	 Both	 open	 and	 closed	 conformations	 are	observed,	which	the	authors	speculate	could	be	controlled	allosterically	via	a	communication	network	of	nearby	NRPS	domains.	An	important	area	in	the	study	of	CPs	is	the	mechanism	of	chain	release	of	the	final	product.	The	myxalamid	biosynthetic	pathway	in	Stigmatella	aurantiaca	is	composed	of	six	PKS	modules	and	one	terminal	NRPS	module.	The	terminal	reductase	domain	catalyzes	a	four-electron,	 non-processive	 reduction	 to	 produce	 myxalamids,	 a	 family	 of	 secondary	metabolites.	Although	common	in	nature,	the	lack	of	structural	and	dynamic	information	for	termination	domains	has	prevented	engineering	attempts	to	improve	or	alter	their	function.	This	was	the	first	MD	simulation	that	deciphers	protein-substrate	interactions	in	the	active	site	of	a	NRPS	reductase.106	In	addition,	MD	and	docking	studies	were	used	to	understand	protein-protein	 interactions	between	the	MxaA	reductase	(MxaAR)	and	 its	corresponding	PCP	(MxaAPCP).	This	study	is	further	detailed	in	Chapter	3.	Dowling	 et	 al.	 recently	 determined	 the	 crystal	 structure	 of	 an	 NRPS	 cyclization	domain,	 EpoB	 (EpoBCy),	 which	 is	 responsible	 for	 assembling	 the	 thioazole	 moiety	 of	epothilones,	a	class	of	PKS-NRPS	hybrids	with	anti-cancer	activity.46	The	growing	substrates	are	passed	between	large	multi-domain	NRPS	modules	by	way	of	docking	domains.	A	major	engineering	goal	in	these	pathways	is	to	change	the	linear	logic	of	modular	processivity.	The	ability	 to	delete,	 insert,	or	swap	modules	would	give	the	protein	designer	greater	control	over	chain	length	and	tailoring.	It	was	proposed	that	the	EpoA	docking	domain	(EpoAdd)	and	the	EpoB	docking	domain	(EpoBdd)	serve	as	the	recognition	domains,	which	prevent	cross	communication	between	wrong	modules.	More	than	one	conformation	of	EpoBdd	was	observed	by	crystallographic	studies.	MD	simulations	revealed	high	flexibility	in	the	docking	
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domain,	 consistent	with	 the	 crystallographic	 studies.	 Furthermore,	MD	 simulations	were	used	 to	produce	 snapshots	of	open	and	closed	 states	of	EpoBCy,	 resulting	 in	a	proposed	model	that	correlates	protein	conformational	changes	to	active	site	availability.	In	order	to	gain	a	better	understanding	of	intra-	and	inter-modular	interactions	in	these	systems,	more	native	structures	need	to	be	solved,	including	multidomain	structures	of	CP	and	its	partners	so	that	different	conformational	states	of	CPs	can	be	evaluated.107			
1.4 Objectives	and	overview	of	dissertation	research	Crystal	 structures	of	 enzymes	bound	with	 their	natural	substrates	have	proven	 to	be	difficult,	if	not	impossible,	to	obtain	for	these	megasynthases	because	the	intermediates	are	highly	 reactive.	 The	 innate	 reactivity	 of	 PPant-tethered	 intermediates	 has	 hampered	our	mechanistic	understanding	of	protein-substrate	and	protein-protein	interactions	during	the	biosynthesis	of	these	natural	products.	Therefore,	there	is	a	need	to	address	the	knowledge	gap	 of	 the	 protein-protein	 and	 protein-substrate	 interactions	 in	 these	 megasynthases	through	 the	 development	of	 alternative	methods	 to	 elucidate	 the	 structure,	 function	 and	dynamics.	The	goal	of	my	research	has	been	to	better	understand	how	PKSs,	NRPSs	and	FASs	biosynthesize	 these	 complex	 molecules,	 and	 how	 protein-substrate	 and	 protein-protein	interactions	affect	product	generation,	using	MD	simulations.			Chapter	2	details	the	development	of	a	computational	force	field	that	provides	a	tool	to	model	these	enzymes	in	silico	using	molecular	dynamics.	In	chapter	3,	MD	simulations	served	as	the	basis	for	the	biochemical	investigations	of	an	NRPS	reductase	domain,	in	which	MD	simulation	 helps	 engineer	 mutants	 that	 changed	 the	 product	 outcomes	 for	 biofuel	engineering.	 Chapter	 4	 describes	 MD	 simulations	 and	 a	 crystal	 structures	 of	 a	 protein	
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complex	that	contains	the	ketosynthase	(FabB)	and	its	partner	carrier	protein	(AcpP)	from	type	II	FAS,	 in	which	MD	simulation	guides	the	mutations	of	FabB	that	 led	to	a	change	of	product	outcomes	that	can	be	utilized	for	future	biofuel	production.	The	dynamics	of	a	type	III	PKS	at	different	pHs	is	investigated	in	Chapter	5,	where	MD	simulations	help	explain	how	this	PKS	biosynthesizes	different	products	at	different	pHs.	The	results	of	the	dissertation	research	demonstrate	that	the	development	and	application	of	MD	methods	in	parallel	with	structural	 and	 biochemical	 studies	 can	 aid	 engineering	 efforts	 in	 the	 biosynthesis	 of	“unnatural”	natural	products	and	engineered	biofuels.			
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CHAPTER	2	
Fatty	Acid	and	Natural	Product	Biosynthesis	Force	Field	for	Investigation	of	
Conformational	Dynamics	
	
2.1 Summary	Fatty	acid	synthases	(FAS),	polyketide	synthases	(PKS),	and	nonribosomal	peptide	synthetases	(NRPS)	can	generate	chemically	diverse	and	complex	bioactive	natural	products	in	an	assembly	line	fashion.	A	common	thread	between	these	systems	is	the	tethering	of	the	growing	 intermediates	 and	 extender	 units	 to	 a	 carrier	 protein	 that	 has	 been	 post-translationally	 modified	 with	 a	 phosphopantetheine	 (PPant)	 prosthetic	 group.	 Lack	 of	knowledge	 about	 how	 PPant-tethered	 intermediates	 are	 sequestered	 and	 transported	during	natural	product	biosynthesis	has	hampered	our	understanding	of	protein-substrate	and	 protein-protein	 interactions	 during	 the	 biosynthesis	 of	 these	 natural	 products,	ultimately	 impeding	 the	 engineering	 of	 these	 systems	 for	 the	 generation	 of	 “unnatural”	natural	products.	This	chapter	outlines	the	development	of	a	pantetheinyl-protein	force	field	with	 comparison	 to	 experimental	 structural	 characterization,	 electronic	 structure	calculations,	and	normal-mode	frequencies.	This	initial	force	field	represents	the	first	force	field	specifically	designed	to	probe	carrier	protein-mediated	natural	product	biosynthesis	through	in	silico	methods	and	provides	a	framework	for	an	all-inclusive	force	field	capable	of	 handling	 natural	 or	 unnatural	 building	 blocks.	 Ultimately,	 this	 new	 tool	 will	 provide	experimentalists	with	the	ability	to	model	these	systems	in	silico	and	aid	in	the	exploitation	of	these	systems	for	the	production	of	novel	compounds.		
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2.2 Introduction	Carrier	 protein-based	 biosynthesis	 of	 fatty	 acids,	 polyketides	 and	 nonribosomal	peptides	 provides	 a	 plethora	 of	 complex,	 bioactive	 natural	 products	 including	 valuable	pharmaceuticals	and	precious	commodity	chemicals	(Fig	1-1).1-4	These	 industrially	useful	compounds	 are	 assembled	 incrementally	 through	 the	 addition	 of	 extender	 units	 to	 the	starter	 unit	 by	 multi-domain	 fatty	 acid	 synthases	 (FAS),	 polyketide	 synthases	 (PKS),	 or	nonribosomal	 peptide	 synthetases	 (NRPS).5-7	 The	 building	 blocks	 of	 these	 systems	 are	primarily	acyl	malonates	or	amino	acids.	Their	intermediate	products,	often	highly	reactive,	are	 shuttled	 between	 the	 catalytic	 domains	 via	 the	 carrier	 proteins	 (CPs)	 in	 a	 well-choreographed	order	that	results	in	the	generation	of	the	final	product	with	high	fidelity.8	Recent	efforts	have	been	made	to	engineer	these	systems	to	expand	their	product	diversity	as	well	 as	optimize	 systems	 for	expression	 in	heterologous	hosts.9-10	A	major	hurdle	 that	remains	is	our	poor	understanding	of	the	transient	substrate-protein	interactions	between	the	 CP	with	 its	 pantetheine	 bound	 intermediates,	 as	well	 as	 protein-protein	 interactions	between	 CPs	 and	 their	 catalytic	 partner	 domains.11	Molecular	 dynamics	 (MD)	 and	 other	computational	techniques	can	be	used	to	provide	models	of	these	transient	interactions	that	are	difficult	to	capture	experimentally,	thus	providing	an	additional	tool	to	increase	yields	and	expand	diversity	when	we	utilize	the	mega-synthases	for	the	biosynthesis	of	“unnatural”	natural	products.11		The	 simplest	model	system	available	 for	 study	 is	 the	Type	 II	FAS	 in	E.	 coli.	 In	 this	system,	the	acyl	carrier	protein	AcpP	has	to	interact	with	more	than	10	different	catalytic	partners,	and	it	does	so	with	high	efficiency	and	fidelity.1	The	final	products	generated	are	long	 fatty-acyl	chains.	Next	comes	PKS.	Nature	has	co-opted	the	assembly	 line	strategy	to	
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produce	linear	and	macrocyclic	polyketide	natural	products	by	utilizing	additional	tailoring	domains	for	increased	chemical	diversity	and	biological	function.2	Third,	NRPSs	utilize	the	carrier	protein	machinery	as	well,	with	elongation	by	amino	acids	 instead	of	acyl	groups.	Further	expansion	of	the	products	generated	by	these	systems	can	be	achieved	through	the	use	 of	 non-standard	 starter	 units	 and	 extender	 units.	 One	 example	 is	 fujimycin,	 an	immunosuppressant	 that	 is	 assembled	 by	 a	 PKS	 and	 an	 NRPS	 using	 an	 assortment	 of	substrates	 including	 two	methoxymalonyl-acyl	 carrier	proteins	 (-ACPs),	one	allylmalonyl-CoA,	 five	methylmalonyl-CoAs,	 two	malonyl-CoAs,	and	one	pipecolic	acid	molecule	(Fig	1-1).12	 One	 example	 that	 combines	 in	 silico,	 in	 vitro	 and	 in	 vivo	 studies	was	 reported	 by	Dowling	et	al.,	who	recently	determined	the	crystal	structure	of	an	NRPS	cyclization	domain	EpoB	(EpoBCy)	that	is	responsible	for	assembling	the	thioazole	moiety	of	epothilones,	a	class	of	 natural	 products	 with	 anti-cancer	 activity	 (Fig	 1-1).13	 Growing	 substrates	 are	 passed	between	large	multi-domain	NRPS	modules	by	way	of	docking	domains.	It	was	proposed	that	the	 EpoA	 docking	 domain	 (EpoAdd)	 and	 the	 EpoB	 docking	 domain	 (EpoBdd)	 serve	 a	recognition	 function,	 thus	 preventing	 cross	 communication	 between	 the	wrong	modules.	More	 than	one	 conformation	of	EpoBdd	was	observed	using	 crystallographic	 studies.	MD	simulations	of	EpoBdd	revealed	high	flexibility	in	the	docking	domain	consistent	with	the	crystallographic	 studies.	 Furthermore,	 MD	 was	 used	 to	 produce	 snapshots	 of	 open	 and	closed	states	of	EpoBCy,	resulting	in	a	comprehensive	model	that	correlate	active	site	access	to	product	outcome.	This	in-depth	study	demonstrates	the	power	of	incorporating	structural	computational	biology	techniques	towards	understanding	the	sequence-structure-function	relationships	of	mega-synthases.	
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In	 addition	 to	 the	 potential	 for	 interface	 engineering	 via	 docking	 domain	manipulation,	 computational	 biology	 can	 also	 help	 expand	 starter	 and	 extender	 unit	diversity	in	the	mega-synthases.	For	example,	starter	unit	selection	was	investigated	using	MD	 to	 develop	 a	 model	 of	 an	 acyltransferase	 (AT5mon)	 in	 the	 monensin	 PKS	 by	 Bravo-Rodriguez	et	al.14	The	MD	model	was	successfully	used	to	engineer	the	active	site	in	AT5mon	for	 incorporation	of	non-native	 substrates	 through	computationally	guided	predictions.	A	similar	 study	 was	 performed	 by	 Barajas	 et	 al,	 where	 MD	 served	 as	 the	 basis	 for	 their	biochemical	investigations	and	ultimately	the	design	of	an	enzyme	for	use	in	the	biosynthesis	of	potential	biofuels.15	A	surge	in	creativity	has	also	led	to	the	design	of	novel	cross-linking	compounds	 that	 have	 enabled	 the	 determination	 of	 complex	 crystal	 structures	 involving	many	classes	of	the	illusive	carrier	protein	with	varying	partner	enzymes	(Table	2-S1).	These	complexes	provide	an	excellent	starting	structure	that,	when	coupled	with	MD	simulations,	can	provide	a	basis	for	biochemical	investigation	and	eventual	engineering	and	design.		The	MD	simulations	can	provide	insight	into	unresolved	questions	that	are	difficult	to	answer	experimentally.	For	example,	are	the	dynamics	of	the	multiple	carrier	proteins	in	a	megasynthase	 independent	 of	 each	 other,	 or	 are	 they	 coupled?	 Is	 there	 a	 functional	advantage	to	covalently	tethering	the	carrier	protein	to	the	megasynthase,	or	should	the	CP	be	tethered	close	to	the	location	of	the	catalytic	sites	in	each	of	the	enzyme	domains?5	Is	the	motion	of	the	carrier	protein	stochastic	when	it	tries	to	enter	several	enzymes	until	it	finds	a	“perfect	fit”	for	the	reaction	to	occur,	or	are	the	pathways	more	predetermined	by	the	adaptor	region	between	the	carrier	protein	and	its	partner	enzymes?	These	questions	represent	a	small	sampling	of	what	may	be	explored	through	molecular	modeling	techniques.	
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A	 major	 obstacle	 when	 studying	 these	 multi-protein	 complex	 systems	 using	computational	structural	biology	techniques	is	the	covalently-bound	phosphopantetheine	in	the	CPs.	Current	force	fields	support	modeling	standard	amino	acids,	nucleic	acids,	sugars,	and	lipids.16-17	A	host	of	non-standard	cases	can	also	be	investigated,	thanks	in	part	to	the	development	of	 intrinsically	disordered	 protein	 (IDP),	 non-canonical	 amino	 acid	 (NCAA),	phosphorylated	 amino	 acids,	 and	 post-translational	 modified	 (PTM)	 force	 fields.18-22	 At	present,	no	force	field	exists	that	is	capable	of	modeling	a	PPant	group	bound	to	a	protein.	Performing	 MD	 simulations	 on	 this	 class	 of	 systems	 requires	 parameterization	 of	 the	pantetheine	moiety	and	its	relatively	large	bound	intermediates	each	time,	thus	reducing	the	computational	 accessibility	 to	 potentially	 critical	 information	 on	 protein-protein	 and	protein-substrate	 interactions.11,	15,	23	Parameterization	of	 ligands	 is	often	straightforward	and	common	practice	in	molecular	modeling	applications;	however,	non-standard	residues,	such	 as	 a	 phosphopantetheinyl-serine	 embedded	 in	 a	 protein,	 require	 extra	parameterization	and	care.	Furthermore,	pantetheine	 is	relatively	 flexible	and	moderately	sized	 at	 40	 atoms,	 and	 Coenzyme	 A	 or	 phosphopantetheinyl-serine	 compounds	 are	 at	minimum	 80	 or	 52	 atoms,	 respectively.	 A	 parameterization	 scheme	 utilizing	 modular	splitting	was	employed,	resulting	in	a	fragmentation	strategy	that	allowed	for	construction	of	 a	 library	 of	many	 compounds	 including	 biosynthetic	 starter	 units,	 extender	 units,	 and	intermediate	units	(Fig	2-1).		Here	we	report	a	pantetheine	force	field	(PFF)	built	specifically	to	 model	 and	 simulate	 pantetheine-bound	 biosynthetic	 intermediates	 either	 as	 a	phosphopantetheinyl-serine	side	chain	or	as	a	standalone	Coenzyme	A.	MD	and	many	other	computational	approaches	rely	on	the	availability	and	quality	of	force	 fields	 to	 build	 and	 design	 models,	 and	 the	 current	 lack	 of	 a	 publicly-available	
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pantetheine	force	field	restricts	current	and	future	research	in	the	area	of	natural	product	biosynthesis	 as	 evidenced	 by	 the	 limited	 number	 of	 published	MD	 simulations	 on	 these	systems.11,	 15,	 23-29	 Here,	 we	 present	 	 a	 PFF	 library	 with	 41	 compounds,	 as	 well	 as	 a	nomenclature	scheme	compatible	with	the	Protein	Data	Bank	(Table	2-1).	This	library	will	have	a	significant	impact	on	modelers,	engineers	and	experimentalists	who	wish	to	conduct	MD	simulations	of	any	enzyme	that	requires	PPant	as	a	cofactor.			 	
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Figure	2-1.	The	parameterization	scheme	employed	in	the	development	of	the	PFF	involved	modular	splitting.	A)	CoA	compounds	were	constructed	using	six	smaller	 fragments,	with	fragment	6	providing	the	structural	diversity	 in	 the	CoA	 library.	CoA	bound	starter	units,	extender	 units	 and	 intermediates	 can	 be	 modeled	 with	 the	 above	 library.	 B)	 The	phosphopantetheinyl-serine	library	was	constructed	using	five	smaller	fragments,	with	the	structural	diversity	generated	by	the	fragment	5.	This	library	serves	to	model	starter	units,	extender	 units,	 and	 intermediates	 bound	 to	 a	 phosphopantetheinyl-serine	 as	 a	 thioester	incorporated	 in	an	ACP	or	PCP.	 	C)	The	 fragmentation	strategy	allows	the	possibility	of	a	future	 expansion	 including	 amino	 acid	 adenylates,	 allowing	 the	 incorporation	 of	proteinogenic	 or	 non-canonical	 amino	 acids	 as	 shown	 above.	 The	 library	 can	 be	 simply	constructed	from	three	fragments,	with	fragment	9	providing	structural	diversity.		
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Table	2-1.	Residues	present	in	the	pantetheine	force	field	(PFF)	
	 	
PFF ID Library Entry ID PDB Ligand ID Structures in PDB
C01 Coenzyme A COA 459
C02 acetyl-CoA ACO 177
C03 malonyl-CoA MLC 11
C04 acetoacetyl-CoA CAA 30
C05 propionyl-CoA 1VU 9
C06 butyryl-CoA BCO 8
C07 hexanoyl-CoA HXC 10
C08 octanoyl-CoA CO8 9
C09 decanoyl-CoA MFK 4
C10 dodecyl-CoA DCC 6
C11 tetradecanoyl-CoA MYA 54
C12 2-oxopentadecyl-CoA NHW 19
C13 4-hydroxyphenacyl-CoA 4CO 10
C14 carboxymethyl-CoA CMC 10
C15 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) HMG 9
C16 crotonyl-CoA COO 7
C17 oxidized-CoA CAO 7
C18 methylmalonyl-CoA MCA 5
C19 3-hydroxybuatonyl-CoA 3HC 5
C20 benzoyl-CoA BYC 4
C21 stearoyl-CoA ST9 4
C22 acetyltryptamine-CoA COT 4
C23 persulfide-CoA COS 4
C24 phenAcyl-CoA 0FQ 3
C25 4-hydroxybenzoyl-CoA BCA 3
C26 isovaleryl-CoA IVC 4
C27 p -coumaroyl-CoA WCA 3
C28 N ''-(2-coenzyme A)-popanoyl-lysine LYX 3
C29 2-oxopropyl-CoA SOP 3
C30 S-(2-oxo)pentadecyl-CoA NHM 3
PFF ID Library Entry ID PDB Ligand ID Structures in PDB
S01 4'-phosphopantetheinyl serine PNS 44
S02 acetyl- 6VG 1
S03 propionyl- - -
S04 butyryl- PSR 2
S05 hexanoyl- PM4, SXH 3
S06 octanoyl- SXO 2
S07 decanoyl- PM8 1
PFF ID Library Entry ID PDB Ligand ID Structures in PDB
X01 4'-phosphopantetheine PNS 44
X02 S-acetyl-phosphopantetheine 6VG 1
PFF ID Library Entry ID PDB Ligand ID Structures in PDB
P01 pantetheine PNY 2
P02 S-acetyl-pantetheine - -
Coenzyme A (CoA) Library
Phosphopantetheinyl (PPant) Serine Library
Phosphopantetheine Library
Pantetheine Library
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2.3 Results	and	Discussion	The	biosynthesis	of	 fatty	acids,	polyketides	and	nonribosomal	peptides	utilizes	an	assortment	of	building	blocks,	but	at	their	core	is	the	shared	pantetheine	moiety.	A	force	field	was	generated	of	these	pantetheine	derivatives,	including	information	on	partial	charges	for	each	 atom	 as	 well	 as	 their	 bond	 parameters.	 All	 of	 the	 members	 of	 the	 force	 field	 are	compatible	with	the	Amber	ff14SB,	GAFF	and	LIPID17	forcefields.16-17,	30-31	The	purpose	of	the	pantetheine	force	field	is	to	provide	anyone	who	wishes	to	conduct	MD	simulations	of	these	 megasynthases	 with	 appropriate	 parameters,	 which	 in	 turns	 improves	 the	understanding	of	how	PKSs,	NRPSs,	 and	FASs	biosynthesize	 complex	bioactive	molecules	and	how	protein-substrate	and	protein-protein	interactions	can	affect	product	generation.	It	is	the	authors’	hope	that	this	tool	will	help	to	provide	much-needed	insight	to	successfully	engineer	 these	 systems	 for	 product	 exploitation.	 At	 the	 time	 of	 this	writing,	 a	 search	 on	PubMed	revealed	~26,800	publications	with	the	words	“molecular	dynamics”	in	conjunction	with	 “enzyme”	 or	 “protein.”	 A	 search	 for	 “molecular	 dynamics”	 with	 “Coenzyme	 A,”	“polyketide,”	or	“pantetheine”	revealed	only	62,	18	and	3	publications	respectively.	This	is	surprising	considering	that	4%	of	enzymes	utilize	 the	cofactor	Coenzyme	A.32	The	 lack	of	work	for	MD	studies	of	PKS	is	directly	linked	to	the	lack	of	PPant	force	field	library;	therefore,	outcomes	 from	 this	work	 can	 have	 a	 significant	 impact	 in	 facilitating	 PKS	 researchers	 to	conduct	MD	simulations	of	PKSs.		
2.3.1 A	new	force	field	for	the	study	of	pantetheine-containing	compounds	The	 electrostatic	 potential	 which	 serves	 as	 the	 basis	 in	 RESP	 charge	 fitting	 is	dependent	 on	 the	 geometry	 of	 the	 compound.	 Large,	 flexible	 molecules	 easily	 produce	
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unwanted	intramolecular	interactions,	resulting	in	a	bias	in	the	charge	fitting	step.	To	reduce	this	bias,	 a	 fragmentation	approach	was	employed.	This	 library	of	 compounds	provides	a	consistent	 charging	 scheme	 built	 on	 a	 modular	 approach.	 This	 approach	 was	 deemed	necessary	due	primarily	to	the	flexibility	and	relatively	large	size	of	the	pantetheine	moiety	itself.	 Indeed,	 it	 is	 common	 for	 primed	 Coenzyme	 A	 and	 phosphopantetheinyl-serine	compounds	to	achieve	sizes	greater	than	200	atoms.33				
2.3.1.1 Compound	names,	residue	names,	and	atom	names	nomenclature	When	possible,	atom	names	were	assigned	using	the	same	atom	and	residue	names	as	found	in	the	protein	data	bank	(PDB).	The	unloaded	variants	of	Coenzyme	A	(Ligand	ID:	COA)	and	phosphopantetheinyl-serine	(Ligand	ID:	PNS)	were	the	most	common	with	459	and	44	entries	present,	respectively.	There	are	100	Coenzyme	A	compounds	present	in	the	PDB	 (Table	S2-2),	 and	 the	 thirty	most	 common	compounds	were	 included	 in	our	 library	(present	in	887	of	979	or	90.6%	of	structures).			
2.3.1.2 Restrained	 electrostatic	 potential	 charges	 derived	 for	 41	 pantetheine-
containing	compounds	Partial	charges	were	calculated	 for	every	atom	present	 in	 the	 force	 field	using	the	restrained	 electrostatic	 potential	 (RESP)	method	 utilized	 for	 the	majority	 of	 force	 fields	developed	 for	AMBER.34	RESP	charges	were	 calculated	 for	each	 fragment	with	 intra-	 and	intermolecular	charge	constraints	applied	to	ensure	integer	charges	for	each	member	in	the	library	 using	 the	 R.E.D.	 Development	 Server.35	 Partial	 charges	 for	 phosphopantetheinyl-serine	were	calculated	with	Ψ	specified	as	the	mean	value	present	across	structures	in	the	
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PDB	at	-40	degrees	(Fig	2-2).	During	the	charge	fitting	step,	charges	were	compared	between	individual	fragments	and	the	final	conjoined	compounds.	Partial	charges,	atom	names,	and	atom	 types	 for	Coenzyme	A,	Acetyl	CoA	and	phosphopantetheinyl-serine	are	provided	 in	tabular	 form	 (Table	 2-2).	 Differences	 in	 charges	 were	 investigated	 for	 both	 primary	compounds,	and	only	four	out	of	80	atoms	on	Coenzyme	A	had	a	difference	greater	than	0.07.	O3B	on	 fragment	1,	C3B	on	 fragment	2,	C9P	on	 fragment	4,	 and	N4P	on	 fragment	6	had	differences	of	0.0878,	0.0973,	0.0952,	and	0.0867,	respectively.	Four	atoms	having	charges	greater	 than	0.07	but	 less	 than	0.15	were	considered	acceptable	based	on	other	modular	splitting	approaches.17	The	 splitting	approach	was	primarily	performed	at	peptide	bonds	with	acetyl	and	N-methyl	groups,	or	alternatively	at	methylene	groups	with	methyl	caps.			 	
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Figure	2-2.	Φ/Ψ	values	of	covalently	bound	pantetheine	from	the	protein	data	bank	(PDB)	for	a	total	of	644	data	points	(17	NMR	solution	structures,	50	X-ray	crystal	structures,	and	2	cryo-EM	structures).	All	pantetheine	moieties	were	covalently	bound	to	a	serine	residue.	All	cryo-EM	and	X-ray	crystallographic	structures	present	in	the	protein	data	bank	(PDB)	have	Φ	and	Ψ	angles	characteristic	of	an	alpha-helix.	All	covalently	bound	phosphopantetheine	moieties	present	in	the	PDB	are	bound	to	a	serine	residue	nested	in	an	alpha-helix.	
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Table	2-2.	Atom	names,	atom	types,	and	partial	charges	of	phosphopantetheine,	Coenzyme	A	and	acetyl	CoA	from	the	Protein	Data	Bank.	
	
	 	
Atom 
Name
Atom 
Type
RESP 
Charge
Atom 
Name
Atom 
Type
RESP 
Charge
Atom 
Name
Atom 
Type
RESP 
Charge
Atom 
Name
Atom 
Type
RESP 
Charge
Atom 
Name
Atom 
Type
RESP 
Charge
C28 CI -0.0978 C1B  CT  0.0391 O8A  O2  -0.913 C1   C  0.4691 O8A  O2 -0.9135
C29 CT 0.301 C2A  CQ  0.5694 O9A  O2  -0.913 C1B  CT 0.0385 O9A  O2 -0.9135
C30 CT -0.2278 C2B  CT  0.1678 O9P  O   -0.5405 C2   CT -0.116 O9P  O  -0.5411
C31 CT -0.2278 C2P  CT  0.0282 OAP  OH  -0.6319 C2A  CQ 0.5688 OAP  OH -0.6324
C32 CT 0.1051 C3B  CT  -0.016 P1A  P   1.1583 C2B  CT 0.1673 P1A  P  1.1578
C34 C 0.5484 C3P  CT  -0.0979 P2A  P   1.1548 C2P  CT 0.2306 P2A  P  1.1542
C37 CT 0.0864 C4A  CB  0.234 P3B  P   1.2248 C3B  CT -0.0165 P3B  P  1.2243
C38 CT -0.1466 C4B  CT  0.1681 S1P  SH  -0.3678 C3P  CT -0.0361 S1P  SS -0.3142
C39 C 0.5494 C5A  CB  0.1214 H1B  H2  0.1962 C4A  CB 0.2335 H1B  H2 0.1957
C42 CT 0.0954 C5B  CT  0.0588 H21  H1  0.082 C4B  CT 0.1675 H21  HC 0.0647
C43 CT -0.0506 C5P  C   0.5358 H22  H1  0.082 C5A  CB 0.1209 H22  HC 0.0647
N36 N -0.3856 C6A  CA  0.6739 H2A  H5  0.0497 C5B  CT 0.0583 H2A  H5 0.0491
N41 N -0.513 C6P  CT  -0.063 H2B  H1  0.0962 C5P  C  0.5292 H2B  H1 0.0956
O23 OS -0.309 C7P  CT  0.0103 H31  H1  0.1088 C6A  CA 0.6733 H2P2 H1 0.0114
O25 O2 -0.7796 C8A  CK  0.1404 H32  H1  0.1088 C6P  CT -0.0603 H2P3 H1 0.0114
O26 O2 -0.7796 C9P  C   0.5056 H3B  H1  0.0955 C7P  CT 0.0103 H3B  H1 0.0949
O27 OS -0.4904 CAP  CT  -0.02 H4B  H1  0.1748 C8A  CK 0.1398 H3P1 H1 0.0845
O33 OH -0.6121 CBP  CT  0.2119 H4P  H   0.2728 C9P  C  0.5051 H3P2 H1 0.0845
O35 O -0.557 CCP  CT  -0.0476 H5B2 H1  0.0613 CAP  CT -0.0206 H4B  H1 0.1743
O40 O -0.5125 CDP  CT  -0.0679 H5B3 H1  0.0613 CBP  CT 0.2114 H4P  H  0.2945
P24 P 1.1792 CEP  CT  -0.1908 H6A1 H   0.4135 CCP  CT -0.0482 H5B2 H1 0.0608
S44 SH -0.3519 N1A  NC  -0.7406 H6A2 H   0.4135 CDP  CT -0.0684 H5B3 H1 0.0608
H281 H1 0.0932 N3A  NC  -0.6578 H6P2 HC  0.0508 CEP  CT -0.1914 H6A1 H  0.4129
H282 H1 0.0932 N4P  N   -0.4577 H6P3 HC  0.0508 N1A  NC -0.7412 H6A2 H  0.4129
H301 HC 0.0501 N6A  N2  -0.924 H7P2 H1  0.0648 N3A  NC -0.6584 H6P2 HC 0.0496
H302 HC 0.0501 N7A  NB  -0.6035 H7P3 H1  0.0648 N4P  N  -0.4748 H6P3 HC 0.0496
H303 HC 0.0501 N8P  N   -0.4511 H8A  H5  0.1885 N6A  N2 -0.9245 H7P2 H1 0.064
H311 HC 0.0501 N9A  N*  0.0091 H8P  H   0.264 N7A  NB -0.604 H7P3 H1 0.064
H312 HC 0.0501 O1A  O2  -0.8236 HAP  H1  0.1301 N8P  N  -0.4513 H8A  H5 0.1879
H313 HC 0.0501 O2A  O2  -0.7724 HCP2 H1  0.076 N9A  N* 0.0086 H8P  H  0.2635
H32 H1 0.0524 O2B  OH  -0.6376 HCP3 H1  0.076 O1   O  -0.4397 HAP  H1 0.1296
H33 HO 0.3885 O3A  OS  -0.4671 HDP1 HC  0.019 O1A  O2 -0.8242 HC21 HC 0.0647
H36 H 0.229 O3B  OS  -0.6292 HDP2 HC  0.019 O2A  O2 -0.7729 HCP2 H1 0.0754
H371 H1 0.0422 O4A  O2  -0.7729 HDP3 HC  0.019 O2B  OH -0.6381 HCP3 H1 0.0754
H372 H1 0.0422 O4B  OS  -0.393 HEP1 HC  0.0521 O3A  OS -0.4676 HDP1 HC 0.0185
H381 HC 0.0701 O5A  O2  -0.8224 HEP2 HC  0.0521 O3B  OS -0.6297 HDP2 HC 0.0185
H382 HC 0.0701 O5B  OS  -0.5054 HEP3 HC  0.0521 O4A  O2 -0.7734 HDP3 HC 0.0185
H41 H 0.3043 O5P  O   -0.522 HO2B HO  0.4333 O4B  OS -0.3935 HEP1 HC 0.0515
H421 H1 0.0692 O6A  OS  -0.5025 HOAP HO  0.4252 O5A  O2 -0.8229 HEP2 HC 0.0515
H422 H1 0.0692 O7A  O2  -0.913 HS1  HS  0.2007 O5B  OS -0.506 HEP3 HC 0.0515
H431 H1 0.0826 O5P  O  -0.5214 HO2B HO 0.4328
H432 H1 0.0826 O6A  OS -0.503 HOAP HO 0.4246
H44 HS 0.187 O7A  O2 -0.9135
PDB Ligand ID: PNS PDB Ligand ID: ACOPDB Ligand ID: COA
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2.3.1.3 Force	field	parameters	Parameters	were	obtained	from	the	AMBER	ff14SB	force	field	when	available.	Missing	parameters	 were	 adopted	 from	 the	 General	 Amber	 Force	 Field	 (GAFF)	 to	 serve	 as	 a	preliminary	parameter	set	to	newly	defined	atom	types	as	was	done	in	the	initial	LIPID	11	force	field.17	Forcefield_NCAA,	another	AMBER	force	field,	utilized	a	similar	approach	with	no	additional	parameterization,	highlighting	the	promise	of	such	an	initial	approach	for	force	field	development.19		New	atom	types	were	assigned	for	these	existing	force	constants	and	equilibrium	values	(Table	2-3)	such	that	they	can	be	easily	revised	in	future	investigations	while	maintaining	compatibility	with	existing	force	fields.			
Table	2-3.	Bond,	angle	and	dihedral	parameters,	and	atom	types.		
	 	
Atom Type mass pol Notes
SS 32.06 2.9 gaff2.dat (ss) thio-ester/thio-ether sp3 sulfur
Bond K (kcal mol-1 ang -2) Dist0 (ang) Notes
C -SS 204.39 1.783 gaff2.dat (c -ss: 1.800) [MP2/aug-cc-PVTZ: 1.78293]
CT-SS 182.96 1.811 gaff2.dat (c3-ss: 1.839) [MP2/aug-cc-PVTZ: 1.81073]
HS-S 294.59 1.337 gaff2.dat (hs-sh: 1.347) [MP2/aug-cc-PVTZ: 1.33612]
Angle K (kcal mol-1 rad -2) Theta0 (deg) Notes
C -CT-C 65.424 111.63 gaff2.dat (c -c3-c : 111.630) 
C -CT-OH 85.627 108.79 gaff2.dat (c -c3-oh: 108.790)
C -SS-CT 71.828 104.271 gaff2.dat (c -ss-c3:  99.160) [MP2/aug-cc-PVTZ: 104.271]
CT-CT-SS 63.222 113.075 gaff2.dat (c3-c3-ss: 110.270) [MP2/aug-cc-PVTZ: 113.075]
CT-C -SS 63.438 118.576 gaff2.dat (c3-c -ss: 113.510) [MP2/aug-cc-PVTZ: 118.576]
CT-S -SH 51.361 97.417 gaff2.dat (c3-sh-hs:  96.400) [MP2/aug-cc-PVTZ: 97.417]
H1-CT-SS 42.463 105.425 gaff2.dat (h1-c3-ss: 108.760) [MP2/aug-cc-PVTZ: 105.425]
O -C -SS 79.009 117.999 gaff2.dat (o -c -ss: 123.320) [MP2/aug-cc-PVTZ: 117.999]
Dihedral Path V(kcal mol2-1 rad-1) Phase Period Notes
C -SS-CT-CT 3 1 0 3 gaff2.dat (X -c3-ss-X: 3 1.0 0.0 3.0)
C -SS-CT-H1 3 1 0 3 gaff2.dat (X -c3-ss-X: 3 1.0 0.0 3.0)
CT-SS-C -CT 1 2.1 180 2 gaff2.dat (c3-ss-c -c3: 1 2.1 180.0 2)  
X -SS-C -X 2 6.2 180 2 gaff2.dat (X -ss-c -X: 2 6.2 180.0 2)    
CT-SS-C -O 2 6.2 180 2 gaff2.dat (X -ss-c -X: 2 6.2 180.0 2)  
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2.3.2 Validation	Existing	parameters	and	new	calculated	partial	charges	were	validated	by	performing	normal	 mode	 analysis.	 Root	 mean	 square	 fluctuations	 (RMSF)	 of	 a	 simulation	 using	Coenzyme	A	were	compared	to	B-factors	present	in	a	crystal	structure,	and	root	mean	square	deviation	(RMSD)	values	of	the	individual	fragments	of	the	molecular	mechanics	optimized	structures	were	compared	to	optimized	electronic	structure	calculations.			
2.3.2.1 Comparison	of	optimized	structures	The	compound	structures	were	optimized	by	Gaussian	and	compared	to	experimental	values	for	missing	parameters.36	The	use	of	Mg2+	and	Na+	counterions	were	employed	to	find	consistent	agreement	with	experimental	values	as	was	shown	by	Schneider	et	al	(Table	S2-4).37	The	appropriate	basis	set	to	match	MP2/aug-cc-pVTZ	and	experimental	values	using	the	B3LYP	functional	was	found	to	be	6-311+G(2d,p).	Additional	diffuse	and	polarizable	basis	functions	were	needed	to	find	good	agreement	with	the	O-P	bond	lengths	and	angles	of	the	phosphate	groups.	The	RMSD	between	QM	and	MM	optimized	fragments	ranged	from	0.072	and	 0.606.	 The	methylphosphate	 and	 dimethylphosphate	 fragments	 had	 RMSD	 values	 of	0.0726	 and	 0.0982,	 respectively,	 between	 the	 AMBER	 minimized	 fragments	 and	 the	MP2/aug-cc-pVTZ	optimized	fragments.	The	relatively	high	RMSD	of	0.606	Å	was	observed	in	adenosine	due	to	the	C-N-C-O	torsion.	This	parameter	was	previously	fit	for	the	AMBER	ff14SB	force	field;	therefore,	it	was	considered	acceptable.		
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Figure	 2-3.	 Normal	 mode	 frequency	 calculations	 were	 performed	 using	 B3LYP/6-311+G(2d,p),	MP2/aug-cc-pVDZ	and	MP2/aug-cc-pVTZ	levels	of	theory.	A	low	mode	search	was	performed	using	the	Amber	ff14SB	forcefield	with	additional	phosphopantetheine	force	field	(PFF)	parameters.			
2.3.2.2 Normal	mode	analysis	Normal	mode	frequencies	were	obtained	in	AMBER	using	a	low	mode	search	as	well	as	 from	 electronic	 structure	 calculations	 (Fig.	 2-3).	 Calculations	 were	 performed	 at	 the	B3LYP/6-311+G(2d,p)	 and	 MP2/aug-cc-pVDZ	 levels	 of	 theory	 for	 all	 the	 fragments.	Fragments	 containing	 parameters	 which	 were	 adopted	 from	 GAFF,	 utilized	 additional	electronic	structure	calculations	performed	at	the	MP2/aug-cc-PVTZ	level	of	theory	to	match	the	 level	of	 theory	used	 in	the	Forcefield_NCAA,	 ff03,	 and	Amber	FB15	force	 fields.19,	38-40	Projections	 of	 normal	modes	 agreed	well	 between	Amber	 and	Gaussian.	 The	 frequencies	
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observed	in	the	450-1100	cm-1	range	include	C-O	and	O-P	bond-stretching,	O-P-O	twisting,	O-P-O	wagging,	and	O-P-O	scissoring.	The	GAFF	parameters	were	in	good	agreement	and	able	to	 reproduce	 the	 normal	modes	 for	 this	 range.	 To	 perform	normal	mode	 analysis	on	 the	thioester	portion,	an	S-methyl	thioacetate	fragment	was	generated.	S-C	bond	stretching	was	observed	at	645	and	749	cm-1,	O-C-S	scissoring	observed	at	439	cm-1,	and	the	characteristic	intense	carbonyl	stretch	for	thioesters	at	1720	cm-1	at	the	MP2/aug-cc-pVTZ	level	of	theory.			
2.3.2.3 Robustness	of	parameters	over	relatively	long	simulations	An	aminoglycoside	N3-acetyltransferase,	BA2930,	was	selected	as	a	system	to	study	the	robustness	of	adopted	phosphate	parameters	from	GAFF.	A	crystal	structure	containing	Coenzyme	 A	 (PDB	 ID:	 3IJW)	 was	 used	 as	 a	 starting	 structure.	 A	 200	 ns	 simulation	was	performed	with	the	final	20	ns	used	to	generate	an	average	structure	(Fig	2-4).	The	RMSD	of	the	 active	 site	 residues	 and	 Coenzyme	 A	 of	 the	 average	 structure	 was	 0.821	 Å,	 and	 all	hydrogen	 bonds	 and	 electrostatic	 interactions	 observed	 in	 the	 crystal	 structure	 were	observed	 in	 the	 average	 structure	 generated	 from	 MD.	 RMSFs	 for	 alpha	 carbons	 were	measured	over	the	 final	20	ns	of	 the	simulation	(Fig	2-5).	Normalized	RMSF	and	B-factor	values	 were	 in	 relatively	 good	 agreement,	 with	 the	 similar	 fluctuations	 observed	 in	 MD	compared	to	the	X-ray	crystallographic	experiment.		
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Figure	2-4.	Comparison	between	X-ray	structure	(PDB	ID:	3IJW)	and	a	representative	frame	of	the	largest	cluster	of	the	final	20	ns	of	the	200	ns	MD	simulation	performed	on	BA2930	using	the	pantetheine	force	field.	The	average	RMSD	for	active	site	residues	and	Coenzyme	A	was	0.821,	and	the	RMSD	between	the	frame	above	compared	to	the	X-ray	structure	was	0.778.	Active	site	contacts	of	the	MD	structure	are	in	consistent	agreement	with	the	X-ray	structure.		
 51 
	
Figure	2-5.	RMSFs	for	alpha	carbons	were	measured	over	the	final	20	ns	of	the	simulation.	Alpha	carbon	RMSFs	and	B-factors	were	normalized.	Active	site	residues	are	shown	in	grey.			
2.3.3 Phosphopantetheine	Force	Field	(PFF)	website	interface	A	website	to	host	the	pantetheine	force	field	(http://www.irvineforcefields.org/)	has	been	 developed	 (Fig.	 2-6).	 Contained	 on	 the	website	 are	 four	 libraries	 of	 force	 fields	 for	Coenzyme	 A,	 phosphopantetheinyl-serine,	 phosphopantetheine	 and	 pantetheine	compounds.	A	parameter	modification	file	with	all	necessary	bond	parameters,	a	library	file	with	all	structures	and	charges,	and	a	LEaP	configuration	file	that	defines	atom	types	for	all	compound	are	also	present.	Every	 individual	compound	 is	present	on	the	 force	 field	page	
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along	with	their	corresponding	Cartesian	coordinates	and	RESP	charges	stored	in	the	AMBER	prep	and	Tripos	Mol2	file	formats.		An	all-encompassing	force	field	can	be	downloaded	from	the	website	free	of	charge	and	includes	 a	 parameter	modification	 file	with	 all	 necessary	 bond	 parameters,	 a	 library	 file	containing	all	structures	with	 their	 respective	 charges,	 and	a	LEaP	configuration	 file	 that	defines	atom	types	for	all	the	compounds.	In	conclusion,	this	work	paved	the	foundation	for	future	researchers	wishing	to	conduct	MD	simulations	of	mega-synthases	such	as	FAS,	PKS	and	NRPS.	
 
Figure 2-6. The pantetheine force field (PFF) can be found at the Irvine Force Fields website 
(http://www.irvineforcefields.org/). Contained on the website are Tripos mol2 files containing 
Cartesian coordinates and restrained electrostatic potential (RESP) charges for every compound. 
These structures include the same atom names as present in the Protein Data Bank for increased 
compatibility. These structures can be used for MD simulations, or as part of docking studies. A 
LEaP configuration file, parameter modification file and library file contained on the website 
provides all the necessary charges and parameters to model and simulate structures. 
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2.3.4 Methods	
2.3.5 Parameterization	strategy	
A fragmentation approach was utilized which provided a degree of modularity to the force 
field while at the same time reducing the size, complexity and degrees of freedom during the 
charge fitting and parameterization steps. When possible, bond parameters were assigned using 
the parameter databases present in the Amber ff14SB, the primary protein and nucleic acid force 
fields in AMBER.16-17 As these primary parameter databases are not all inclusive, missing 
parameters were preliminarily adopted from GAFF.30 Gaussian 09 was used to optimize the 
geometries of the fragments using density functional theory with the B3LYP functional at the 6-
311+G(2d,p) level of theory.36 Parameters obtained from geometry optimizations were compared 
to values present in the existing AMBER force fields, as well as those present in existing 
experimentally derived structures. 
	
2.3.5.1 Procedure	for	derivation	of	partial	charges	
Fragments were capped with acetyl, N-methyl, methyl, and/or hydroxyl caps which 
mimicked the natural neighboring chemical environment of the fragments. The R.E.D. 
Development Server was used for charge fitting of the fragments.35  A two-step restricted 
electrostatic potential (RESP) fitting strategy used in other AMBER force fields was employed to 
derive partial charges. The electrostatic potential was calculated using Gaussian 09 with the HF/6-
31G(d,p) level of theory. Intramolecular charge constraints were applied on the non-standard 
residues, forcing an integer charge on the central intramolecular fragment. Fragments were stitched 
together through the use of intermolecular charge constraints, which were applied between 
corresponding caps on connecting fragments.  
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2.3.5.2 Procedure	 for	 derivation	 of	 missing	 bond,	 angle,	 and	 dihedral	 angle	
parameters	
Existing bond parameters in the Amber ff14SB force fields were used where possible to 
ensure compatibility with existing force fields. Missing parameters were adopted from GAFF and 
compared to experimental measurements and electronic structure calculations. Electronic structure 
calculations were performed using MP2/aug-cc-pVTZ level of theory, with Na+ counterions 
present to achieve measurements in agreement with experimental values.37 
 
2.3.5.3 Pantetheine	parameters	
Atom names of the pantetheine moiety were matched to PDB ligand ID PNY.41 The 
pantetheine unit was fragmented into three modules during parameterization: cysteamine linker 
(6), providing the thiol responsible for loading, ß-alanine (5), and pantoic acid (4).42 Fragment 4 
is capable of existing by itself, or connected to a mono- or di-phosphate species. The cysteamine 
linker was modeled as the free thiol, or the S-acetyl cysteamine species to mimic the acetyl unit. 
Di-fragments capable of representing several chemical environments were capped and optimized. 
Intramolecular and intermolecular charge restraints were applied, and RESP charges were fit using 
the method described previously. 
 
2.3.5.4 Phosphopantetheine	parameters	
Atom names of the phosphopantetheine moiety were matched to PDB ligand ID PNS. 
Fragment 4 was modeled with a connecting mono-phosphate group (8). Fragment 8 was capped 
with a methyl cap to mimic a covalent linkage to a serine moiety. Intra- and inter-molecular charge 
restraints were applied, and RESP charges fit using the method described previously. 
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2.3.5.5 Coenzyme	A	parameters	
A chemical component search was performed using PDB ligand ID COA as the initial 
substructure. A table containing 100 coenzyme A compounds was generated from the PDB, 
covering a total of 979 structures (Table S2-2). A coenzyme library was generated for the 30 CoA 
compounds with three or more structures present in the PDB, representing 91% of all PDB 
structures containing a CoA compound. CoA entries present in the pantetheine force field (PFF) 
have atom names and residue names matched to those present in the PDB. Three fragments 
representing a methyl phosphate (1), adenosine (2), and dimethyl diphosphate (3) were joined to 
the ß-alanine (5), and pantoic acid (4) fragments of pantetheine. An acetyl cap was added to 
fragment (5). Thirty cysteamine linker fragments were generated and capped with N-methyl caps. 
Intramolecular and intermolecular charge restraints were applied, and RESP charges fit using the 
method described previously. 
 
2.3.5.6 Phosphopantetheinyl-serine	parameters	
Care was taken during the optimization of the phosphopantetheinyl serine residue, with the 
Ψ dihedral being fixed to -40.0 degrees, while imposing no restriction on the Φ dihedral to match 
experimental data collected from the Protein Data Bank. 
 
2.3.6 Validation	of	parameters	
The pantetheine force field was validated by comparison of normal-mode frequencies, 
comparison of QM and MM structures, and comparison of root mean square fluctuations in MD 
samples to B-factor values from crystallographic experiments.  
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2.3.6.1 Normal	mode	analysis	
The quality of utilizing existing force field parameters from ff14SB and GAFF was 
measured through the distribution of normal modes. Experimentally derived parameters for 
phosphate geometry in the presence of various metal cations was used to benchmark and compare 
electronic structure calculations.37 Second order Møller–Plesset perturbation theory (MP2) with 
an augmented version of the correlation-consistent triple-zeta (aug-cc-pVTZ) basis set was used. 
It was found that the B3LYP functional with the 6-311+G(2d,p) basis set was in close agreement 
to MP2/aug-cc-pVTZ. Normal modes were obtained through electronic structure calculations at 
B3LYP/6-311+G(2d,p), MP2/aug-cc-pVDZ and MP2/aug-cc-pVTZ level of theory. Optimized 
fragments from electronic structure calculations were used as starting structures in Amber, and 
were minimized using the pantetheine force field. A low mode search was performed using 
Kolossváry’s algorithm implemented in AMBER in order to obtain the normal mode frequencies.43 
The RMSD between QM and MM optimized fragments ranged from 0.072 and 0.606.  
 
2.3.6.2 Molecular	dynamics	simulations	on	BA2930	
MD was carried out using AMBER 16.44 The structure of BA2930, an aminoglycoside N-
acetyltransferase, bound to Coenzyme A was acquired from the PDB (PDB ID: 3IJW), and 
prepared for MD using the program UCSF Chimera.45-46 Charges and parameters for the amino 
acids were used from the AMBER ff14SB force field, and charges and parameters for Coenzyme 
A were obtained from the force field described in this research report. LEaP was used to add 
hydrogens, neutralize the system through the addition of 10 Na+ ions, and solvation of the system 
in a 10-Å water buffer TIP3P truncated octahedron box. Using the program SANDER, the system 
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was subjected to a two-step minimization process to remove any steric clashes present in the initial 
crystal structure. The first step of minimization was carried out over 5,000 steps for the solvent 
and ions, with the protein and Coenzyme A restrained by a force constant of 500 kcal/mol/Å2, 
followed by a second stage of minimization with no restraints. Using a Langevin temperature 
equilibration scheme, the system was heated to 298 K using the NVT ensemble over 1 ns with 
weak 10 kcal/mol/Å2 restraints on the protein and Coenzyme A. Then, the system was equilibrated 
using the NPT ensemble for 3 ns. Periodic boundary conditions were used, and hydrogens were 
restrained using the SHAKE algorithm. The simulation was run over 200 ns. The final 20 ns was 
used to generate an average structure, which was subsequently minimized. The average structure 
had an RMSD of 0.821 compared to the crystal structure. 
 
2.3.6.3 B-factor	comparisons	
Using the program CPPTRAJ, root mean square fluctuations (RMSFs) were measured on 
the final 20 ns of the simulation.47 RMSF values from the MD simulation, and B-factors from the 
crystal structure were normalized and compared. Normalized RMSF and B-factor values for active 
site residues in contact with Coenzyme A were in close agreement.  
	
2.4 	Conclusions	and	future	directions	This	chapter	presented	a	new	force	 field	to	describe	41	compounds,	either	as	CoA	analogs,	or	covalently	attached	to	a	serine	residue	on	a	carrier	protein.	This	 force	 field	 is	compatible	with	the	PDB	and	adopted	a	similar	naming	scheme.	This	force	field	provides	an	initial	 framework	 for	 performing	 MD	 simulations,	 it	 has	 left	 open-ended	 the	 ability	 to	
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optimize	 existing	 parameters,	 as	 well	 as	 add	 additional	 compounds	 dependent	 on	 user	demands.	
	
2.5 	Supplementary	figures	and	tables		
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Table	S2-1.	List	of	all	PDBs	with	a	phosphopantetheine	covalently	linked	to	a	carrier	protein	
	*	This	does	not	include	apo-carrier	protein	complex	structures	(PDB	IDs:	2FHS,	2XZ0,	4DXE).	
	
PDB ID Ligand IDs Modification Native Organism Complex Notes
1F80 PN2 holo-ACP Bacillus subtilis Yes in complex with holo-ACP synthase (AcpS)
1L0I PSR butyryl-ACP Escherichia coli No I62M mutant
2FAC PM4 hexanoyl-ACP Escherichia coli No
2FAD PM5 heptanoyl-ACP Escherichia coli No
2FAE PM8 decanoyl-ACP Escherichia coli No
2X2B SXM malonyl-ACP Bacillus subtilis No
3EJB ZMP tetradecanoyl-ACP Escherichia coli Yes in complex with Cytochrome P450BioI (CYP107H1) from B. 
subtilis
3EJD ZMQ hexadec-9Z-enoyl-ACP Escherichia coli Yes in complex with Cytochrome P450BioI (CYP107H1) from B. 
subtilis
3EJE ZMO octadec-9Z-enoyl-ACP Escherichia coli Yes in complex with Cytochrome P450BioI (CYP107H1) from B. 
subtilis
3GZL PNS disulfide linked-ACP Plasmodium falciparum No disulfide linked-pfACP dimer
3GZM PNS holo-ACP Plasmodium falciparum No
3NY7 SXM malonyl-ACP Escherichia coli Yes  in complex with SLC26 anion transporter STAS domain from 
YchM
3RG2 PNS holo-PCP Escherichia coli Yes NRPS EntE adenylation domain and EntB PCP didomain complex
4BPH PNS holo-DCP Bacillus subtilis No D-alanyl carrier protein (Dcp) DltC
4DG9 DG9 valine-AVS inhibitor-PCP Pseudomonas aeruginosa Yes valine-adenosine vinylsulfonamide (Val-AVS) inhibitor 
4ETW ZMK methyl-pimeloyl-ACP Shigella flexneri Yes in complex with BioH S82A
4H2S PNS holo-aa:CP Bradyrhizobium diazoefficiens Yes in complex with an amino acid carrier protein (aa:CP) ligase
4H2T PNS holo-aa:CP Bradyrhizobium diazoefficiens Yes in complex with an amino acid carrier protein (aa:CP) ligase
4H2U PNS holo-aa:CP Bradyrhizobium diazoefficiens Yes in complex with an amino acid carrier protein (aa:CP) ligase
4H2V H2V PNS glycl-aa:CP Bradyrhizobium diazoefficiens Yes in complex with an amino acid carrier protein (aa:CP) ligase
4H2W PNS holo-aa:CP Bradyrhizobium diazoefficiens Yes in complex with an amino acid carrier protein (aa:CP) ligase from 
Agrobacterium fabrum 
4H2X PNS holo-aa:CP Bradyrhizobium diazoefficiens Yes in complex with an amino acid carrier protein (aa:CP) ligase from 
Agrobacterium fabrum 
4H2Y PNS holo-aa:CP Bradyrhizobium diazoefficiens Yes in complex with an amino acid carrier protein (aa:CP) ligase from 
Agrobacterium fabrum 
4IHF 1F7 (R)-3-hydroxytetradecanoyl-ACP Escherichia coli Yes in complex with LpxD
4IHG PNS holo-ACP Escherichia coli Yes in complex with LpxD
4IHH PNS holo-ACP Escherichia coli Yes in complex with LpxD
4IZ6 PNS DHB-AVS inhibitor-PCP Escherichia coli Yes NRPS EntE adenylation domain and EntB PCP didomain complex  
via 2,3-dihydroxybenzoate-AVS inhibitor
4KEH 1R3 sulphonyl-3-alkyne-based probe-ACP Escherichia coli Yes in complex with FabA (Type II FAS Dehydratase)
4PWV KH4 4-imidazole carboxyl-PCP Streptomyces sp. Acta 2897 Yes in complex with Cytochrome P450sky (CYP163B3) from 
Streptomyces sp. Acta 2897 
4PXH KH4 4-imidazole carboxyl-PCP Streptomyces sp. Acta 2897 Yes in complex with Cytochrome P450sky (CYP163B3) from 
Streptomyces sp. Acta 2897 
4ZJB PNS holo-ACP Helicobacter pylori Yes in complex with FabZ (Type II FAS Dehydratase)
4ZXH PNS holo-PCP Acinetobacter baumannii Yes complete holo-AB3403 NRPS module (adenylation, 
condensation, PCP and thioesterase)
4ZXI PNS holo-PCP Acinetobacter baumannii Yes complete holo-AB3403 NRPS module (adenylation, 
condensation, PCP and thioesterase)
5CZD PNS malemide-based inhibitor-ACP Streptomyces halstedii Yes in complex with acyltransferase (AT) VinK
5EJD 5PD holo-PCP Penicillium aethiopicum Yes NRPS TqaA condensation domain and PCP didomain complex
5ES8 5S4 valine-NH-PCP  Brevibacillus parabrevis Yes NRPS LgrA initiation NRPS module (formylation, adenylation, and 
PCP)
5ES9 PNS holo-PCP  Brevibacillus parabrevis Yes NRPS LgrA initiation NRPS module (formylation, adenylation, and 
PCP)
5H9H 4HH holo-ACP Helicobacter pylori No
5ISX PNS holo-PCP Brevibacillus brevis Yes NRPS GrsA epimirization domain and PCP didomain complex
5JA1 75C serine-AVS inhibitor-PCP Escherichia coli Yes NRPS EntF NRPS module bound to the MbtH-like protein (MLP) 
from E. coli
5JA2 75C serine-AVS inhibitor-PCP Escherichia coli Yes NRPS EntF NRPS module bound to the MbtH-like protein (MLP) 
from P. aeruginosa
5KP7 PNS holo-ACP Lyngbya majuscula Yes in complex with 3-hydroxy-3-methylglutaryl synthas (HMGS) CurD 
from Moorea producens 
5KP8 PNS6VG acetyl-ACP Lyngbya majuscula Yes
in complex with 3-hydroxy-3-methylglutaryl synthas (HMGS) CurD 
from Moorea producens 
5T3D 75C serine-AVS inhibitor-PCP Acinetobacter baumannii Yes complete holo-AB3403 NRPS module (adenylation, 
condensation, PCP and thioesterase)
5U89 MJ8 glycine-AVS inhibitor-PCP  Geobacillus sp. Y4.1MC1 Yes NRPS DhbF cross-modular tri-domain (MLP, adenylation, PCP 
and condenstation)
20Total Complex Papers Published*
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Table	S2-2.	List	of	all	Coenzyme	A	ligands	present	in	the	PDB	
	
Ligand Name PDB Ligand ID
Structures 
in PDB M.W.
4-Chlorophenacyl-coenzyme A 01A 1 920.11
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-oxidanyl-3-phosphonooxy-oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(3R)-2,2-dimethyl-3-oxidanyl-4-oxidanylidene-4-[[3-oxidanylidene-3-[2-[(2R)-2-oxidanylundecyl]sulfanylethylamino]propyl]amino]butyl] 
hydrogen phosphate 0ET 1 937.83
phenacyl coenzyme A 0FQ 3 885.67
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-oxidanyl-3-phosphonooxy-oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(3R)-2,2-dimethyl-3-oxidanyl-4-oxidanylidene-4-[[3-oxidanylidene-3-(4-oxidanylidenepentylamino)propyl]amino]butyl] hydrogen 
phosphate 0RQ 1 791.53
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-oxidanyl-3-phosphonooxy-oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(3R)-2,2-dimethyl-3-oxidanyl-4-oxidanylidene-4-[[3-oxidanylidene-3-(propylamino)propyl]amino]butyl] hydrogen phosphate 0T1 3 749.50
(2S)-2-({(3S,5R,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14,20-trioxo-2,4,6-trioxa-18-thia-11,15-diaza-3lambda~5~,5lambda~5~-
diphosphaicosan-20-yl}amino)pentanedioic acid (non-preferred name) 1C4 1 954.68
(3S,5S,9R,21S)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9,21-tetrahydroxy-8,8,21-trimethyl-10,14-dioxo-19-thioxo-2,4,6-trioxa-18-thia-11,15-diaza-3,5-diphosphatricosan-23-oic acid 3,5-
dioxide 1CZ 1 927.72
3-methylmercaptopropionate-CoA (MMPA-CoA) 1HE 1 869.69
propionyl Coenzyme A 1VU 9 823.60
2-CARBOXYPROPYL-COENZYME A 2CP 2 853.62
METHACRYLYL-COENZYME A 2MC 1 835.61
Salicylyl CoA 2NE 2 887.64
(3R,5S,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3,5-diphosphaheptadecane-17-sulfinic acid 3,5-dioxide (non-preferred 
name) 30N 1 799.53
3-CARBOXYPROPYL-COENZYME A 3CP 1 853.62
(S)-3-Hydroxyhexanoyl-CoA 3H9 2 877.65
3-HYDROXYBUTANOYL-COENZYME A 3HC 5 853.62
3-oxo-4-pregnene-20-carboxyl-Coenzyme A 4BN 1 1094.01
4-HYDROXYBENZYL COENZYME A 4CA 2 873.66
4-HYDROXYPHENACYL COENZYME A 4CO 10 901.67
pivalyl-coenzyme A 52O 1 851.65
(25S)-3-oxocholest-4-en-26-oyl-CoA 5JB 1 1164.14
[[(2~{S},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-4-oxidanyl-3-phosphonooxy-oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(3~{R})-4-[[3-[2-[2-[3-[[(2~{R})-4-[[[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-4-oxidanyl-3-phosphonooxy-oxolan-2-
yl]methoxy-oxidanyl-phosphoryl]oxy-oxidanyl-phosphoryl]oxy-3,3-dimethyl-2-oxidanyl-butanoyl]amino]propanoylamino]ethyldisulfanyl]ethylamino]-3-oxidanylidene-propyl]amino]-2,2-dimethyl-3-oxidanyl-4-oxidanylidene-butyl] hydrogen phosphate 5NG 1 1533.05
~{S}-[2-[3-[[(2~{R})-4-[[[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-4-oxidanyl-3-phosphonooxy-oxolan-2-yl]methoxy-oxidanyl-phosphoryl]oxy-oxidanyl-phosphoryl]oxy-3,3-dimethyl-2-oxidanyl-butanoyl]amino]propanoylamino]ethyl] 5-
[(2~{R},3~{R},5~{R},6~{S})-6-methyl-3,5-bis(oxidanyl)oxan-2-yl]oxypentanethioate 6QA 1 997.79
(2~{S})-2-[2-[3-[[(2~{R})-4-[[[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-4-oxidanyl-3-phosphonooxy-oxolan-2-yl]methoxy-oxidanyl-phosphoryl]oxy-oxidanyl-phosphoryl]oxy-3,3-dimethyl-2-oxidanyl-
butanoyl]amino]propanoylamino]ethylsulfanyl]propanoic acid 8HB 2 839.60
(3R,5S,9R,26S)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14,20-trioxo-26-({[(phenylacetyl)amino]acetyl}amino)-2,4,6-trioxa-18-thia-11,15,21-triaza-3,5-
diphosphaheptacosan-27-oic acid 3,5-dioxide (non-preferred name) 93M 1 1128.93
(3R,5S,9R,23S)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14-dioxo-23-({[(phenylacetyl)amino]acetyl}amino)-2,4,6-trioxa-18-thia-11,15-diaza-3,5-
diphosphatetracosan-24-oic acid 3,5-dioxide (non-preferred name) 93P 1 1071.88
isopentyl-Coenzyme A A1S 1 837.67
[(2R,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-bis(phosphonooxy)tetrahydrofuran-2-yl]methyl (3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-({3-oxo-3-[(2-sulfanylethyl)amino]propyl}amino)butyl dihydrogen diphosphate AC8 1 847.51
ACETYL COENZYME *A ACO 177 809.57
AMIDOCARBOXYMETHYLDETHIA COENZYME *A AMX 1 792.52
4-HYDROXYBENZOYL COENZYME A BCA 3 887.64
Butyryl Coenzyme A BCO 8 837.62
benzoyl coenzyme A BYC 4 871.64
COA-S-TRIMETHYLENE-ACETYL-TRYPTAMINE CA3 1 1009.85
COA-S-ACETYL 5-BROMOTRYPTAMINE CA5 1 1046.67
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-oxidanyl-3-phosphonooxy-oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(3R)-2,2-dimethyl-4-[[3-(4-methylsulfonylbutylamino)-3-oxidanylidene-propyl]amino]-3-oxidanyl-4-oxidanylidene-butyl] hydrogen 
phosphate CA6 1 841.61
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-oxidanyl-3-phosphonooxy-oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(3R)-2,2-dimethyl-3-oxidanyl-4-oxidanylidene-4-[[3-oxidanylidene-3-[4-(phenylsulfonyl)butylamino]propyl]amino]butyl] hydrogen 
phosphate CA8 1 903.68
ACETOACETYL-COENZYME A CAA 30 851.61
ethyl 5-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-oxidanyl-3-phosphonooxy-oxolan-2-yl]methoxy-oxidanyl-phosphoryl]oxy-oxidanyl-phosphoryl]oxy-3,3-dimethyl-2-oxidanyl-butanoyl]amino]propanoylamino]pentanoate CAJ 1 835.59
OXIDIZED COENZYME A CAO 7 783.53
CITRYL-THIOETHER-COENZYME *A CIC 1 927.66
CARBOXYMETHYL COENZYME *A CMC 10 825.57
CARBOXYMETHYLDETHIA COENZYME *A CMX 2 793.51
ISOBUTYRYL-COENZYME A CO6 2 837.62
S-{(9R,13R,15S)-17-[(2R,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxy-4-(phosphonooxy)tetrahydrofuran-2-yl]-9,13,15-trihydroxy-10,10-dimethyl-13,15-dioxido-4,8-dioxo-12,14,16-trioxa-3,7-diaza-13,15-diphosphaheptadec-1-yl}(2E)-but-2-
enethioate CO7 1 835.61
OCTANOYL-COENZYME A CO8 9 893.73
COENZYME A COA 459 767.53
DEPHOSPHO COENZYME A COD 8 687.55
TRIFLUOROACETONYL COENZYME A COF 1 877.57
[(2R,3S,4R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-4-HYDROXY-3-(PHOSPHONOOXY)TETRAHYDROFURAN-2-YL]METHYL (3R)-3-HYDROXY-4-{[3-({2-[(2-HYDROXYETHYL)DITHIO]ETHYL}AMINO)-3-OXOPROPYL]AMINO}-2,2-DIMETHYL-4-
OXOBUTYL DIHYDROGEN DIPHOSPHATE COK 4 843.65
COENZYME A PERSULFIDE COS 4 799.60
COA-S-ACETYL TRYPTAMINE COT 4 967.77
Anthraniloyl-coenzyme A COW 1 886.66
3-THIAOCTANOYL-COENZYME A CS8 1 911.77
4-(N,N-DIMETHYLAMINO)CINNAMOYL-COA DAK 1 940.74
DESULFO-COENZYME A DCA 4 735.47
DODECYL-COA DCC 6 949.84
ALPHA-FLUORO-AMIDOCARBOXYMETHYLDETHIA COENZYME A COMPLEX FAM 1 810.51
Phenylacetyl coenzyme A FAQ 2 885.67
ALPHA-FLUORO-CARBOXYMETHYLDETHIA COENZYME A COMPLEX FCX 1 811.50
S-{(9R,13S,15R)-17-[(2R,3S,4R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-4-HYDROXY-3-(PHOSPHONOOXY)TETRAHYDROFURAN-2-YL]-9,13,15-TRIHYDROXY-10,10-DIMETHYL-13,15-DIOXIDO-4,8-DIOXO-12,14,16-TRIOXA-3,7-DIAZA-13,15-
DIPHOSPHAHEPTADEC-1-YL} THIOFORMATE FYN 1 795.54
glutaryl-coenzyme A GRA 2 881.63
N-HYDROXYAMIDOCARBOXYMETHYLDETHIA COENZYME *A HAX 1 808.52
3R-HYDROXYDECANOYL-COENZYME A HDC 1 937.78
2,4-dihydroxyphenacyl coenzyme A HFQ 2 917.67
(3R,5S,9R,21S)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9,21-tetrahydroxy-8,8-dimethyl-10,14,19-trioxo-2,4,6-trioxa-18-thia-11,15-diaza-3,5-diphosphatricosan-23-oic acid 3,5-dioxide HGG 1 897.63
3-HYDROXY-3-METHYLGLUTARYL-COENZYME A HMG 9 906.62
(S)-3-HYDROXYDECANOYL-COA HSC 3 933.75
HEXANOYL-COENZYME A HXC 10 865.68
S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-2-hydroxy-3,3-dimethyl-butanoyl]amino]propanoylamino]ethyl] (2R)-2-hydroxy-4-methyl-
pentanethioate IRC 1 881.68
Isovaleryl-coenzyme A IVC 4 851.65
GDP-N-acetylperosamine-coenzyme A JBT 1 1381.93
N''-(2-COENZYME A)-PROPANOYL-LYSINE LYX 3 967.77
METHYLMALONYL-COENZYME A MCA 5 867.61
METHYLMALONYL(CARBADETHIA)-COENZYME A MCD 1 849.57
decanoyl-CoA MFK 4 921.78
MALONYL-COENZYME A MLC 11 853.58
(R)-2-METHYLMYRISTOYL-COENZYME A MRR 1 991.92
(S)-2-METHYLMYRISTOYL-COENZYME A MRS 1 991.92
TETRADECANOYL-COA MYA 54 977.89
S-4-NITROBUTYRYL-COA NBC 1 882.62
(3R)-27-AMINO-3-HYDROXY-2,2-DIMETHYL-4,8,14-TRIOXO-12-THIA-5,9,15,19,24-PENTAAZAHEPTACOS-1-YL [(2S,3R,4S,5S)-5-(6-AMINO-9H-PURIN-9-YL)-4-HYDROXY-3-(PHOSPHONOOXY)TETRAHYDROFURAN-2-YL]METHYL 
DIHYDROGEN DIPHOSPHATE NHQ 1 1009.90
2-oxopentadecyl-CoA NHW 19 991.92
NITROMETHYLDETHIA COENZYME A NMX 1 794.49
OXALYL-COENZYME A OXK 1 839.55
3-[(4-AMINO-2-METHYLPYRIMIDIN-5-YL)METHYL]-2-{(1R,11R,15S,17R)-19-[(2R,3S,4R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-4-HYDROXY-3-(PHOSPHONOOXY)TETRAHYDROFURAN-2-YL]-1,11,15,17-TETRAHYDROXY-12,12-DIMETHYL-
15,17-DIOXIDO-6,10-DIOXO-14,16,18-TRIOXA-2-THIA-5,9-DIAZA-15,17-DIPHOSPHANONADEC-1-YL}-5-(2-{[(R)-HYDROXY(PHOSPHONOOXY)PHOSPHORYL]OXY}ETHYL)-4-METHYL-1,3-THIAZOL-3-IUM OXT 1 1220.86
Palmitoyl-CoA PKZ 2 1005.94
(R)-IBUPROFENOYL-COENZYME A RFC 1 956.81
SUCCINYL(CARBADETHIA)-COENZYME A SCD 1 849.57
(S)-IBUPROFENOYL-COENZYME A SFC 1 956.81
[(2R,3S,4R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-4-HYDROXY-3-(PHOSPHONOOXY)TETRAHYDROFURAN-2-YL]METHYL (3R)-3-HYDROXY-2,2-DIMETHYL-4-OXO-4-{[3-OXO-3-({2-[(2-
OXOPROPYL)THIO]ETHYL}AMINO)PROPYL]AMINO}BUTYL DIHYDROGEN DIPHOSPHATE SOP 3 823.60
STEAROYL-COENZYME A ST9 4 1034.00
(2E)-Hexenoyl-CoA TC6 1 859.63
3-thiaglutaryl-CoA TGC 1 899.67
S-{(3S,5R,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3lambda~5~,5lambda~5~-diphosphaheptadecan-17-yl} 
undecanethioate UCC 1 935.81
p-coumaroyl-CoA WCA 3 913.68
[(2R,3S,4R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-4-HYDROXY-3-(PHOSPHONOOXY)TETRAHYDROFURAN-2-YL]METHYL (3R)-4-({3-[(2-{[(3,5-DIHYDROXYPHENYL)ACETYL]AMINO}ETHYL)AMINO]-3-OXOPROPYL}AMINO)-3-HYDROXY-2,2-
DIMETHYL-4-OXOBUTYL DIHYDROGEN DIPHOSPHATE YE1 5 900.61
[[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-4-oxidanyl-3-phosphonooxy-oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(3~{R})-4-[[3-[2-[(~{E})-2-[3,5-bis(oxidanyl)phenyl]-1-oxidanyl-ethenyl]sulfanylethylamino]-3-oxidanylidene-propyl]amino]-
2,2-dimethyl-3-oxidanyl-4-oxidanylidene-butyl] hydrogen phosphate YE2 1 917.67
TETRADEC-13-YNOIC ACID - COA THIOESTER YNC 1 973.86
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Table	S2-3.	Charge	fitting	between	di-fragments	to	generate	final	partial	charges	present	on	Coenzyme	A.		
	
Atom No. Atom	Name No	Restraints Fragment	1-2 Fragment	2-3 Fragment	3-4 Fragment	4-5 Fragment	5-6 New	Charges Diff all vs frag
1 P3B 1.2362 1.2248 0.0114 1.2248 0.0114
2 O7A -0.9153 -0.9149 0.0004 -0.9130 0.0023
3 O8A -0.9153 -0.9149 0.0004 -0.9130 0.0023
4 O9A -0.9233 -0.9092 0.0141 -0.9130 0.0103
5 O3B -0.5414 -0.6292 0.0878 -0.6292 0.0878
6 C1B   0.0381 0.0374 0.0407 0.0007 0.0026 0.0391 0.00095
7 H1B   0.1986 0.1959 0.1965 0.0027 0.0021 0.1962 0.0024
8 N1A   -0.7375 -0.7445 -0.7368 0.007 0.0007 -0.7407 0.00315
9 C2A   0.5625 0.577 0.5617 0.0145 0.0008 0.5694 0.00685
10 H2A   0.0508 0.0488 0.0505 0.002 0.0003 0.0497 0.00115
11 C2B   0.1633 0.1716 0.164 0.0083 0.0007 0.1678 0.0045
12 H2B   0.0863 0.1088 0.0835 0.0225 0.0028 0.0962 0.00985
13 O2B   -0.6519 -0.626 -0.6492 0.0259 0.0027 -0.6376 0.0143
14 HO2B 0.4434 0.4263 0.4403 0.0171 0.0031 0.4333 0.0101
15 C3B   0.0813 -0.1296 0.0976 0.2109 0.0163 -0.0160 0.0973
16 H3B   0.0569 0.1313 0.0596 0.0744 0.0027 0.0955 0.03855
17 N3A   -0.6483 -0.6696 -0.6461 0.0213 0.0022 -0.6579 0.00955
18 C4A   0.2263 0.2454 0.2226 0.0191 0.0037 0.2340 0.0077
19 C4B   0.2375 0.1456 0.1905 0.0919 0.047 0.1681 0.06945
20 H4B   0.1439 0.1876 0.162 0.0437 0.0181 0.1748 0.0309
21 O4B   -0.4209 -0.3791 -0.4069 0.0418 0.014 -0.3930 0.0279
22 C5A   0.126 0.1138 0.129 0.0122 0.003 0.1214 0.0046
23 C5B   0.1087 0.1074 0.0102 0.0013 0.0985 0.0588 0.0499
24 H5B2 0.0402 0.0519 0.0707 0.0117 0.0305 0.0613 0.0211
25 H5B3 0.0402 0.0519 0.0707 0.0117 0.0305 0.0613 0.0211
26 C6A   0.6712 0.6777 0.67 0.0065 0.0012 0.6739 0.00265
27 N6A   -0.9238 -0.9244 -0.9236 0.0006 0.0002 -0.9240 0.0002
28 H6A1 0.4136 0.4135 0.4134 0.0001 0.0002 0.4135 0.00015
29 H6A2 0.4136 0.4135 0.4134 0.0001 0.0002 0.4135 0.00015
30 N7A   -0.6045 -0.6021 -0.6049 0.0024 0.0004 -0.6035 0.001
31 C8A   0.1403 0.1434 0.1373 0.0031 0.003 0.1404 5E-05
32 H8A   0.1894 0.1862 0.1907 0.0032 0.0013 0.1885 0.00095
33 N9A   0.008 0.0074 0.0108 0.0006 0.0028 0.0091 0.0011
34 P1A  1.1573 1.16 1.1566 0.0027 0.0007 1.1583 0.001
35 P2A  1.1531 1.1541 1.1554 0.001 0.0023 1.1548 0.00165
36 O1A  -0.8261 -0.8221 -0.8252 0.004 0.0009 -0.8237 0.00245
37 O2A  -0.7708 -0.7735 -0.7713 0.0027 0.0005 -0.7724 0.0016
38 O3A  -0.466 -0.4674 -0.4668 0.0014 0.0008 -0.4671 0.0011
39 O4A  -0.7706 -0.7728 -0.773 0.0022 0.0024 -0.7729 0.0023
40 O5A  -0.8245 -0.8238 -0.821 0.0007 0.0035 -0.8224 0.0021
41 O5B  -0.4849 -0.5263 -0.4846 0.0414 0.0003 -0.5055 0.02055
42 O6A  -0.4852 -0.4851 -0.5199 0.0001 0.0347 -0.5025 0.0173
43 CAP   -0.0031 -0.0186 -0.0215 0.0155 0.0184 -0.0201 0.01695
44 HAP 0.1377 0.1425 0.1177 0.0048 0.02 0.1301 0.0076
45 OAP   -0.6404 -0.6135 -0.6503 0.0269 0.0099 -0.6319 0.0085
46 HOAP 0.4318 0.4145 0.4358 0.0173 0.004 0.4252 0.00665
47 CBP   0.2412 0.1794 0.2444 0.0618 0.0032 0.2119 0.0293
48 CDP   -0.0468 -0.0483 -0.0875 0.0015 0.0407 -0.0679 0.0211
49 HDP1 0.0115 0.0177 0.0203 0.0062 0.0088 0.0190 0.0075
50 HDP2 0.0115 0.0177 0.0203 0.0062 0.0088 0.0190 0.0075
51 HDP3 0.0115 0.0177 0.0203 0.0062 0.0088 0.0190 0.0075
52 CEP   -0.1901 -0.1784 -0.2033 0.0117 0.0132 -0.1909 0.00075
53 HEP1 0.0492 0.0528 0.0513 0.0036 0.0021 0.0521 0.00285
54 HEP2 0.0492 0.0528 0.0513 0.0036 0.0021 0.0521 0.00285
55 HEP3 0.0492 0.0528 0.0513 0.0036 0.0021 0.0521 0.00285
56 C9P   0.4104 0.428 0.5832 0.0176 0.1728 0.5056 0.0952
57 O9P   -0.5198 -0.52 -0.5611 0.0002 0.0413 -0.5406 0.02075
58 CCP   -0.0084 -0.0952 -0.0001 0.0868 0.0083 -0.0477 0.03925
59 HCP2 0.0615 0.0912 0.0607 0.0297 0.0008 0.0760 0.01445
60 HCP3 0.0615 0.0912 0.0607 0.0297 0.0008 0.0760 0.01445
61 N8P -0.5166 -0.3816 -0.5207 0.135 0.0041 -0.4512 0.06545
62 H8P 0.2827 0.2458 0.2822 0.0369 0.0005 0.2640 0.0187
63 C7P -0.015 0.0575 -0.037 0.0725 0.022 0.0103 0.02525
64 H7P2 0.0747 0.0439 0.0857 0.0308 0.011 0.0648 0.0099
65 H7P3 0.0747 0.0439 0.0857 0.0308 0.011 0.0648 0.0099
66 C6P -0.0163 -0.0341 -0.0919 0.0178 0.0756 -0.0630 0.0467
67 H6P2 0.0396 0.0411 0.0604 0.0015 0.0208 0.0508 0.01115
68 H6P3 0.0396 0.0411 0.0604 0.0015 0.0208 0.0508 0.01115
69 C5P 0.5012 0.4887 0.5828 0.0125 0.0816 0.5358 0.03455
70 O5P -0.5158 -0.5137 -0.5303 0.0021 0.0145 -0.5220 0.0062
71 S1P -0.3637 -0.3678 0.0041 -0.3678 0.0041
72 C2P -0.0013 0.0282 0.0295 0.0282 0.0295
73 H21 0.091 0.082 0.009 0.082 0.009
74 H22 0.091 0.082 0.009 0.082 0.009
75 C3P -0.0576 -0.0979 0.0403 -0.0979 0.0403
76 H31 0.1054 0.1088 0.0034 0.1088 0.0034
77 H32 0.1054 0.1088 0.0034 0.1088 0.0034
78 N4P -0.5459 -0.4577 0.0882 -0.4577 0.0882
79 H4P 0.2963 0.2728 0.0235 0.2728 0.0235
80 HS1 0.2004 0.2007 0.0003 0.2007 0.0003
Fr
ag
m
en
t	6
Absolute value of difference between two joined fragments, and one individual 
fragment.
Fr
ag
m
en
t	1
Fr
ag
m
en
t	2
Fr
ag
m
en
t	3
Fr
ag
m
en
t	4
Fr
ag
m
en
t	5
 62 
Table	S2-4.	Bond	length	and	angle	measurements	of	phosphate	fragments*	
	*	Bond	standard	deviations	are	colored	from	blue	to	red	on	a	scale	of	0.0057	–	0.0988.				Angle	standard	deviations	are	colored	from	blue	to	red	on	a	scale	of	0.0519	–	6.4948.		
	
MP2/aug-cc-pVTZ MP2/aug-cc-pVDZ expt.
Bond Definition chg = -2 chg = -2 chg = -2 chg = 0 (2 Na+) chg = 0 (Mg2+) chg = -2 std dev MP2/aug-cc-pVDZ
R(1,2)    C-H 1.0996 1.1114 1.1044 1.0974 1.0900 - 0.0080 Bond Definition chg = -2 chg = -2chg = 0 (2 Na+) std dev
R(1,3)    C-H 1.0996 1.1114 1.1044 1.0934 1.0900 - 0.0086 R(1,2)  C-H 1.1054 1.0979 1.0896 0.0079
R(1,4)    C-H 1.1017 1.1140 1.1083 1.0911 1.0872 - 0.0113 R(1,3)  C-H 1.1048 1.0963 1.0907 0.0071
R(1,9)    C-O 1.3957 1.4067 1.3895 1.4180 1.4458 1.433 0.0222 R(1,4)  C-H 1.1020 1.0935 1.0897 0.0063
R(5,6)    O-P 1.5430 1.5761 1.5329 1.5836 1.5670 1.514 0.0217 R(1,12) C-O 1.4359 1.4223 1.4388 0.0088
R(5,7)    O-P 1.5430 1.5761 1.5329 1.5233 1.5670 1.514 0.0224 R(5,7)  O-P 1.5327 1.4927 1.5027 0.0208
R(5,8)    O-P 1.5329 1.5661 1.5244 1.5164 1.5507 1.514 0.0202 R(5,8)  O-P 1.5419 1.5015 1.5152 0.0205
R(5,9)    O-P 1.7553 1.8119 1.7802 1.6441 1.5781 1.621 0.0988 R(5,9)  O-P 1.6854 1.6459 1.6239 0.0312
Angle Definition std dev R(5,12) O-P 1.7004 1.6605 1.6030 0.0490
A(2,1,3)  H-C-H 107.4476 107.4657 107.1928 109.4472 110.3618 - 1.4301 R(6,9)  O-P 1.6854 1.6459 1.6239 0.0312
A(2,1,4)  H-C-H 108.7147 108.5007 108.1537 108.5601 110.2783 - 0.8290 R(6,10) O-P 1.5419 1.5015 1.5152 0.0205
A(2,1,9)  H-C-O 111.5211 111.7074 112.0174 111.2105 110.0271 - 0.7677 R(6,11) O-P 1.5327 1.4927 1.5027 0.0208
A(3,1,4)  H-C-H 108.7147 108.5007 108.1537 109.2831 110.2783 - 0.8307 R(6,13) O-P 1.7004 1.6605 1.6030 0.0490
A(3,1,9)  H-C-O 111.5211 111.7074 112.0173 110.9862 110.0271 - 0.7805 R(13,14) C-O 1.4359 1.4223 1.4388 0.0088
A(4,1,9)  H-C-O 108.8444 108.8597 109.1575 107.2835 105.7745 - 1.4367 R(14,15) C-H 1.1048 1.0963 1.0907 0.0071
A(6,5,7)  O-P-O 114.2659 114.4773 114.5799 108.1003 101.9873 113.0 5.5836 R(14,16) C-H 1.1020 1.0935 1.0897 0.0063
A(6,5,8)  O-P-O 116.3116 116.7081 116.2931 108.8042 103.5278 113.0 5.9295 R(14,17) C-H 1.1054 1.0979 1.0896 0.0079
A(6,5,9)  O-P-O 102.8882 102.4865 102.8622 106.2535 116.0711 107.5/105.2 5.7728 Angle Definition std dev
A(7,5,8)  O-P-O 116.3116 116.7081 116.2931 120.5946 103.5278 113.0 6.4948 A(2,1,3)   H-C-H 109.3877 109.28 109.8949 0.3284
A(7,5,9)  O-P-O 102.8882 102.4865 102.8622 108.4002 116.0711 107.5/105.2 5.8650 A(2,1,4)   H-C-H 110.0018 109.9917 110.5203 0.3023
A(8,5,9)  O-P-O 100.9696 100.2950 100.6170 103.8056 113.8957 107.5/105.2 5.7507 A(2,1,12)  H-C-O 106.2729 106.6523 105.9272 0.3627
A(1,9,5)  C-O-P 112.7463 111.7131 114.5334 118.7649 118.5850 119.1 3.2698 A(3,1,4)   H-C-H 109.3065 108.9524 109.9569 0.5095
A(3,1,12)  H-C-O 110.5302 110.6254 110.2724 0.1826
MP2/aug-cc-pVTZ MP2/aug-cc-pVDZ b3lyp/6-311+g(2d,p) expt. A(4,1,12)  H-C-O 111.2923 111.3051 110.2013 0.6336
Bond Definition chg = -1 chg = -1 chg = -1 chg = -1 std dev A(7,5,8)   O-P-O 122.9940 122.0049 113.7134 5.0967
R(1,2)     C-H 1.0926 1.1042 1.0955 - 0.0060 A(7,5,9)   O-P-O 105.5877 106.4240 106.5364 0.5183
R(1,3)     C-H 1.0939 1.1057 1.0974 - 0.0061 A(7,5,12)  O-P-O 105.0411 105.1959 108.9508 2.2139
R(1,4)     C-H 1.0905 1.1023 1.0945 - 0.0060 A(8,5,9)   O-P-O 111.4962 110.9183 110.8481 0.3557
R(1,13)    C-O 1.4151 1.4270 1.4131 1.439 0.0075 A(8,5,12)  O-P-O 107.7740 108.1309 111.4888 2.0495
R(5,10)    O-P 1.5069 1.5370 1.4967 1.485 0.0210 A(9,5,12)  O-P-O 101.7973 102.3109 104.8120 1.6128
R(5,11)    O-P 1.4968 1.5271 1.4871 1.485 0.0209 A(9,6,10)  O-P-O 111.4962 110.9183 110.8481 0.3557
R(5,12)    O-P 1.6448 1.6871 1.6483 1.595 0.0235 A(9,6,11)  O-P-O 105.5877 106.4241 106.5364 0.5184
R(5,13)    O-P 1.6693 1.7135 1.6737 1.595 0.0243 A(9,6,13)  O-P-O 101.7973 102.3111 104.8120 1.6128
R(6,7)     C-H 1.0903 1.1020 1.0941 - 0.0060 A(10,6,11) O-P-O 122.9940 122.0050 113.7134 5.0967
R(6,8)     C-H 1.0930 1.1042 1.0965 - 0.0057 A(10,6,13) O-P-O 107.7740 108.1310 111.4888 2.0495
R(6,9)     C-H 1.0908 1.1023 1.0934 - 0.0060 A(11,6,13) O-P-O 105.0411 105.1952 108.9508 2.2141
R(6,12)    C-O 1.4177 1.4303 1.4169 1.439 0.0075 A(5,9,6)   P-O-P 135.9497 139.8095 135.7177 2.2984
Angle Definition std dev A(1,12,5)  C-O-P 115.2582 118.3887 121.1092 2.9279
A(2,1,3)   H-C-H 108.7519 108.8077 108.6778 - 0.0652 A(6,13,14) C-O-P 115.2582 118.3888 121.1092 2.9279
A(2,1,4)   H-C-H 109.6238 109.5003 109.3680 - 0.1279 A(13,14,15) O-C-H 110.5302 110.6258 110.2724 0.1828
A(2,1,13)  H-C-O 110.8670 111.0550 111.1312 - 0.1360 A(13,14,16) O-C-H 111.2923 111.3051 110.2014 0.6336
A(3,1,4)   H-C-H 108.9838 108.8860 108.6534 - 0.1697 A(13,14,17) O-C-H 106.2729 106.6528 105.9272 0.3629
A(3,1,13)  H-C-O 111.0381 111.1675 111.3624 - 0.1632 A(15,14,16) H-C-H 109.3065 108.9525 109.9569 0.5094
A(4,1,13)  H-C-O 107.5461 107.3832 107.5979 - 0.1120 A(15,14,17) H-C-H 109.3877 109.2794 109.8949 0.3286
A(10,5,11) O-P-O 123.1208 124.0762 123.2799 119.3000 0.5119 A(16,14,17) H-C-H 110.0018 109.9911 110.5203 0.3025
A(10,5,12) O-P-O 109.8847 110.0665 109.9485 111.1/105.1 0.0922
A(10,5,13) O-P-P 107.3383 107.1974 107.4930 111.1/105.1 0.1479
A(11,5,12) O-P-O 107.5172 107.2294 107.0773 111.1/105.1 0.2234
A(11,5,13) O-P-O 109.5324 109.4349 109.5144 111.1/105.1 0.0519
A(12,5,13) O-P-O 96.0927 94.9448 96.1527 105.0 0.6807
A(7,6,8)   H-C-H 109.2447 109.2887 108.9415 - 0.1890
A(7,6,9)   H-C-H 110.0229 109.9395 109.7894 - 0.1183
A(7,6,12)  H-C-O 107.2196 106.9275 107.3268 - 0.2067
A(8,6,9)   H-C-H 108.7618 108.8593 108.7719 - 0.0536
A(8,6,12)  H-C-O 110.7782 110.8474 110.9800 - 0.1025
A(9,6,12)  H-C-O 110.7955 110.9533 110.9999 - 0.1071
A(5,12,6)  C-O-P 115.8832 114.6512 117.7789 120.1 1.5755
A(1,13,5)  C-O-P 113.9638 112.7531 116.0331 120.1 1.6586
Dimethyldiphosphate (DMDP) b3lyp/6-311+g(2d,p)
b3lyp/6-311+g(2d,p)Methylphosphate (MP)
Dimethylphosphate (DMP)
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CHAPTER	3	
	
Comprehensive	Structural	Analysis	of	the	Terminal	Myxalamid	Reductase		
	
Domain	for	the	Engineered	Production	of	Primary	Alcohols	
	
	
3.1	Summary	Termination	 domains	 found	 in	 modular	 mega-synthases	 such	 as	 polyketides	synthases	 (PKS)	 and	 non-ribosomal	 peptide	 synthetases	 (NRPS)	 are	 responsible	 for	 the	release	of	covalently	attached	intermediates	and,	in	the	process,	generate	functional	group	diversity	contingent	on	the	mechanism	employed.	The	terminal	reductase	(R)	domain	from	the	non-ribosomal	peptide	synthetase	(NRPS)	module	MxaA	in	Stigmatella	aurantiaca	Sga15	catalyzes	 a	 non-processive	 four-electron	 reduction	 to	 produce	 the	myxalamide	 family	 of	secondary	metabolites.	Despite	widespread	use	in	nature,	a	lack	of	structural	and	dynamic	information	 concerning	 reductive	 release	 from	 polyketide	 synthase	 (PKS)	 and	 NRPS	assembly	lines	principally	limits	our	ability	to	redesign	R	domains	with	altered	or	improved	activity.	The	reductase	domain	of	MxaA	(MxaAR)	was	recently	solved	to	1.90	Å	and	1.84	Å	in	the	presence	and	absence	of	NADPH,	respectively.	This	structure	represents	the	first	cofactor	bound,	and	highest	resolution	reductase	domain.	Molecular	dynamic	simulations	delivered	an	 improved	picture	–	beyond	 traditional	structural	 studies	–	of	key	protein-protein	and	protein-substrate	 interactions	 that	 combined	with	 structural	data	and	provided	basis	 for	biochemical	investigations.	This	was	also	the	first	time	MD	was	used	to	decipher	the	protein-substrate	interactions	in	the	active	site	of	a	reductase.	In	addition,	MD	and	docking	studies	
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were	used	to	understand	protein-protein	interactions	between	the	MxaA	reductase	and	its	corresponding	peptidyl	carrier	protein	(MxaAPCP).	Mutational	analysis	focused	both	on	the	putative	 catalytic	 residues	 and	 substrate-binding	 pocket	 to	 define	 the	 necessity	 of	 the	catalytic	triad	and	reveal	select	residues	that	are	highly	influential	in	catalysis.	The	combined	data	provides	an	unparalleled	view	of	this	unique	termination	mechanism	that	spans	from	macromolecular	movements	 essential	 for	 catalysis	 to	 the	 identification	 of	 key	 substrate-residue	interactions.	In	summary,	studies	presented	here	will	aid	efforts	to	improve	these	domains	for	the	production	of	diverse	primary	alcohols.	This	possibility	was	highlighted	by	the	enhancement	of	activity	towards	fully	saturated	compounds,	specifically	C10	derivatives,	through	mutation	guided	by	our	structural,	biochemical	and	computational	results.	
	
3.2	Introduction	The	myxobacterium	Stigmatella	aurantiaca	Sga15	contains	a	myxalamid	biosynthetic	pathway	 composed	 of	 six	 PKS	 modules,	 and	 one	 terminal	 NRPS	 module	 (Fig.	 3-1).	Myxalamids	have	been	identified	as	potent	inhibitors	of	the	respiratory	electron	transport	chain.1-2	 What	 makes	 this	 particular	 system	 interesting	 is	 its	 use	 of	 a	 rare	 termination	mechanism	to	release	6	as	a	primary	alcohol,	in	contrast	to	more	commonly	observed	chain	release	mechanisms	using	thioesterases	(TEs)	that	produce,	for	instance,	macro–lactones	or	–lactams.1,3-5	 The	 biosynthesis	of	myxalamid	 is	 a	multi-step	 process	 initiated	 by	 a	 type	 I	modular	PKS	that	consists	of	six	modules	to	biosynthesize	3,	a	polyene	intermediate	that	is	translocated	to	the	NRPS	module	for	final	processing.	In	the	terminal	NRPS	module,	MxaA,	the	adenylation	(A)	domain	activates	alanine	as	a	building	block	while	the	condensation	(C)	
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domain	 catalyzes	 peptide	 bond	 formation	 between	 alanine	 and	 the	 PKS-generated	intermediate	to	yield	the	final	product.6	The	last	step	in	biosynthesis	requires	the	reductive	release	of	myxalamid	(mxa)	from	the	phosphopantetheine	(PPant)	prosthetic	group	covalently	attached	to	the	peptidyl	carrier	protein	(PCP).	This	action	is	catalyzed	by	a	recently	described	class	of	NADPH-dependent	terminal	 reductase	 (R)	 domains	 that	 execute	 chain	 termination	 by	 a	 4e-	 non-processive	reduction	to	generate	primary	alcohols.1,	4,	7	To	accomplish	this,	the	PCP-bound	thioester	is	first	reduced	to	the	aldehyde	5,	which,	following	reduction	by	a	second	NADPH	equivalent,	affords	the	final	2-aminopropanol-containing	6.	
	
Figure	3-1.	Myxalamid	biosynthetic	pathway:	The	pathway	is	composed	of	six	PKS	modules	(MxaB1	–	MxaF)	and	one	terminal	NRPS	module	(MxaA)	containing	a	reductase	domain	(in	red).	
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Here,	 we	 report	 the	 1.84-Å	 and	 1.90-Å	 structures	 of	 the	MxaA	 R	 domain	 from	 S.	
aurantiaca	Sga15	in	the	presence	and	absence	of	NADPH,	respectively.	This,	in	combination	with	 molecular	 dynamics	 (MD)	 and	 structure-based	 mutagenesis,	 provided	 an	unprecedented	view	of	 local	and	global	 interactions	between	the	PCP	and	R	domain,	and	those	 between	 the	 R	 domain	 and	 cofactor/substrate	 that	 are	 essential	 for	 catalysis.	Furthermore,	mutational	 analysis	of	 the	R	domain	enabled	us	 to	 rationally	mutate	a	key	active	site	arginine	that	resulted	in	an	MxaA	variant	with	improved	activity	towards	highly	reduced	 substrates	 (e.g.,	 dodecanoyl-PCP).	 Combined	 structural,	 computational	 and	biochemical	results	presented	here	provide	a	comprehensive	understanding	of	these	unique	termination	 domains	 and,	 in	 the	 process,	 set	 a	 strong	 foundation	 for	 future	 efforts	 to	generate	new	PKS-	or	NRPS-based	routes	to	diverse	terminal	alcohol	containing	compounds.	
	
3.3	Results	and	discussions	
	
3.3.1	The	crystal	structure	of	the	MxaR	R	domain	The	MxaA	reductase	is	composed	of	an	N-terminal	subdomain	that	contains	NADPH	bound	 in	 a	Rossman	 fold,	 and	 the	 C-terminal	 subdomain	 that	 contains	 a	 helix-turn-helix	motif	(Fig.	3-2).8,9	A	comparison	of	the	apo	and	NAPDH-bound	MxaA	reductase	shows	a	slight	conformational	change	with	an	overall	RMSD	of	0.63	Å.			
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Figure	3-2.	Structure	of	the	MxaA	R	domain.	(a)	The	MxaA	R	domain	monomer	is	composed	of	 an	 N-terminal	 subdomain	 that	 contains	 an	 NADPH	 Rossmann	 fold	 (in	 blue)	 and	 a	 C-terminal	subdomain	which	contains	a	helix-turn-helix	motif	(shown	in	green).	The	NADPH	cofactor	is	displayed	in	gray	sticks.	(b)	The	MxaA	R	domain	crystallizes	as	a	dimer,	monomer	A	 shown	 in	yellow	and	monomer	B	 shown	 in	gray.	 (c)	The	 cofactor	NADPH	binds	 to	 the	TGxxGxxG	motif	close	to	the	T,	Y,	and	K	catalytic	site.	An	SA-omit	map	of	the	NADPH	co-factor	contoured	at	1.0σ	is	shown	in	the	gray	isomesh	map.		
	
3.3.2	Molecular	dynamic	studies	To	elucidate	the	structural	dynamics	of	NADPH	and	substrate	binding	in	MxaA	R	we	conducted	molecular	dynamic	(MD)	simulations	by	analyzing	conformational	changes	in	100	ns	MD	runs.	Atomic	 coordinates	of	 the	MxaA	R	domain	were	obtained	 from	 the	NADPH-bound	MxaA	R	domain	(chain	B)	crystal	structure.	The	 ff14SB	forcefield	 in	Amber14	was	used	for	 the	protein	 	and	the	general	AMBER	force	 field	(GAFF)	was	used	for	 the	NADPH	cofactor.10-15	NADPH	was	parameterized	using	Gaussian	09	to	obtain	the	initial	electrostatic	potential	using	the	HF/6-31G(d,p)	basis	set,	followed	by	the	use	of	antechamber	to	obtain	
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the	HF/6-31G(d,p)	restricted	electrostatic	potential	(RESP)	fit	with	final	overall	net	charge	of	-4.	The	system	was	explicitly	solvated	with	a	buffer	of	10	Å	TIP3P	waters	in	a	truncated	octahedron	 box	 after	 neutralizing	 with	 counter	 ions.	 A	 two-system	 minimization	 was	performed	using	SANDER	and	PMEMD	was	used	for	production	runs.16	The	 NADPH-bound	 MxaA	 R	 domain	 was	 allowed	 to	 equilibrate	 after	 heating	 the	system	 to	 300K	 and	 subsequently	 allowed	 to	 run	 over	 100	 ns.	 2D	 RMSD	 maps	 were	generated	using	Chimera	and	an	in-house	MATLAB	script	by	comparing	RMSD	fluctuations	of	the	protein	backbone.	The	maps	revealed	an	RMSD	range	of	0.61-2.41	Å	for	the	MxaA	R	domain	 (Fig.	 3-3a).	 Further	 dissection	 of	 the	 N-	 vs.	 C-term	 subdomains	 revealed	 RMSD	ranges	of	0.54-1.49	Å	and	0.52-2.25	Å,	respectively	(Fig.	3-3b,c).	These	results,	combined	with	RMSD	values	found	in	our	crystal	structures,	indicate	higher	flexibility	and	movement	of	the	C-terminal	subdomain.	
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Figure	3-3.	Molecular	Dynamic	Analysis	(a)	2D	RMSD	map	analysis	of	the	MxaA	R	domain	backbone	with	NADPH	over	the	entire	100	ns	molecular	dynamics	simulation.	Low	RMSD	is	observed	 in	blue	and	high	RMSD	is	observed	 in	red.	 (b,c)	Dissecting	the	N-	vs.	C-terminal	subdomain	of	MxaA	R	bound	to	NAPDH	reveals	higher	RMSD	deviations	in	the	C-terminal	subdomain.	(d)	2D	RMSD	map	was	generated	with	the	MxaA	R	domain	bound	to	NADPH	and	docked	with	mxa-PPant.	(e,f)	Dissection	of	the	N-	vs.	C-terminal	of	the	bound	NADPH,	mxa-PPant	R	domain	demonstrate	a	decrease	in	movement	of	the	C-terminal	subdomain.		The	most	noticeable	region	of	flexibility	was	observed	in	the	C-terminal	helix-turn-helix	 (HTH)	 motif,	 specifically	 the	 conserved	 hydrophobic	 residues	 between	 Y1430	 and	Q1455	of	α16-α17,	which	display	an	average	RMSD	of	0.82	Å	in	the	NADPH	bound	model	(Fig.	3-2a,	Fig.	3-4g-i).	Numerous	 salt	bridges	are	 critical	 in	 stabilizing	 the	α16-α17	HTH	motif,	such	as	R1426	and	E1436	(Fig.	3-4a-c).	During	the	100	ns	NADPH	bound	run,	the	ζC	of	R1426	maintains	a	distance	of	≤	6.0	Å	with	either	εO	of	E1436.	D1444,	the	turn	residue	between	helix-16	and	helix-17,	also	maintains	a	tight	salt	bridge	interaction	with	a	distance	≤	3.5	Å	between	the	ζC	of	R1364	through	stochastic	sampling	of	either	helix-13	D1444	δO	
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during	73.2%	of	the	simulation	(Fig.	3-4a).	
	
Figure	3-4.	Further	MD	analysis	of	residues	within	the	HTH	of	the	C-terminal	subdomain	(a-c).		(d-f)	Residue	analysis	of	mxa-PPant	interactions	and	NADPH	(g-i).	Moderate	 electrostatic	 interactions	were	 observed	 between	 helix-12	R1357	 and	 helix-17	E1446,	with	the	ζC	of	R1357	maintaining	a	distance	≤	6.0	Å	for	68.7%	of	the	simulation.	The	catalytic	triad	(T1283,	Y1311	and	K1315)	exhibits	little	movement	with	an	average	of	0.07	Å	per	residue	throughout	the	entire	100	ns	run.	The	phosphate	attached	to	the	nicotinamide	ribose	5’	carbon	remains	stable,	within	1.99	and	2.09	Å	of	the	Rossmann	TGxxGxxG	motif.	
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Figure	3-5.	(a)	Cartoon	and	ribbon	docking	model	of		MxaA	PCP-R	domain	interactions.	The	green	dot	represents	the	active	site	cavity	of	the	MxaA	R	domain.	(b)	Model	of	the	MxaA	PCP-R	 interface	 reveals	 possible	 electrostatic	 and	 pi-stacking	 interactions	 between	 these	 two	domains.	A	representative	cluster	ensemble	was	generated	 from	MD	using	RMSD	scoring	as	implemented	in	Chimera.17	RMSD	scoring	reduced	the	initial	set	of	1000	frames	generated	to	the	46	most	unique	frames.	In	silico	docking	of	the	PPant-bound	substrate	using	all	of	the	46	unique	frames	from	the	previous	MD	run	by	the	program	GOLD	revealed	a	large	binding	cavity	under	the	α16-α17	helix-turn-helix	motif	(Fig.	3-2a).16	In	order	to	identify	substrate-binding	residues	for	MD	analysis,	we	docked	the	myxalamid	substrate	using	the	46	unique	clusters	from	the	NADPH-bound	MxaAR	MD	analysis.	We	ranked	the	docking	solutions	using	the	ChemPLP	scoring	function	and	identified	the	most	consistent	binding	orientation	of	the	myxalamid	substrate	by	tallying	residues	involved	in	substrate	binding	(Fig.	3-5).	The	frame	
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from	the	top	ChemPLP	solution	that	was	pre-screened	by	binding	orientation	was	utilized	for	MD	analysis	of	 the	MxaA	R	with	the	myxalamid	substrate.	Using	the	same	MD	system	parameters	as	before	we	allowed	the	PPant-bound	substrate	and	NADPH-bound	R	domain	chain	 B	 simulation	 to	 run	 for	 100	 ns.	 RMSD	2D	map	 analysis	 of	 the	MxaA	 R	 domain	 in	complex	with	the	PPant	substrate	revealed	a	RMSD	range	of	0.60-	1.99	Å	(Fig.	3-3d).	This	value	 is	 lower	 than	 the	 RMSD	 range	 for	 the	 R	 domain	 with	 NADPH	 bound,	 but	 lacking	substrate	(Fig.	3-3a),	and	indicates	a	decrease	in	protein	motion	upon	substrate	binding.	The	NADPH	binding	N-terminal	subdomain	demonstrates	a	similar	RMSD	range	of	0.55-1.49	Å,	whether	 substrate	 is	 bound	 or	 not,	 while	 the	 C-terminus	 reduces	 its	 flexibility	 upon	substrate	binding	(Fig.	3-3c,f).	In	light	of	results	that	indicated	substrate	binding	stabilized	the	C-terminus	we	opted	to	focus	additional	attention	on	the	C-terminal	HTH	motif,	specifically	those	residues	that	are	steadied	 through	 interactions	 with	 the	 substrate	 (Fig.	 3-5a-c).	 The	 terminal	 HTH	 motif	displays	a	 slightly	 lower	average	RMSD	of	0.76	Å,	while	 the	PPant	moiety	exhibits	 larger	movements	 than	 the	 sequestered	 myxalamid	 segment.	 D1353	 shows	 strong	 hydrogen	bonding	with	the	amide	moiety	of	the	PPant	group,	averaging	a	3.0-Å	distance	for	more	than	70	ns	of	the	MD	run	(Fig.	3-4e).	The	amide	carbonyl	group	of	the	terminal	alanine	in	the	mxa	intermediate	 generates	 a	 tight	 2.0-Å	 interaction	 with	 R1339,	 highlighting	 the	 likely	importance	of	electrostatic	interactions	between	myxalamid	and	the	R	domain	(Fig.	3-4d).	The	methyl-branched	diene	moiety	of	the	mxa	substrate	forms	intramolecular	hydrophobic	interactions,	kinking	the	aliphatic	substrate	back	towards	the	PPant	thioester	to	minimize	its	 hydrophobic	 surface	 area.	 F1248	 in	 MxaA	 R	 aids	 in	 stabilizing	 these	 hydrophobic	interactions.	The	C9	and	C15	hydroxyl	groups	in	myxalamid	intermediate	4	hydrogen	bond	
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with	S1285	and	D1461,	respectively	(Fig.	3-5a,c).	S1285	forms	an	average	3.0-Å	hydrogen	bond	with	the	terminal	hydroxyl	group	in	the	myxalamid	intermediate	for	more	than	95%	of	the	MD	simulation.	Similarly,	D1461	forms	an	average	3.2-Å	hydrogen	bond	with	the	first	hydroxyl	group	for	more	than	80%	of	the	MD	run.	Both	S1285	and	D1461	along	with	R1339	and	F1248	appear	to	play	a	key	role	in	myxalamid	substrate	recognition	and	orienting	the	substrate	for	reduction	by	NADPH.	In	summary,	MD	simulation	results	suggest	that	the	C-terminal	domain	is	highly	mobile	until	myxalamid	substrate	binding	quenches	movement,	more	precisely	at	the	HTH	motif,	for	the	first	round	of	reduction.		
	
3.3.3	Docking	analysis	of	PPant-mxa	substrate	and	PCP	domain	Initial	 structural	 analysis	 in	 parallel	 with	 the	NADPH-bound	MxaA	 R	MD	 analysis	revealed	a	large	substrate	cavity	with	various	potential	substrate	binding	residues.	In	depth	docking	studies	were	needed	because	the	deep	active	site	cavity	contains	many	potential	substrate-binding	motifs,	and	the	long	chain	substrate	is	inherently	flexible.	Using	in	silico	docking	we	further	probed	for	residues	important	in	substrate	binding	by	docking	the	PPant-tethered	mxa	intermediate	in	the	R	domain	active	site.	The	100-ns	MD	simulation	of	NADPH	bound	 MxaA	 R	 identified	 46	 unique	 clusters,	 indicative	 of	 46	 distinct	 MxaA	 R	 domain	conformations.	One	frame	from	each	cluster	was	obtained	and	was	used	as	the	receptor	to	dock	against	 the	PPant-mxa	 ligand	using	the	program	GOLD.18	Each	 frame	generated	100	solutions	that	were	scored	and	ranked	using	the	ChemPLP	scoring	function.19	The	program	LIGPLOT,	in	parallel	with	visual	inspection,	was	used	to	analyze	and	identify	ligand-protein	residue	interactions	(Fig.	3-6).20		
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Figure	 3-6.	LIGPLOT	 analysis	 revealing	 key	 protein-substrate	 interactions	 from	 cluster-analysis.			The	residue–ligand	interactions	between	2.5-4.0	Å	for	each	frame	were	tallied,	and	a	heat	 map	 was	 generated,	 indicative	 of	 ligand-residue	 proximity	 in	 different	 R	 domain	conformations	(Fig.	3-5b).	Not	surprisingly,	 the	catalytic	 triad	was	revealed	to	 frequently	associate	with	the	PPant-bound	substrate.	T1283	showed	interactions	close	to	the	thioester	linkage	in	28	out	of	the	46	frames.	Additionally,	Y1311	interacted	with	the	thioester	in	18	out	of	the	46	frames.	The	water	coordinating	S1285	associated	with	the	thioester	in	35	out	of	the	46	frames.	The	majority	of	residues	that	interacted	with	the	MxaA	portion	of	the	ligand	were	localized	on	the	C–terminal	subdomain.	Out	of	the	46	frames,	37	showed	that	R1339	engages	in	electrostatic	interactions	with	one	of	the	two	carbonyl	groups	in	the	substrate	near	the	thioester	 linkage.	Residues	that	outline	the	back	of	 the	substrate-binding	pocket	revealed	 several	 hydrogen	 bonding	 and	 hydrophobic	 interactions	 with	 the	 substrate,	specifically,	V1308,	Y1430	and	R1468.	Taken	together,	residues	with	high	substrate	contact	
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probabilities—derived	from	resultant	heat	maps—indicate	the	likely	importance	of	specific	residues	in	substrate	recognition	and	orientation.	
	
Figure	3-7.	(a)	Cartoon	and	ribbon	docking	model	of	MxaA	PCP-R	domain	interactions.	The	green	dot	represents	the	active	site	cavity	of	the	MxaA	R	domain.	(b)	Model	of	the	MxaA	PCP-R	 interface	 reveals	 possible	 electrostatic	 and	 pi-stacking	 interactions	 between	 these	 two	domains.	
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	 To	situate	the	R	domain	 in	the	perspective	of	the	termination	module	MxaA,	more	specifically	the	protein	interactions	between	PCP	and	R	domain	for	the	reductive	release	of	the	 final	 product,	 we	 computationally	 docked	 the	 R	 domain	 with	 the	 PCP	 domain.	 The	previously	solved	SrfA-C	terminal	module	structure	from	Bacillus	subtilis	revealed	that	the	PCP	 domain	 is	 positioned	 in	 close	 proximity	 to	 the	 catalytic	 C,	 A	 and	 TE	 domains,	 thus	providing	 evidence	 for	 the	 spatial	 relationships	 of	 the	 PCP	 in	 the	 termination	module.21	Accordingly,	we	used	the	SrfA-C	terminal	domain	structure	(PBD	ID:	2VSQ)	as	a	template	on	which	to	base	our	protein-protein	docking	studies.	Using	the	HHPRED	server	we	generated	a	tertiary	homology	model	of	the	MxaA	PCP	domain	and	proceeded	to	dock	the	R	domain	using	 the	 ZDOCK	 server.19,22-23	 Most	 of	 helix	 III	 in	 the	 PCP	 forms	 contacts	 with	 surface	residues	 in	 both	 N-	 and	 C-terminal	 subdomains	 of	 the	 MxaA	 R	 domain	 (Fig.	 3-7a-b).	Dissecting	the	PCP	surface	reveals	electrostatic	interactions	between	the	surfaces	of	the	R	and	PCP	domain.	The	conserved	serine	(part	of	the	signature	D/HSL	motif)	contained	in	the	PCP	domain	that	covalently	binds	the	PPant	prosthetic	group	(S56)	is	located	12.0	Å	away	from	the	catalytic	triad:	T1283,	Y1311	and	K1315.	The	HTH	motif	of	the	MxaA	R	C-terminal	subdomain	has	both	electrostatic	 and	pi-pi	 stacking	 interactions	with	helix	 III	of	 the	PCP	domain.	These	include	the	Q1445	of	the	R	domain	with	R77	from	the	PCP	domain	and	the	carbonyl	backbone	of	S1442	of	the	R	domain	with	the	D73	side	chain	of	the	PCP.	Additionally,	a	face-to-face	pi	stacking	interaction	occurs	between	F1453	in	the	R	domain	and	Y60	of	the	loop	connecting	helix	 II	and	III	 in	 the	PCP	domain	(Fig.	3-7b).	These	results	highlight	 the	importance	of	 electrostatic	 and	aromatic	 residues	on	 the	 surfaces	of	both	 the	R	and	PCP	domains	for	protein-protein	interactions	and	provide	a	basis	for	the	engineering	of	chimeric	ACP/PCP-R	domain	fusions.	
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3.3.4	Structure	of	the	MxaA	R	domain	To	 visualize	MxaA	R	we	 crystallized	 the	R	 domain	with	 and	without	 the	 cofactor,	NADPH.	 Using	multi-wavelength	 anomalous	 diffraction	 (MAD)	with	 a	 selenomethionine-substituted	protein	the	structure	of	MxaA	R	was	determined	to	a	resolution	of	1.95	Å.	The	apo	MxaA	R	structure	was	further	refined	to	1.84	Å	(Table	3-1).	MxaA	R	was	solved	as	a	dimer	with	an	RMSD	of	0.45	Å	between	monomers	A	and	B.		The	overall	structure	contains	strong	architectural	similarities	to	type	E	short-chain	dehydrogenases/reductases	(SDRs)	that	contain	an	N-terminal	NADPH	binding	region	and	a	C-terminal	substrate-binding	subdomain	(Fig.	3-2a-c).24	Structural	alignment	with	the	type	E	SDR	from	agrobacterium	tumefaciens	(PDB:	4ID9)	displays	an	R.M.S.D.	of	3.88	Å	through	119	residues	of	the	alpha	carbon	backbone.		Hidden	Markov	models	(HMM)	show	that	MxaA	R	has	structural	and	sequence	similarities	with	the	extended	type-E	SDRs	based	on	Kallberg	
et	al.	classification.25	The	N-terminal	subdomain	contains	an	extended	NADPH-binding	α/β	Rossmann	fold	with	seven	parallel	beta	sheets	(β3-	β2-	β1-	β4-	β5-	β6-	β10)	flanked	by	five	alpha	helices	(α2-	α3-	α4-	α6-	α8-	α11)	(Fig.	3-2a,	Fig.	3-8,	Fig.	3-9).	These	structural	features	correlate	well	with	 the	 previously	 solved	Nrp	R	 domain	 structure	 (PDB:	 4DQV)	with	 an	RMSD	 of	 2.19	 Å	 through	 279	 residues	 of	 the	 alpha	 carbon	 backbone.7	 Similar	 features	include	 a	 canonical	 tyrosine-dependent	 catalytic	 triad	 (T1283,	 K1315	 and	Y1311)	 and	 a	distinctive	 helix-turn-helix	 (HTH)	 motif	 (α16-	 α17)	 found	 in	 all	 structurally	 known	terminating	reductase	domains.				
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Table	3-1.	Crystallographic	statistics.		 MxaA	R	Native	 MxaA	R/	NADPH	 	 MxaA	R	SeMet	 	
Data	collection	 	 	 	 	 	Space	group	 P21	 P21	 	 P21	 	Cell	dimensions	 	 	 	 	 					a,	b,	c	(Å)	 50.84,	159.30,	54.90	 51.11,	159.05,	51.18	 	 50.88,	159.23,	54.92	 					a,	b,	g	(°)	 90,	108.88,	90	 90,	106.14,	90	 	 90,	108.85,	90	 		 	 	 Peak	 Inflection	 Remote	Wavelength	 0.9792	 0.9775	 0.9792	 0.9794	 0.9611	Resolution	(Å)	 50.0-1.70		(1.96-1.70)		 50.0-1.84		(2.01-1.84)		 50.0-1.70	(2.01-1.70)	 50.0-1.70	(2.01-1.70)	 50.0-1.70	(2.01-1.70)	
Rsym	or	Rmerge	 0.075	(0.200)	 0.211	(0.545)	 0.140	(0.488)	 0.142	(0.499)	 0.136	(0.460)	CC*	 0.995	 0.980	 0.992	 0.991	 0.989	
I	/sI	 23.0	(7.1)	 9.3	(3.9)	 66.6	(7.4)	 66.7	(7.5)	 58.5	(6.7)	Completeness	(%)	 98.1	(98.1)	 100.0	(100.0)	 96.2(93.3)	 97.3	(92.5)	 97.4	(92.4)	Redundancy	 2.7	(2.6)		 3.6	(3.1)	 6.3	(5.0)	 6.3	(5.0)	 6.3	(5.0)	
	 	 	 	 	 	
Refinement	 	 	 	 	 	Resolution	(Å)	 29.18-1.84	(1.91-1.84)	 41.82-1.90	(1.96-1.90)	 	 33.37-1.95	(2.02-1.95)	 	No.	reflections	 367015	 440613	 	 508072	 	
Rwork	/	Rfree	 0.1750/	0.2150	(0.2233/0.2898)	 0.1630/0.2080	(0.2818/0.3260)	 	 0.2068/0.2393	(0.2380/0.2965)	 	No.	atoms	 	 	 	 	 					Protein	 5991	 6052	 	 5959	 					Ligand/ion	 8	 104	 	 8	 					Water	 934	 786	 	 822	 	
B-factors	 	 	 	 	 					Protein	 24.0	 29.6	 	 20.1	 					Ligand/ion	 17.7	 18.2	 	 20.0	 					Water	 32.3	 35.8	 	 28.7	 	R.m.s	deviations	 	 	 	 	 					Bond	lengths	(Å)	 0.008	 0.015	 	 0.020	 					Bond	angles	(°)	 1.05	 1.4	 	 1.53	 		 Substrate	 recognition	 in	 the	 SDR	 family	 occurs	 in	 the	 C-terminal	 subdomain,	consequently,	while	the	N-terminal	subdomains	in	SDRs	are	highly	conserved,	C-terminal	domains	 often	 differ	 in	 sequence.26	 The	 C-terminal	 subdomain	 of	 MxaA	 R	 consists	 of	 5	helices	 (α12-	 α15-	 α16-	 α17-	 α20)	 and	 two	 parallel	 beta	 sheets	 (β9-	 β11),	 which	 are	substantially	 larger	 (~130	 residues)	 than	 those	 found	 in	 typical	 SDRs	 (Fig	3-9a-c).24-26	 A	notable	 inserted	 helix-turn-helix	 motif	 (α16-	 α17)	 between	 residues	 Y1431	 and	 Q1456	
	 83	
contains	 several	 conserved	 hydrophobic	 residues	 (W1433,	 L1437,	 L1450,	 L1451)	frequently	present	in	R	domains	that	conduct	PKS	or	NRPS	chain	termination	with	2-	or	4-electron	reductions	(Fig.	3-1c).1,	3,	27-30		To	 further	distinguish	true	biological	 interfaces	 from	lattice	contacts	 in	 the	crystal	structure,	we	further	analyzed	the	MxaA	R	domain	utilizing	the	Evolutionary	Protein-Protein	Interface	Classifier	 (EPPIC)	 server,	which	 relies	on	evolutionary	data	 to	detect	biological	interfaces,	 and	 PDBePISA.31,32	 The	 EPPIC	 server	 was	 unable	 to	 reliably	 determine	biologically	relevant	surface	interfaces	due	to	the	lack	of	homolog	sequences	for	comparison.	
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Figure	3-8.	Multiple	 Sequence	Alignment	Analysis.	 	 Representation	was	generated	 using	ESPript.	
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PDBePISA	 generated	 a	 Complex	 Formation	 Significance	 Score	 (CSS)	 of	 0.00,	suggesting	that	the	surface	interface	displayed	by	the	MxaA	homodimer	is	a	result	of	crystal	packing.	The	average	 interface	area	between	both	monomers	was	calculated	to	656.9	Å2,	which	 is	3.85	%	of	 the	total	solvent	accessible	area.	This	constituted	a	 total	of	22	and	20	buried	 surface	 residues	 for	 monomer	 A	 and	 B	 respectively.	 It	 is	 also	 well	 known	 that	biological	interfaces	tend	to	exhibit	large	areas,	with	the	majority	of	cases	exceeding	1000	Å2.33		
	
Figure	3-9.	Topology	analysis	of	 the	MxaA	R,	 the	Nrp	R	domain	and	other	SDR	family	of	reductases.	Rossmann	fold	is	colored	blue.		Furthermore,	 evidence	 for	 its	 biological	 monomeric	 state	 was	 gathered	 from	analytical	 size	 exclusion	 chromatography	 experiments,	 comparing	 the	 MxaA	 PCP-R	didomain	 to	 known	 protein	 standards.	 Overall,	 these	 results	 suggest	MxaA	 R	 exists	 in	 a	
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biologically	monomeric	 form	rather	 than	 the	 crystallographically	 observed	 homodimeric	state.	
	
3.3.5	Structure	analysis	of	NADPH-bound	R	domain	Currently,	 the	Nrp	 terminal	R	domain	 (PDB:	4DQV)	 from	Mycobacteria	 smegmatis	involved	 in	 glycopeptide	 biosynthesis	 and	 the	 AusA	 R	 domain	 (PDB:	 4F6C,	 4F6L)	 from	
Staphyloccoccus	 auresus	 involved	 in	 pyrazinone	 biosynthesis	 are	 the	 sole	 PKS-	or	NRPS-associated	R	domains	to	have	structures	reported.	While	these	monodomain	structures	have	been	 solved	with	moderate	 resolution	 (2.30	Å	 for	NRP	and	2.81	Å	 for	AusA),	 the	 lack	of	bound	NADPH	cofactor	leaves	key	structural	and	mechanistic	details	rather	unclear.7,	34	In	order	 to	 define	 residues	 required	 for	 cofactor	 binding	 in	MxaA	R,	 co-crystals	 of	MxaA	R	complexed	with	NADPH	were	solved	by	molecular	replacement	of	the	apo	structure	to	1.90	Å	 (Table	 3-1).	 NADPH	 binds	 to	 the	 well-known	 Rossmann	 fold	 that	 has	 a	 conserved	nucleotide-binding	motif	TGxxGxxG,	with	the	central	diphosphate	moiety	hydrogen	bonding	to	the	peptide	backbone	of	G1155,	T1157,	G1158,	L1160,	and	G1161	(Fig.	3-2c).	Further,	the	G1155	carbonyl	 forms	a	hydrogen	bond	with	the	adenosine	3’-hydroxyl	 group	while	 the	adenosine	2’-phosphate	oxygen	interacts	with	highly	conserved	T1157,	R1181	and	R1191.	Both	 the	2’-	 and	3’-hydroxyl	groups	of	 the	nicotinamide-containing	ribose	 ring	hydrogen	bond	with	K1315	 and	Y1311.	 The	 nicotinamide	 amine	 hydrogen	 bonds	with	 the	 G1338	carbonyl.	Together,	these	interactions	serve	to	tightly	bind	NADPH	(Kd	=	45	±	3.7	μM,	vide	
supra)	and	properly	orient	it	in	the	active	site	for	reduction	of	the	PPant-bound	intermediate	to	the	terminal	alcohol.	
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Several	 coordinated	 water	 molecules	 are	 present	 between	 the	 catalytic	 residues	Y1311,	T1283	and	the	non-catalytic	S1285.	One	water	molecule	is	positioned	2.7	Å	from	the	hydroxyl	of	Y1311	and	2.8	Å	from	T1283,	possibly	occupying	the	oxyanion	hole	that	these	two	residues	create	to	assist	in	thioester	and	aldehyde	reduction.	T1283	and	S1285	bind	a	second	water	molecule	in	the	active	site,	although	its	positioning	does	not	provide	a	clear	role	 in	 catalysis.	 With	 respect	 to	 these	 observations,	 several	 SDR	 studies	 suggest	 that	ordered	 water	 molecules	 in	 the	 active	 site	 might	 participate	 in	 a	 proton	 relay	 system	involving	the	hydroxyl	of	Y1311,	2’-hydroxyl	of	the	nicotinamide	ribose	and	K1315.35-36	Structural	 comparison	of	 the	apo	 and	NADPH-bound	MxaA	R	 domain	 show	 slight	conformational	changes	with	an	overall	RMSD	of	0.63	Å.	Out	of	these	small	differences,	the	C-terminal	subdomain	experiences	a	 slightly	higher	 conformational	 change	upon	NADPH	binding,	compared	to	the	complete	monomer,	with	a	RMSD	difference	0.73	Å.		
	
3.3.6	MxaR,	NRP	R	and	AusA	R	structural	comparison	
	
Figure	3-10.	Structural	comparison	of	three	known,	crystallized	R	domains:	MxaA,	Nrp	and	AusA.	 (a)	 All	 three	 R	 domain	 structure	 share	 a	 similar	 helix-turn-helix-motif	 at	 the	 C-terminal	 subdomain.	 (b)	 Structural	 alignment	 between	 MxaA,	 NRP	 and	 AusA.	 (c)	 The	conserved	catalytic	T,	Y,	K	triad.	
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	 The	MxaA	R	 domain	 from	Stigmatella	aurantiaca	 displays	homology	 to	 the	 	 short	chain	 dehydrogenase/reductase	 family	 of	 enzymes,	 which	 include	 the	 previously	 solved	putative	 non-ribosomal	 peptide	 synthetase	 (NRP)	 R	 domain	 from	 Mycobacterium	
tuberculosis.7	More	specifically,	both	domains	form	part	of	the	tyrosine-dependent	class	of	oxidoreductase	known	for	 the	common	Thr,	Tyr,	Lys	catalytic	 triad.	Both	MxaA,	and	NRP	reductively	 release	 alcohol	 final	 products	 through	 a	 committed	 aldehyde	 intermediate,	utilizing	2	NADPH	molecules	in	the	process.	Mutants	of	the	T-Y-K	triad	for	both	MxaA	and	NRP	 R	 domains	 significantly	 display	 lower	 affinity	 for	 the	 NADPH	 cofactor	 and	 are	catalytically	inactive.	The	MxaA	shows	29.1	%	sequence	similarity	with	the	NRP	R	domain	respectively.	Structural	alignment	between	the	MxaA	and	NRP	R	domains	reveal	a	2.19	Å	RMSD	of	 the	 alpha	 carbons	 through	 279	 residues.	 A	 close	 inspection	of	 the	T-Y	 catalytic	residues	 in	 both	MxaA	 and	 NRP	 display	 a	 highly	 coordinated	water	molecule,	 providing	evidence	for	water	displacement	by	the	carboxylate	group	of	the	thioester	moiety	during	the	first	reduction.	This	further	supports	the	catalytic	role	of	the	T-Y	residues	of	stabilizing	the	carboxylate	through	an	oxyanion	hole,	typical	of	the	SDR	class	of	reductases.24-26	Structural	similarities	 include	 the	 NADPH	 binding	 Rossmann	 fold	 motif	 position	 at	 the	 N-terminal	subdomain	with	the	“helix-turn-helix”	motif	 insertion.	This	 includes	the	highly	conserved	“TGxxGxxG”	motif	for	NADPH	binding.			Substrate	 binding	 is	 proposed	 to	 occur	 on	 the	 C-terminal	 subdomain.24-26	 The	 	 C-terminal	 subdomain	of	 the	MxaA	R	domain	 is	assembled	by	5	helices	and	2	parallel	beta	sheets.	This	feature	is	present	in	both	the	NRP	R	and	the	two	electron	AusA	reductase	from	
Staphylococcus	aureus	(PDB:	4F6L,	4F6C)	(Fig.	3-10).7,	34	All	three	reductase	domains	share	a	 similar	 “helix-turn-helix”	 feature	 on	 the	 C-terminal	 subdomain.	 This	 HTH	 feature	 is	
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observed	in	helix	16	and	17	of	the	MxaA	R	(Fig.	3-9).		Docking	analysis	of	both	MxaA	and	NRP	R	domains	with	the	decanal	(for	MxaA)	or	valeryl	(NRP)	suggest	that	the	“helix-turn-helix”	motif	is	important	for	substrate	recognition	and	specificity.7		This	HTH	motif	in	the	NRP	R	domain,	referred	to	as	the	helical	insertion	by	Chhabra	et	al.	,	contain	several	hydrophobic	residues	that	in	conjunction	with	other	non-polar	residues	form	a	large	hydrophobic	surface	that	 could	 have	 a	 role	 in	 substrate	 binding.7	 	 Similarly,	 the	 HTH	 of	 the	MxaA	 displays	 a	comparable,	 yet	 distinct	 hydrophobic	 surface,	 which	 forms	 part	 of	 the	 myxalamid	 and	decanal	binding	pocket	in	our	in	silico		docking	analysis.	Such	HTH	structural	features	in	the	C-terminal	subdomains	of	these	currently	known	2	and	4	e-	reductases	provide	insights	into	the	substrate	specificity	of	terminal	R	domains.			
3.3.7	Biochemical	analysis	of	the	NADPH	and	substrate-binding	pocket	Moving	beyond	the	structural	and	computational	results	pertaining	to	the	reduction	of	4	to	6,	and	set	in	the	context	of	advanced	biofuel	production	7	to	9	(Fig.	3-11),	we	aimed	to	provide	biochemical	support	for	residues	involved	in	NADPH	binding	and	the	requirement	of	the	Lys,	Tyr,	Thr	catalytic	triad.	As	the	structural	data	revealed	that	NADPH	contacts	the	amide	backbone	of	G1155,	G1158	and	G1161,	we	generated	single	Gly	 to	Ala	mutants	 for	each	residue	to	examine	the	effect	on	NADPH	binding	capacity.	Likewise,	residues	composing	the	putative	catalytic	triad	were	mutated	one	at	a	time	(T1283A,	K1315A	and	Y1311F)	to	similarly	determine	effects	on	both	NADPH	binding	and	catalytic	activity.	NADPH	binding	studies,	 as	 determined	 by	 intrinsic	 fluorescence	 measurements	 with	 the	 wild-type	 and	mutant	 PCP-R	 didomains,	 clearly	 demonstrated	 disruption	 of	NADPH	binding	 by	 alanine	mutation	in	the	TGxxGxxG	motif,	as	well	as	with	mutants	Y1311F	and	K1315A	(Fig.	3-11,	
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Table	3-2).7,	37	Surprisingly,	although	not	without	precedent,	the	T1283A	mutant	possessed	an	approximate	50%	increase	in	NADPH	binding	affinity	(Kd(w.t.)	=	45	±	3.7	μM	vs.	Kd(T1283A)	=	31.7	±	1.6	μM).7	This	could	be	rationalized	by	the	fact	that	T1283	has	no	direct	contact	with	the	cofactor	and	removal	of	its	steric	bulk	likely	improves	access	of	NADPH	to	the	binding	site.	 These	 mutants	 were	 additionally	 investigated	 for	 activity	 toward	 the	 reduction	 of	decanal.	All	mutants	were	 catalytically	 inactive,	 including	T1283A,	which	 further	verified	requirement	of	the	intact	NADPH	binding	pocket	and	the	complete	catalytic	triad	for	activity	(Fig.	3-12).	
	
Figure	3-11.	Determination	of	NADPH-Binding	Constants	for	Wild-Type	MxaA	R	and	Select	Mutants	of	NADPH-Interacting	Residues	
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		 w.t.	 T1283A	 K1315A	 Y1311F	 G1155A	 G1158A	 G1161A	Flmaxa			 3750	±	128	 5059	±	94	 1408	±	167	 1007	±	100	 1063	±	608	 1183	±	186	 5087	±	8387	Kdb			 45	±	3.7	 31.7	±	1.6	 99.0	±	21.1	 45.4	±	10.8	 149	±	133	 89.9	±	26.2	 1125	±	1767	aFlmax	is	reported	in	arbitrary	units;	b	Kd	is	reported	in	µM.	
	
Table	 3-2.	 Absolute	 values	 for	 maximum	 fluorescence	 (Flmax)	 and	 Kd	 values	 for	 NADPH	binding	with	MxaA	and	select	mutants	of	the	NADPH	binding	pocket.	(Related	to	Figure	3-11)	
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Figure	3-12.	(a)	Proposed	two-step	reduction	of	mxa.	(b)	Electrostatic	interaction	between	decanoyl-PCP	and	R1339	and	(c)	relieved	electrostatic	 interactions	between	R1339A	and	decanoyl-PCP.		
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Moving	 beyond	 characteristic	 analysis	 of	 the	 NADPH	 binding	 motif	 and	 catalytic	residues,	we	sought	to	further	investigate	residues	that	may	interact	with	the	mxa	substrate	as	determined	through	MD	simulations	and	docking	studies.	We	focused	on	 five	residues.	The	 first,	 and	 perhaps	 most	 interesting,	 was	 R1339,	 which	 was	 determined	 by	 MD	simulations	to	possess	the	highest	probability	of	contact	with	the	substrate	–	in	particular	the	 thioester-bound	 alanine	 moiety.	 Four	 additional	 residues	 with	 high	 probability	 of	substrate	interaction	in	the	predominantly	hydrophobic	mxa-binding	pocket	were	mutated	to	 reverse	 their	 polarity	 or	 knockout	 key	 functional	 groups	 (F1248N,	 V1308T,	 Y1430F,	R1468A).	Because	of	the	complexity	of	the	substrates	(PPant-mxa	4	and	mxa	aldehyde	5)	and	 concerns	 of	 their	 aqueous	 solubility,	 we	 opted	 to	 conduct	 the	 enzyme	 assay	 using	simplified	substrates:	decanoyl-PCP	and	decanal.	Moreover,	as	our	ultimate	goal	is	to	use	the	information	gained	in	these	studies	for	the	production	of	biologically	derived	replacement	fuels	 and	 commodity	 chemicals,	 examination	 of	 the	 active	 site	 in	 the	 context	 of	 a	 target	compound	 provides	 valuable	 knowledge	 to	 enable	 our	 desired	 goal.	 Studies	 additionally	offer	critical	 information	pertaining	to	the	mechanism	of	 the	R	domain.	Each	mutant	was	assayed	for	the	full	reductive	reaction	and	the	second	half	reaction.	Owing	to	the	fact	that	aldehyde	reduction	is	several	orders	of	magnitude	faster	than	PCP	thioester	reduction	(Table	3-3),	 assays	 of	 this	 full	 reaction	 provide	 rates	 that	 are	 specific	 to	 the	 first	 half	 reaction.	Therefore,	we	were	able	to	obtain	rates	for	both	reductions:	k1	and	k2.	Due	to	the	fact	that	both	decanoyl-CoA	and	decanoyl-loaded	MxaA	PCP	monodomain	were	not	turned	over	by	MxaA	 R,	 we	 developed	 a	 single	 turnover	 assay	 by	 loading	 decanoyl-CoA	 to	 the	 PCP-R	didomain	with	 the	 promiscuous	 phosphopantethienyl	 transferase	 Sfp	 in	 order	 to	 obtain	kinetic	parameters	for	the	first	reduction.38	Owing	to	low	reactivity	in	the	first-half	reaction,	
	 94	
multiple	time	points	were	taken	within	the	first	three	hours	without	depleting	the	enzyme-substrate	complex	below	5%	of	the	total	concentration.	This	allowed	the	assays	to	be	kept	under	 pseudo-saturating	 (kcat)	 conditions.	 While	 data	 concerning	 the	 first	 reduction	provided	turnover	numbers	that	are	significantly	slower	than	those	found	with	the	second-half	 reaction,	 a	 clear	 dependence	 on	 residue	 identity	was	 observed	 in	 the	 course	 of	 our	studies.	 Moreover,	 as	 this	 system	 is	 a	 truncated	 portion	 of	 the	 complete	 MxaA	module,	changes	in	protein	structure	or	substrate	positioning—a	parameter	that	may	be	altered	by	both	protein	truncation	and	use	of	a	substrate	lacking	a	PCP-bound	amide	bond—may	have	consequences	that	affect	the	upper	limit	of	kcat,	but	still	clearly	represent	changes	brought	on	by	amino	acid	substitution.	In	contrast,	observing	NADPH	consumption	under	saturating,	multiple	turnover	conditions	with	the	intermediate	aldehyde	8	and	yielded	values	similar	to	those	obtained	with	the	Nrp	R	domain	(Table	3-3).		
Table	3-3.	Specific	and	Relative	Activities	for	Wild-Type	and	Select	Mutants	with	Respect	to	the	First-	and	Second-Half	Reactions	
		With	 respect	 to	 the	 first	 reduction,	 we	 found	mutations	 of	 the	 four	 residues	 that	define	 the	 mxa-binding	 pocket	 to	 cause	 significant	 reductions	 in	 activity	 (Table	 3-2).	Mutation	of	residues	closer	to	the	NADPH	binding	site	(F1248N,	approximate	65%	reduction	
Full	Reaction Second-Half	ReactionEnzyme	Activity	(pmol/min/mg	MxaA) Activity	Relative	to	Wild-Type Enzyme	Activity	(pmol/min/mg	MxaA) Activity	Relative	to	Wild-TypeWT 3.69	±	0.19 1.00 21.5	±	1.7 1.00F1248N 1.24	±	0.03 0.34 27.2	±	4.9 1.26V1380T 1.86	±	0.10 0.50 34.1	±	0.7 1.58R1339A 15.19	±	0.46 4.11 134.41	±	12.5 6.22Y1430F 2.45	±	1.56 0.66 37.4	±	4.1 1.73R1468A 1.10	±	0.10 0.30 26.8	±	3.1 1.24
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in	 activity)	 caused	a	greater	 reduction	 in	activity	 than	 those	buried	deeper	 in	 the	pocket	Y1430F	and	V1380T,	(approximate	45%	reduction	in	activity).	This	is	likely	due	to	reduced	substrate-residue	interactions,	as	indicated	by	our	docking	simulations	with	the	non-native	substrates.	 R1468,	 while	 buried	 deep	 in	 the	 binding	 pocket,	 still	 appeared	 to	 have	 an	important	role	in	the	first-half	reaction	as	demonstrated	by	the	sharp	reduction	in	activity	with	 the	 R1468A	 mutant.	 Interestingly,	 for	 the	 second	 reduction,	 the	 same	 mutations	moderately	 increased	activity,	compared	to	the	wild-type.	Aggregate	results	reveal	a	high	probability	 that	 the	 first-half	 reaction	 is	 the	 rate-limiting	step	of	 this	overall	process	and	acutely	sensitive	to	binding	pocket	mutations,	while	aldehyde	reduction	appears	to	be	more	robust.	In	our	investigation,	the	second-half	reaction	turnover	rate	was	actually	improved	by	disruption	of	the	binding	pocket	and	active	site	entrance,	supporting,	that	for	the	second	half	reduction,	product	release	might	be	rate	limiting.	In	 addition	 to	 exploring	 the	mutational	 tolerance	 of	 the	 binding	 pocket	 we	were	interested	to	determine	if	R1339,	as	indicated	by	MD	and	docking	simulations,	interacted	with	the	substrate.	Computational	data	hinted	to	an	electrostatic	 interaction	between	the	R1339	guanidino	group	and	the	terminal	alanine	moiety	contained	within	mxa.	Therefore,	we	aimed	to	determine	if	R1339	in	fact	has	an	impact	on	catalysis.	While	kinetic	analysis	of	substrates	lacking	a	terminal	alanyl	thioester	or	alanal	moiety,	as	found	in	mxa	substrates,	cannot	definitively	demonstrates	 the	role	of	R1339	plays	during	catalysis	with	the	native	substrate,	a	comparison	of	the	C10	substrate	used	in	our	studies	with	both	w.t.	and	R1339A	MxaA	 R	 provides	 a	 general	 understanding	 as	 to	 the	 nature	 of	 the	 residue-substrate	interaction.	Of	significant	importance,	particularly	in	light	of	our	goals	to	apply	this	enzyme	in	the	production	of	fully	reduced	alcohols,	we	found	that	R1339A	dramatically	improved	
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the	ability	of	MxaA	R	to	reduce	C10	substrates	with	a	4.1-	and	6.2-fold	increase	in	activity	for	the	 first	 and	 second	 reduction,	 respectively.	 The	 large	 increases	 in	 activity	 can	 be	rationalized	by	the	fact	that	reduction	of	the	thioester	or	aldehyde	is	guided	by	interactions	between	the	PCP,	R	domain	and	PPant	arm	and	R1339	appears	to	be	poised	to	interact	with	incoming	 substrates	 (Fig.	 3-5a,c).	 Both	 the	 first	 and	 second	 reductions	 with	 alternate	substrates	 are	 improved	 by	 removal	 of	 the	 mismatched	 residue-substrate	 polarity	 (i.e.,	hydrocarbon-guanidino	 interaction)	and,	accordingly,	are	 facilitated	by	an	 increase	 in	 the	hydrophobicity	of	 the	active	 site	 tunnel	 (Fig.	3-12).	 In	 conclusion,	 the	above	biochemical	findings	support	the	combined	crystal	structure	and	computational	data,	and	set	the	stage	for	 future	 endeavors	 to	 further	 tune	 the	 active	 site	 to	 increase	 turnover	 of	 aliphatic	substrates.	
	
3.4	Materials	and	methods	
3.4.1	Molecular	dynamics	Molecular	dynamics	was	carried	out	using	Amber	14.39	Both	protein	and	ligand	were	prepared	for	docking	by	using	the	program	Chimera.17	Charges	were	calculated	using	the	AMBER	ff14SB	force	field.	Selenomethionine	(MSE)	residues	were	converted	to	methionine	(MET)	residues,	solvent	was	deleted	and	hydrogens	were	added.	LEaP	was	used	to	neutralize	the	system	by	adding	eight	Na+	ions,	and	solvating	the	apo	enzyme	in	a	10	Å	water	buffer	TIP3P	 truncated	 octahedron	 box.	 	 The	 fully	 solvated	 system	 contained	 42,865	 atoms.		Minimization	 using	 SANDER	 was	 performed	 in	 two	 stages	 to	 remove	 any	 steric	 clashes	present	in	the	initial	crystal	structure.		The	initial	stage	was	carried	out	over	2500	steps	for	the	 solvent	and	 ions	with	 the	protein	and	cofactor	 restrained	by	a	 force	 constant	of	500	
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kcal/mol/Å2,	followed	by	a	second	stage	carried	out	over	5000	steps	of	the	entire	system.		A	short	20	ps	simulation	with	weak	restraints	(force	constant	of	10	kcal/mol/Å2	on	the	protein	and	cofactor)	was	used	to	heat	up	the	system	to	a	 temperature	of	300K	using	a	 langevin	temperature	equilibration	scheme.	Periodic	boundary	conditions	were	used,	along	with	a	non-bonded	interaction	cutoff	of	10	Å.		For	the	simulation,	hydrogen	atoms	were	constrained	using	the	SHAKE	algorithm,	allowing	for	a	2	fs	time	step.		The	simulation	was	run	over	100	ns	(50,000,000	time	steps).	Simulation	speeds	of	4.0	ns/day	were	observed.	A	representative	cluster	ensemble	was	generated	from	MD	using	RMSD	scoring	as	implemented	in	Chimera	1.9.17		RMSD	scoring	reduced	the	initial	set	of	1000	frames	generated	to	the	46	most	unique	frames.		Molecular	graphics	and	analyses	were	performed	with	the	UCSF	Chimera	package.	RMSD	scoring	was	also	used	to	calculate	changes	in	the	C-terminal	and	N-terminal	domains.	Highly	mobile	residues	were	identified	in	a	similar	approach.	
	
3.4.2	In	silico	docking.		The	docking	program	GOLD	was	used	for	docking	between	the	MxaA	R	domain	and	the	phosphopantetheine-tethered	myxalamid	intermediate.16	Both	protein	and	ligand	were	prepared	for	docking	by	removing	waters,	adding	hydrogens,	and	converting	the	pdb	files	to	Mol2	files	using	the	program	Chimera.40	The	MxaA	R	ligand-binding	pocket	was	defined	as	residues	within	20	Å	of	the	hydrogen	atom	on	the	hydroxyl	group	of	T1283.	Docking	was	performed	 using	 the	 default	 settings	 with	 100	 docking	 trials	 performed.	 The	 docking	solutions	were	ranked	using	the	ChemPLP	scoring	functions.	Molecular	dynamic	simulations	generated	46	clusters	with	significant	RMSD	differences.	A	frame	from	each	cluster	was	used	to	dock	the	phosphopantetheine-tethered	myxalamid	using	the	same	docking	parameters.	
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Prior	 to	 MxaA	 PCP-R	 domain	 docking,	 a	 PCP	 homology	 model	 was	 generated	 using	 the	structure	prediction	HHpred	19.	The	R	domain	monomer	was	docked	with	the	PCP	homology	model	 using	 the	 protein-protein	 docking	 server	 Z-dock.22	 The	 ZDOCK	 3.0/3.02	 scoring	function	was	used	to	identify	the	correct	binding	motif.23	
	
3.4.3	Protein	expression	and	purification	The	recombinant	wild-type	and	mutant	MxaA	R	monodomains	with	an	N-terminal	His6x-tag	were	expressed	in	BL21	(DE3)	E.	coli	cells	(Novagen).	Cells	containing	the	MxaA	R	domain	 plasmid	 were	 grown	 to	 OD600	 =	 0.6	 at	 37	 °C	 in	 LB	media	 containing	 50	 µg/mL	kanamycin.	The	cell	cultures	were	cooled	to	18	°C	and	expression	was	induced	using	0.5	mM	IPTG.	The	cell	cultures	were	incubated	for	an	additional	16	hours	at	18	°C	and	harvested	by	centrifugation	at	5,525	r.c.f.	for	15	minutes.	The	cell	pellets	were	resuspended	in	50mM	tris-HCl	 pH	 7.5,	 10%	 glycerol,	 10	 mM	 imidazole,	 300	 mM	 NaCl	 and	 1mg/ml	 lysozyme.	Resuspended	 cells	 were	 cooled	 on	 ice	 for	 30	 min	 and	 the	 cells	 were	 disrupted	 using	sonication.	 The	 cell	 debris	was	 cleared	 by	 centrifugation	 at	 21,036	 r.c.f.	 for	 1	 hour.	 The	supernatant	was	collected,	and	batch	bound	to	HisPurTM	Cobalt	Resin	(Thermo	Scientific)	for	1	hour	at	4	°C.	MxaA	R	was	purified	according	to	the	manufacturer’s	instructions	using	an	imidazole	step-gradient.	Fractions	containing	pure	protein	were	determined	by	SDS-PAGE	and	fractions	containing	MxaA	R	were	combined	and	dialyzed	against	50mM	tris-HCl	pH	7.5,	10	%	glycerol,	300	mM	NaCl	at	4	°C	for	12	hours.		Removal	of	the	N-terminal	His6-tag	was	conducted	by	 incubating	 the	dialyzed	MxaA	R	 at	18	 °C	 for	24	hours	with	 thrombin	 from	bovine	plasma	(Sigma-Aldrich,	St.	Louis	MO)	at	a	concentration	of	2	U/mg	of	MxaA	R	protein	and	3.5	mM	CaCl2.		Removal	of	thrombin	and	further	purification	of	MxaA	R	was	conducted	
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by	 anion	 exchange	 chromatography	 using	HiTrap	Q	 FF	 (GE	Healthcare)	 according	 to	 the	manufacturer’s	 instructions.	 Purified	MxaA	 R	was	 dialyzed	 against	 crystallization	 buffer,	which	consisted	of	25	mM	tris-HCl	pH	7.5,	5	%	glycerol,	1	mM	dithiothreitol.		Selenomethionine-substituted	(SeMet)	MxaA	R	protein	was	produced	in	Bl21	(DE3)	
E.	 coli	 strain	 in	 M9	 minimal	 medium	 using	 metabolic	 inhibition	 of	 the	 methionine	biosynthetic	pathway.41	A	5	ml	LB	culture	grown	overnight	was	used	to	inoculate	2	X	1L	of	LB	that	were	allowed	to	grow	at	37	°C	in	the	presence	of	50	µg/mL	kanamycin	until	OD600	=	0.6	was	reached.	The	resulting	cells	were	pelleted	at	5,525	r.c.f.	for	15	minutes	and	washed	three	 times	 by	 suspension	 in	 40ml	of	M9	medium	 and	 then	 transferred	 to	 2	 x	 1L	of	M9	medium	 containing	 50	 µg/mL	 kanamycin	 and	 the	 following	 amino	 acids:	 lysine,	phenylalanine	and	threonine	(100	mg/L);	isoleucine,	leucine	and	valine	(50	mg/L);	and	L-selenomethionine	(40	mg/L)	(sigma).	The	temperature	was	reduced	to	18	°C,	induced	with	0.5	mM	IPTG	and	was	allowed	to	grow	overnight	for	16	hours.	The	cells	were	harvested	and	purified	following	the	w.t.	procedure.	The	incorporation	of	selenomethionine	(10	residues	total)	was	confirmed	by	MALDI-TOF	mass	spectrometry.	
	
3.4.4	Crystallization,	data	processing,	refinement	and	analysis.		Both	native	and	SeMet	crystals	of	the	w.t.	MxaA	R	domain	(9	mg/ml)	grew	in	0.22	M	ammonium	acetate,	28	%	PEG	3350	and	0.1	M	Hepes	pH	7.7	overnight	at	25	°C	using	the	hanging	drop	vapor	diffusion	method.	NADPH	bound	MxaA	R	crystals	formed	similarly	with	the	exception	of	incubating	NADPH	and	MxaA	R	at	a	5:1	molar	ratio	for	1	hr	at	4	°C	prior	to	crystal	tray	set	up.	Crystals	were	cryoprotected	in	well	solution	and	flash	frozen	in	liquid	nitrogen	 prior	 to	 data	 collection.	 Data	 was	 collected	 at	 beamline	 12-2	 at	 the	 Stanford	
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Synchrotron	Radiation	Lightsource	(SSRL)	for	SeMet	crystals.	Prior	to	data	collection,	initial	frames	 were	 assessed	 for	 quality	 and	 redundancy	 using	 Mosflm	 and	 Web-ice	 42-43.	Multiwavelength	anomalous	diffraction	(MAD)	data	were	collected	to	1.70	Å	for	SeMet	MxaA	R	at	λ	=	0.9792	Å	(Selenium	peak),	λ	=	0.9611	Å	(inflection),	λ	=	0.9794	Å	(remote).		For	MAD	data	collection,	the	exposure	time	was	set	to	0.2	s;	0.15°	oscillation	width	for	1920	frames.	All	data	was	processed	using	Mosflm	to	the	P21	space	group	(2).	Native	NADPH	bound	MxaA	R	data	was	collected	at	the	Advance	Light	Source	beamline	822	at	the	Lawrence	Berkeley	National	Laboratory.	Single	monochromatic	x-ray	diffraction	data	(λ	=	0.9775	Å,	700	frames	at	0.5°	oscillation	width	for	1	second	exposure)	was	collected	to	1.84	Å	and	processed	with	Mosflm	using	the	P21	space	group	(2).	Initial	phases	for	MAD	data	set	were	obtained	using	PHENIX	Autosol	(site)	and	9	out	of	the	10	heavy-atom	derivatives	were	located.	Initial	model	was	constructed	using	PHENIX	Autobuild.	Refinement	was	done	using	PHENIX.REFINE	and	COOT.44-45	 Improved	phases	were	used	 in	COOT	to	model	missing	side	residues	manually	and	 waters	 were	 added	 during	 the	 last	 refinement	 cycles.	 	 For	 the	 NADPH	 co-crystal	structure,	PHENIX	LigandFit	was	used	to	model	the	NADPH	upon	obtaining	initial	model	and	phases	from	Phenix	Autosol.44	Both	apo	and	NADPH	bound	structures	were	validated	using	PROCHECK	 and	 PDB_REDO.46-47	 Structural	 analysis	 such	 as	 structural	 superimposition,	electrostatic	 potentials	 and	 figure	 generation	 used	 in	 the	 manuscript	 were	 made	 using	PyMol.48	
	
3.4.5	Circular	dichroism	(CD).		All	samples,	both	mutant	and	w.t.,	were	prepared	by	diluting	protein	to	0.2	mg/ml	in	20mM	 Tris-HCl	 (pH	 7.5).	 The	 CD	 data	 was	 collected	 using	 a	 Jasco	 J810	 CD	
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spectropolarimeter.	Spectral	scans	were	collected	at	20	°C	from	190	to	260	nm	using	0.5nm	steps	with	5	repeats.		
	
3.4.6	NADPH	Consumption	Time	course.		Consumption	of	NADPH	by	MxaA,	or	variants	thereof,	was	measured	by	decrease	in	absorption	at	340	nm.	5.0	µM	of	the	MxaA	R	was	incubated	in	100	mM	potassium	phosphate	(pH	 =	 7.0)	 buffer	 containing	 200	µM	NADPH	 and	 1.0	mM	 decanal,	 in	 order	 to	 keep	 the	substrate	 near	 saturating	 conditions.	 Measurements	 were	 recorded	 in	 triplicate	 and	averaged,	spontaneous	NADPH	degradation	was	accounted	for	in	a	control	reaction	lacking	enzyme.	
	
3.4.7	Fluorescence	Titration	of	MxaA	R	and	Mutants.		Assays	 were	 prepared	 by	 adding	 NADPH	 (1	 mM	 stock	 solution,	 1-130	 µM	 final	concentration)	to	10	µM	MxaA	or	mutant	R	in	buffer	containing	100	mM	phosphate	and	300	mM	NaCl	at	pH	7.25.	Fluorescence	was	measured	on	a	Teacan	Safire	fluorometer	(lex	=	340	nm,	lem	=	460	nm	with	excitation	and	emission	slits	set	to	7.5	nm)	and	the	relative	increase	in	 fluorescence	was	measured	by	 subtracting	autofluorescence	of	NADPH	samples	 in	 the	absence	of	enzyme	from	those	 interacting	with	the	reductase	domain.	Plotting	these	data	and	 fitting	 to	 the	 Michaelis-Menten	 equation	 determined	 the	 Kd	 and	 relative	 maximum	fluorescence.	
3.4.8	Determination	of	Enzyme	Specific	Activities	with	Decanal.		MxaA	(w.t.	or	mutant)	(20	µM	final	concentration)	was	added	with	NADPH	(250	µM)	and	decanal	(2	mM,	saturating)	to	the	reaction	buffer	(150	mM	sodium	phosphate,	200	mM	
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NaCl)	 at	 a	 total	 volume	 of	 200	 µL.	 These	 reactions	 were	 monitored	 at	 340	 nM	 for	 the	depletion	of	NADPH	over	six	minutes,	corrected	for	background	NADPH	consumption	and	the	 resultant	 slope	was	used	 to	 calculate	 the	 specific	 activity.	Conversion	 to	decanol	was	verified	by	GCMS.	
	
3.4.9	Single	turnover	assay	for	R	domain	reduction.		MxaA	(w.t.	or	mutant)	(50	µM	final	concentration)	was	combined	with	decanoyl-CoA	(200	µM),	MgCl2	 (10	mM),	 Sfp	 phosphopantetheinyl	 transferase	 (10	µM)	 in	 the	 reaction	buffer	 (150	 mM	 sodium	 phosphate,	 200	 mM	 NaCl)	 at	 a	 total	 volume	 of	 300	 µL.38	 Sfp-mediated	 PPant	 loading	 proceeded	 for	 2	 h	 at	 which	 point	 the	 extent	 of	 loading	 was	determined	by	LC-MS/MS	to	provide	19	µM	of	decanoyl-loaded	MxaA-PCP.49	The	reaction	was	 initiated	with	NADPH	(250	µM).	Control	reactions	showed	no	reduction	of	decanoyl-CoA	 in	 the	 absence	 of	 being	 loaded	 to	 the	MxaA	PCP.	 Reactions,	 done	 in	 duplicate,	were	stopped	at	1h,	2h	and	3h	with	the	addition	of	30	µL	10	%	(v/v)	acetic	acid	and	extracted	with	2	x	300	µL	hexanes	containing	an	internal	standard	of	100	µM	dodecanol.	Combined	extracts	were	 concentrated	 ~10-fold	 and	 mixed	 with	 an	 equal	 volume	 of	 N,O-Bis(trimethylsilyl)trifluoroacetamide	 (BSTFA)	 and	 analyzed	 on	 a	 Hewlett	 Packard	 6890	series	GC	fitted	with	an	Agilent	5973Network	mass	detector	with	a	30m	x	0.25mm	DB-5MS	column	(Agilent).		Samples	were	injected	at	80	°C,	held	at	that	temperature	for	2.0	min	and	then	ramped	to	300	°C	at	25	°C/min	held	at	300	°C	for	1.0	min	and	returned	to	the	initial	temperature.	 Samples	 were	 compared	 to	 an	 authentic	 decanol	 standard	 curve	 and	normalized	to	internal	dodecanol.	
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3.4.10	Analytical	Size	Exclusion	Chromatography.			Six	milligrams	of	 purified	MxaA	PCP-R	 didomain	 suspended	 in	500	µL	 of	 	50	mM	sodium	phosphate	buffer	pH	7.5	and	100	mM	sodium	chloride	buffer	was	 injected	 into	a	Superdex	200	10/300	GL	column	(GE	Healthcare	Life	Sciences)	using	an	Äkta	explorer	FPLC	system	 (GE	 Healthcare	 Life	 Sciences).	 The	 sample	 was	 allowed	 to	 run	 over	 1.3	 column	volumes	at	a	flow	rate	of	0.5	mL/min	using	filtered	50	mM	sodium	phosphate	buffer	pH	7.5	and	100	mM	sodium	chloride	buffer.	MxaA	PCP-R	didomain	sample	was	monitored	at	280	nm.	The	molecular	weight	and	multimeric	state	of	the	MxaA	PCP-R	didomain	was	assessed	and	compared	to	low	and	high	molecular	weight	gel	filtration	calibration	protein	standards	(GE	Healthcare	Life	Sciences).		
	
3.4.11	Cloning.		The	MxaA	PCP	and	R	monodomains	were	amplified	using	the	myxobacterium	S.	
aurantiaca	PCP-R	didomain	previously	cloned	into	pET28a	with	NdeI	tagged	5’	forward	primer	and	the	HindIII	tagged	3’	flanking	primer.	The	subsequent	amplified	product	was	inserted	into	the	corresponding	sites	in	pET28b	(Novagen,	Madison,	WI)	generating	N-terminal	thrombin	cleavable	His6x-tagged	constructs.	The	constructs	were	transformed	into	Rosetta	BlueTM	(Millipore)	Nova	Blue	competent	cells	for	construct	amplification.	Sequence	was	confirmed	through	automated	DNA	sequencing.	Cloning	Primer						 Sequence	MxaA	PCP	Forward:	 5’-		ATATATCATATGCGCGCTGCTCTGCCG	MxaA	PCP	Reverse:	 5’-	ATATATAAGCTTTTAATCATGCGCCGGCAGAGAGC	 	MxaA	R	Forward:	 5’-	ATATATCATATGTCTCTGCCGGCGCATGATGT	
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MxaA	R	Reverse:	 	 5’-	ACATATATAAGCTTTTATTCTGGAGCCTTCAGGAAGCCAC	
	
3.4.11	Site-directed-mutagenesis.		The	online	program	PrimerX	was	used	to	design	primers	for	all	the	R	mutants	using	the	previously	described	cloned	pET28b	w.t.	R	DNA	template	50.The	following	primers	were	used	for	mutagenesis.	All	mutations	were	confirmed	though	automated	DNA	sequencing.	Mutant	Primer	 	 	 									 Sequence	MxaA	R	Y1311F		 Forward:		 5’-	GCGGCTTTGCTCAGAGTAAATGGG	MxaA	R	Y1311F	 Reverse:		 5’-	CTCTGAGCAAAGCCGCCCACC	MxaA	R	K1315A		 Forward:		 5’-	GAGTGCGTGGGTCGCGGAAAAGCTGG	MxaA	R	K1315A		 Reverse:		 5’-	GACCCACGCACTCTGAGCATAGCCGC	MxaA	R	T1283A	 Forward:		 5’-	GTTAGCGCGGTCTCTGTGCTGCCGC	MxaA	R	T1283A		 Reverse:	 5’-	CAGAGACCGCGCTAACATAGTGCAGCGG	MxaA	R	G1155A		 Forward:	 5’-	ACCGCGGCTACGGGTTTTCTGGGC	MxaA	R	G1155A		 Reverse:	 5’-	CCCGTAGCCGCGGTCAGCAGG	MxaA	R	G1158A		 Forward:	 5’-	ACGGCGTTTCTGGGCGCGTTCCT	MxaA	R	G1158A			 Reverse:	 5’-	CCCAGAAACGCCGTAGCACCGGTC	MxaA	R	G1161A		 Forward:	 5’-	TTCTGGCGGCGTTCCTGCTGGAAG	MxaA	R	G1161A		 Reverse:	 5’-	GGAACGCCGCCAGAAAACCCGTAG	MxaA	R	F1248N	 Forward:		 5’-	TGGTCAATAATCTGTATCCGTACGAAAGC	MxaA	R	F1248N	 Reverse:		 5’-	CGGATACAGATTATTGACCAGTGCACC	MxaA	R	V1308T		 Forward:		 5’-	AGCCTGACGGGCGGCTATGCTCAGAG	MxaA	R	V1308T		 Reverse:		 5’-	CGCCCGTCAGGCTGCTCGGAC	
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MxaA	R	R1339A	 Forward:		 5’-	GGGTGCGGTGACCGGTCATTCACGC	MxaA	R	R1339A		 Reverse:	 5’-	GGTCACCGCACCCGGACGCAGG	MxaA	R	Y1430F		 Forward:	 5’-	CCGTTTGACCAGTGGCTGAGC	MxaA	R	Y1430F		 Reverse:	 5’-	CACTGGTCAAACGGCAGAACG	C	MxaA	R	R1468A			 Reverse:	 5’-	CGGTCCGGCGATGGTGGTTTGCG	MxaA	R	R1468A		 Forward:	 5’-	GCAACCGCCAGGCCGCTACCAC	
	
3.4.12	Determining	of	the	Extent	of	PCP	Loading	by	Sfp.		Apo-MxaA(PCP-R)	was	purified	in	BL21(DE3)	as	reported	above.	Loading	of	acylated	CoA	(decanoyl	CoA)	was	performed	as	described	in	the	main	text.	Following	the	reaction	of	MxaA(PCP-R)	 (50	 µM)	 with	 decanoyl	 CoA	 (200	 µM)	 and	 Sfp	 (10	 µM)	 the	 reaction	 was	incubated	with	10%	(w/w)	trypsin	and	allowed	to	digest	 for	2h	at	ambient	 temperature.	Reactions	lacking	Sfp	and	decanoyl	CoA	were	performed	as	controls.		Samples	were	analyzed	on	an	Agilent	4640	Triple	Quad	LC/MS	(Santa	Clara,	CA)	mass	spectrometer	operating	in	SRM	mode	coupled	to	an	Agilent	1260	Infinity	HPLC	(Santa	Clara,	CA).		5	µg	of	peptide	was	injected	on	a	Supelco	Acentis	Express	Peptide	ES_C18	column	(5cm	x	 2.1mm	 x	 2.7	 µm)	 (Sigma-Aldrich,	 St.	 Louis,	 MO)	 column	 with	 the	 following	 gradient	applied:	Buffer	A	=	H2O	+	0.1%	 trifluoroacetic	 acid;	Buffer	B	=	98%	acetonitrile	+	0.1	%	trifluoroacetic	acid;	t	=	0	min	95%	A;	t	=	0.2	min	95%	A	ramped	to	65%	A	at	5.7	min;		5.7	min	to	6.0	min	ramp	to	10%	A;	6.0	min	to	8.0	min	hold	at	10%	A;	8.0	min	to	8.5	min	ramp	down	to	5.0%	A	and	hold	to	11.0	min.	The	flow	rate	was	held	constant	at	0.4	mL/min.	The	following	parent	(p)	and	daughter	(d)	ions	were	monitored	to	determine	the	relative	amounts	of	apo,	
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holo	and	C10	acylated	PCP:	apo	(p:	1084.8685,	d:	175.1190);	holo	(p:1084.8686,	d:	261.1267)	and	decanoyl	(p:1136.2472,	d:	415.2625)	with	z=3.	Data	was	analyzed	using	Skyline.	It	was	determined	that	unreacted	apo	MxaA(PCP-R)	contained	~5%	holo	protein	with	the	remainder	as	the	apo	form.	Reaction	with	Sfp	and	no	decanoyl	CoA	provided	significantly	increased	amounts	of	the	holo	form	(~2:1	holo:apo).	This	is	presumably	from	co-purification	of	coenzyme	A,	despite	dialysis	of	the	Sfp	protein	itself.	Similarly,	reaction	of	apo	MxaA(PCP-R)	 with	 Sfp	 and	 decanoyl	 CoA	 provided	 an	 approximate	 2:1	 ratio	 of	 holo	 to	 decanoyl	phosphopantetheine.	The	 final	concentration	of	active	MxaA	(enzyme	substrate	complex)	was	adjusted	to	reflect	these	data.	
	
3.5	Conclusions		Products	generated	by	PKSs	and	NRPSs	require	release	from	PPant-tethered	carrier	proteins	 contained	 in	 mega-synthases.	 Both	 thioesterase	 and	 R	 domains	 mediate	 chain	release	 to	provide	distinct	 terminal	 functional	 groups	 to	enrich	 the	 chemical	diversity	of	polyketide	 and	 non-ribosomal	 peptide	 natural	 products.4	 R	 domains	 are	 an	 NADPH	dependent	 class	 of	 SDR-like	 enzymes	 capable	 of	 reductively	 releasing	 acyl	 and	 peptide	intermediates	 from	 the	 PPant-tethered	 carrier	 protein.	 Prior	 to	 this	 study,	 no	 co-factor	bound	structure	was	available	for	modular	enzyme-associated	terminal	R	domains.	Here,	we	report	the	crystal	structure,	with	significantly	increased	resolution,	of	the	myxalamid	PKS-NRPS	terminal	R	domain	that	catalyzes	the	non-processive	four-electron	reduction	of	4	to	6	and	 decanoyl-PCP	 to	 1-decanol.	 Computational	 MD	 and	 biochemical	 analysis	 support	assertions	 that	 the	 C-terminal	 subdomain	 of	 the	 R	 domain	 is	 the	 most	 flexible	 region,	responsible	for	substrate	binding	and	selectivity.	With	respect	to	kinetic	parameters	the	first	
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reduction	of	decanoyl-	PCP	to	yield	the	decanal	intermediate	is	significantly	slower	than	the	second	reduction	of	decanal	 to	1-decanol,	 thus	providing	 insight	 to	 the	rate-limiting	step	during	R	domain	mediated	product	 release.	 Structure-based	mutations	helped	determine	residues	important	for	substrate	binding	and	reduction.	Furthermore,	mutational	analysis	of	the	putative	gatekeeping	residue	(R1339)	improved	reduction	of	both	decanoyl-PCP	and	decanal.	Combined,	the	mechanistic	insights	gained	by	our	comprehensive	investigation	of	MxaA	 R	 provide	 not	 only	 a	 deeper	 understanding	 of	 structural	 and	 catalytic	 features	required	 for	 activity	 but	 set	 a	 foundation	 for	 future	 engineering	 efforts	 using	 modular	catalyst	associated	R	domains.	Efforts	 in	combining	R	domains	with	novel	PKS-	or	NRPS-based	assembly	lines	could	produce	alternate	substrates	that,	for	example,	can	be	screened	for	new	bioactivity	or	used	in	the	production	of	biologically	derived	commodity	chemicals.	
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CHAPTER	4	
	
Structural	Characterization	of	the	Crucial	Interaction	Between	the	Acyl	Carrier		
	
Protein	and	a	Ketosynthase	
	
	
	
4.1	Summary	Fatty	 acid	 synthases	 are	 dynamic	 ensembles	 of	 enzymes	 that	 can	 efficiently	biosynthesize	long	hydrocarbon	chains.	Here	we	visualize	the	interaction	between	the	E.	coli	acyl	 carrier	 protein	 (AcpP)	 and	 β-ketoacyl-ACP-synthase	 I	 (FabB)	 using	 X-ray	crystallography,	NMR,	and	MD	simulations.	We	leveraged	this	structural	information	to	alter	lipid	profiles	in	vivo	and	provide	a	molecular	basis	for	how	protein-protein	interactions	can	regulate	the	fatty	acid	profile	in	E.	coli.	
	
4.2	Introduction	The	E.	coli	fatty	acid	synthase	(FAS)	produces	metabolites	that	comprise	the	cellular	membrane	through	an	iterative	cycle	via	the	activities	of	13	discrete	proteins	that	yield	both	saturated	 and	 unsaturated	 products,	 with	 each	 enzyme	 carrying	 out	 a	 single,	 simple	transformation.1-2	These	crucial	enzymes	are	targets	for	antibiotic	drug	discovery,	and	the	ability	 of	 this	 pathway	 to	 efficiently	 form	 carbon-carbon	 bonds	 and	 generate	 long	hydrocarbon	 chains	 has	 made	 it	 a	 target	 for	 biofuel	 development.3-4	 However,	 the	 rate	limiting	steps	in	this	pathway	remains	poorly	understood,	and	attempts	to	understand	the	fundamental	 phenomena	 of	 fatty	 acid	 metabolism	 have	 been	 hindered	 by	 a	 lack	 of	information	about	the	molecular	interactions	of	the	pathway	enzymes.5-7	
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The	acyl	carrier	protein,	AcpP,	at	the	center	of	E.	coli	fatty	acid	biosynthesis,	shuttles	cargo	from	one	enzyme	partner	to	another	through	iterative	biosynthetic	cycles	(Fig.	4-1).	As	a	small,	dynamic,	monomeric	helical	bundle,	AcpP	provides	protection	of	 the	growing	fatty	 acid	 from	 non-selective	 reactivity	 in	 the	 cytosol	 by	 sequestration	 within	 a	 central	hydrophobic	 core.8-10	 Cargo	 is	covalently	 tethered	 to	 AcpP	 via	thioester	 linkage	to	the	end	of	a	post-translationally	 added	phosphopantetheine	 (PPant)	arm.11	 During	 interaction	 with	partner	 proteins,	 the	 cargo	translocates	 from	 the	hydrophobic	 core	 of	 AcpP	completely	 into	 the	 partner,	 a	process	called	“chain	flipping”.12-
13	 Figure	4-1.	Biosynthesis	of	saturated	and	unsaturated	fatty	acids	in	E.	coli.	FabA	(the	dehydratase)	and	FabB	(the	 ketosynthase),	 in	 blue	 and	 working	 in	 tandem,	produce	 and	 elongate	 unsaturated	 fatty	 acids.	 FabZ	(the	 second	 dehydratase)	 and	 FabF	 (the	 second	ketosynthase),	 in	 red,	working	 in	 tandem	with	 FabG	(the	 ketoreductase)	 and	 FabI	 (the	 enoylreductase),	produce	 and	 elongate	 saturated	 fatty	 acids.	 These	cycles	 are	 iterated	 to	 produce	 full-length	 fatty	 acid	chains.	R	=	acyl,	varying	in	length	based	on	how	many	upstream	iterations	of	the	cycle	have	occurred.	
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Figure	 4-2.	 Enzyme	 mechanism	 and	 mechanism-based	 crosslinking.	 (a)	 mechanism	 for	ketosynthase	reaction	and	enzyme	turnover.	(b)	mechanism-based	crosslinking.		The	β-ketoacyl-ACP-synthases	(KSs)	facilitate	the	key	carbon-carbon	bond	formation	step	of	fatty	acid	biosynthesis	in	three	discrete	steps	(Fig.	4-2).	First,	an	active	site	cysteine	attacks	the	PPant	thioester	and	releases	the	AcpP.	Next,	a	malonyl-loaded	AcpP	associates	and,	by	Claisen-like	condensation,	extends	the	chain.	Finally,	the	AcpP	dissociates,	carrying	with	it	the	elongated	β-keto-acyl	chain.	We	recently	applied	a	mechanism-based	probe	to	crosslink	AcpP	with	β-hydroxyacyl-AcpP-dehydratase	(FabA),	and	the	crystal	structure	of	the	 complex	 was	 solved.14-15	 The	 FabA-AcpP	 complex	 structure	 reveals	 unprecedented	information	 about	 how	 ACP	 interacts	 with	 its	 partner	 enzymes.	 However,	 to	 date,	 no	information	is	available	about	how	KS	interacts	with	ACP.	To	address	this	knowledge	gap,	here,	we	report	the	investigation	of	KS-ACP	interactions	using	a	mechanism	based	inhibitor	(Fig.	4-2B)	using	protein	NMR,	protein	crystallography,	and	MD	simulation.	16	
	
	
	 115	
4.3	Results	and	discussions	
4.3.1	The	crystal	structure	of	the	AcpP-FabB	complex	
To	prepare	an	AcpP-FabB	complex,	we	developed	a	covalent	chloroacrylyl	probe	to	exploit	the	nucleophilicity	of	the	FabB	active	site	cysteine	(Fig.	4-2a).17	The	chloroacrylyl-based	probe	was	chemoenzymatically	appended	to	AcpP	followed	by	incubation	with	FabB	to	generate	a	covalent	AcpP2-FabB2	complex	(Fig.	4-2b).16	The	2.4	Å	resolution	AcpP2-FabB2	crystal	structure	was	solved	by	molecular	replacement	using	a	FabB	structure	(PDB	code:	2VB9)	as	a	search	model	followed	by	manual	placement	of	the	crosslinked	AcpPs	(Fig.	4-3).18	 The	 AcpP2-FabB2	 complex	 consists	 of	 a	 core	 FabB	 dimer	 with	 each	 monomer	crosslinked	 to	a	 single	AcpP	 (Fig.	4-3a),	 	 similar	 to	 the	AcpP-FabA	complex.15	Each	AcpP	displays	a	four-helix	bundle	fold,	and	the	probe	extends	from	the	conserved	S36	sidechain	at	the	bottom	of	AcpP	helix	II	to	the	active	site	catalytic	cysteine	(C163)	of	FabB	(Fig.	4-3b	and	Fig.4-4).	
Figure	4-3.	Crystal	structure	of	E.	coli	AcpP-FabB	complex.	(a)	Overall	AcpP-FabB	complex	structure,	with	the	FabB	monomers	shown	in	dark	green	and	light	tan,	the	AcpP	monomers	shown	 in	 dark	 blue	 and	 light	 cyan,	 and	 the	 crosslinker	 in	 pink.	 (b)	 FabB	 active	 site	interactions	with	the	crosslinker.	(c)	AcpP-FabB	interface.	
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Figure	4-4.	Composite	omit	maps	at	1.0	sigma.	(a)	probe	2	in	the	FabB	active	site.	(b)	probe	2	connection	with	AcpP.	(c)	AcpP-FabB	interface	residues	with	AcpP	shown	in	light	cyan	and	FabB	shown	in	dark	green	and	light	tan.		 Each	AcpP	contacts	FabB	primarily	through	helix	II,	which	is	well	conserved	in	carrier	proteins	(Fig.	4-3c).19	Both	AcpP-FabB	interfaces	share	a	set	of	common	interactions.	At	the	bottom	of	AcpP	helix	II,	D35	and	D38	interact	with	R62,	K63,	and	R66	on	FabB,	while	E47	at	the	top	of	helix	II	interacts	with	R124	and	K127	on	FabB.	Additionally,	D56	on	helix	III	of	each	AcpP	forms	a	salt	bridge	with	R45	of	its	FabB	partner.	A	comparison	of	the	AcpP:FabB	and	AcpP:FabA	interfaces	reveals	distinct	AcpP	docking	motifs	for	each	partner	enzyme	(Fig.	4-5);	 close	 contacts	with	FabB	appear	 throughout	helix	 II,	whereas	 the	 interactions	with	FabA	are	predominantly	at	the	top	of	helix	II.	In	both	structures,	salt	bridges	are	observed	between	 helix	 III	 and	 the	 partner	 protein	 to	 facilitate	 chain	 flipping	 through	 a	 channel	between	helixes	II	and	III	(Fig.	4-5c,f).	
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Figure	4-5.	Comparison	of	AcpP-FabB	and	AcpP-FabA	complex	structures.	(a)	Overall	AcpP-FabB	complex	structure,	with	the	FabB	monomers	shown	in	dark	green	and	light	tan,	the	AcpP	monomers	shown	in	dark	blue	and	light	cyan,	and	the	crosslinker	in	pink.	(b)	FabB	active	site	interactions	with	the	crosslinker.	(c)	AcpP-FabB	interface.	(d)	Overall	AcpP-FabA	complex	structure,	with	the	FabA	monomers	shown	in	light	green	and	light	yellow,	the	AcpP	monomers	shown	in	dark	blue	and	light	cyan,	and	the	crosslinker	in	pink.	(e)	FabA	active	site	interactions	with	the	crosslinker.	(f)	AcpP-FabA	interface		 A	comparison	of	the	individual	AcpP-FabB	pairs	reveals	that	the	pantetheine	binding	sites	and	protein-protein	interfaces	overlay	well,	but	there	are	key	differences.	Most	notably,	divergence	in	the	structure	is	observed	in	helix	III	of	AcpP2	near	D56;	AcpP1	maintains	its	secondary	 structure	 at	 this	 location,	while	AcpP2	 is	 completely	 disordered	 (Fig.	 4-5b,e).	Additionally,	high	crystallographic	B-factors	support	the	observation	that	helix	III	of	AcpP2	is	more	 disordered	when	 compared	 to	 the	 ordered	 helix	 III	 on	AcpP1	 (Fig.	 4-6).	 Similar	differences	were	also	observed	 in	 the	AcpP	monomers	of	 the	AcpP-FabA	and	AcpP-FabZ	
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structures.15,	 20	 Together,	 these	 suggest	 that	 AcpP	 interactions	 with	 dimeric	 partner	enzymes	may	be	influenced	by	allosteric	regulation.	
	
Figure	4-6.	AcpP	comparison	between	AcpP-FabB	and	AcpP-FabA.	(a)	Overlay	of	AcpP	from	AcpP-FabA	(red)	and	from	AcpP-FabB	(green).	(b)(c)	B-factor	putty	representation	of	AcpP-FabB	(b)	and	AcpP-FabA	(c)	where	thin,	blue	tubes	correspond	to	low	B-factors	and	thicker,	darker	red	tubes	correspond	to	higher	B-factors.				
4.3.2	NMR	titration	studies	Solution-state	protein	NMR	experiments	were	performed	to	characterize	the	AcpP-FabB	interaction	in	vitro	for	comparison	with	crystallographic	observations.	1H,15N-HSQC	titration	experiments	were	performed	in	which	octanoyl-AcpP	was	exposed	to	increasing	molar	equivalents	of	FabB	(Fig.	4-7a	and	Fig.	4-8).	Observed	peak	shifts	due	to	the	acyl-AcpP	FabB	 interaction	matched	well	 with	 crystallographic	 observations.	 D35	 and	 D38	 exhibit	dramatic	chemical	shift	perturbations	(CSPs)	upon	interaction,	as	well	as	E47	demonstrating	a	moderate	CSP.	Overall,	the	NMR	CSP	plots	suggest	the	transient	interaction	between	AcpP	and	FabB	depends	significantly	on	helix	II,	and	to	a	lesser	extent	on	helix	III.	
	 119	
	
Figure	 4-7.	 Protein-protein	 interactions	 and	 the	 fatty	 acid	 profile.	 (a)	 Chemical	 shift	perturbation	plot	for	1H,15N-HSQC	titration	experiments	of	WT	AcpP	and	D38A	AcpP	against	increasing	concentrations	of	FabB.	Residue	number	represented	on	the	lower	axis.	(b)	MD	observed	contact	durations	for	helix	II	and	III	between	different	AcpP	species	FabB.	(c)	AcpP	complementation	temperature	response.	WT	AcpP	 is	shown	in	 light	green,	D38A	AcpP	 is	shown	 in	 dark	 green.	 Four	 biological	 replicates	 were	 prepared.	 ***	 denotes	 statistical	significance	with	P	values	<	0.001.		 Due	to	the	observed	importance	of	D38,	a	D38A	variant	was	prepared	and	subjected	to	the	same	NMR	titration	study	as	the	wild-type	AcpP	(Fig.	4-7a	and	Fig.	4-8).	D35A	was	not	selected	 to	 avoid	 perturbing	 the	 DSL	 motif	 necessary	 for	 covalent	 attachment	 of	 the	prosthetic	arm.	The	D38A	variant	is	still	observed	to	interact	with	the	FabB;	however,	the	observed	CSPs	are	smaller,	suggesting	a	weaker	interaction	with	FabB.	Additionally,	the	top	of	helix	II	appears	less	perturbed	in	the	D38A	variant	than	in	the	wild	type,	confirming	that	the	 D38	 (AcpP)	 –	 K63	 (FabB)	 and	 D38	 (AcpP)	 –	 R62	 (FabB)	 salt	 bridges	 observed	crystallographically	are	important	in	stabilizing	the	complex	in	solution.	
	 120	
	
Figure	4-8.	NMR	studies	of	the	AcpP-FabB	complex.	1H,15N-HSQC	titration	experiments	of	wildtype	AcpP	(at	left)	and	D38A	AcpP	(at	right)	against	increasing	concentrations	of	FabB.		
4.3.3	Molecular	dynamics	simulations	Molecular	 dynamics	 (MD)	 was	 applied	 to	 the	 AcpP-FabB	 complex	 to	 explore	 the	mechanism	and	dynamics	involved	in	AcpP	interactions	with	FabB.	Several	long	simulations	were	performed	on	the	complex	with	AcpP	in	different	states	to	identify	changes	in	protein-protein	dynamics.	The	AcpPs	were	modeled	as	apo	(no	PPant),	holo	(empty	PPant),	C8	acyl-substrate	 loaded,	 or	 C10	 acyl-product	 loaded.	 Comparisons	 of	 the	 average	 structures	obtained	 from	 the	 various	 complex	 states	 revealed	 a	 possible	 mechanism	 for	communication	and	recognition	between	AcpP	and	FabB	(Fig.	4-7b,	Fig.4-9,	Fig.4-10).	In	the	
apo	state,	AcpP	loses	its	ability	to	make	specific	salt	bridge	contacts	observed	in	the	crystal	structure.	However,	upon	being	activated	to	its	holo	state,	salt	bridge	contacts	strengthen	on	helix	 II.	 Interestingly,	upon	actual	 loading	of	 the	PPant	with	a	C8	FabB	substrate	or	C10	
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product,	AcpP	helix	 III	makes	specific	strong	 interactions	with	FabB.	A	closer	 look	at	 the	
Figure	4-9.	A	comparison	of	MD	derived	RMSFs	and	crystallographic	B-factors.	All	the	above	structures	are	displayed	as	putty,	with	higher	RMSF/	B-factor	values	shown	in	red	with	increased	thickness,	and	lower	values	shown	in	blue	with	decreased	thickness.	All	MD	structures	are	the	average	structure	generated	from	the	1000	frames	representing	140	to	150	ns.	The	RMSF	MD	structures	are	normalized	with	the	crystallographic	B-factors	for	comparison	purposes.	(a)	Crystallographic	structural	for	reference.	Higher	disorder	is	observed	in	FabB2	of	the	homodimer.	(b)	Both	AcpPs	in	apo	state.	(c)	Both	AcpPs	loaded	with	C8-substrate.	(d)	AcpP1	(left)	and	AcpP2	(right)	loaded	with	C8-substrate	and	C8-product,	respectively.	(e)	Both	AcpPs	in	holo	state.	(f)	Both	AcpPs	loaded	with	C8-product.	(g)	AcpP1	(left)	and	AcpP2	(right)	loaded	with	C8-product	and	C8-substrate,	respectively.			
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secondary	structure	reveals	increased	movement	in	the	α6-α7	helix-turn-helix	(HTH)	motif	present	 in	FabB,	which	 is	 in	close	proximity	to	 interact	with	another	highly	 flexible	helix	(α10)	 on	 the	 same	 monomer.	 Both	 motifs	 also	 are	 able	 to	 interact	 with	 substrates	 or	products	in	the	active	sites;	further,	α10	is	able	to	interact	with	helix	III	of	AcpP.	Therefore,	binding	 of	 the	 substrate	 to	 monomer	 1	 may	 trigger	 the	 protein	 conformation/dynamic	change	of	monomer	2,	resulting	in	product	release	that	completes	the	enzyme	turnover	of	monomer	 2.	 Together,	 these	 results	 highlight	 the	 importance	 of	 anchoring	 helix	 II	interactions	to	facilitate	correct	orientation	of	the	AcpP	for	productivity.	Helix	III	becomes	important	when	AcpP	is	loaded	with	the	“cargo”	(substrate	or	product	of	FabB),	suggesting	that	chain	translocation	is	facilitated	by	interactions	between	FabB	and	helix	III	of	AcpP.		
4.3.4	Root-mean	square	fluctuations	(RMSF)	analysis	RMSFs	of	the	non-hydrogen	atoms	of	each	residue	were	computed	on	a	total	of	1000	frames,	corresponding	to	140	to	150	ns	of	each	MD	simulation	using	CPPTRAJ	and	a	custom	script.21	Prior	 to	performing	the	RMSF	computations	 for	each	simulation,	all	 frames	were	superimposed	on	the	first	frame,	followed	by	stripping	of	all	water	molecules	and	sodium	ions.	Average	structures	with	embedded	RMSF	values	were	generated	for	each	simulation	(Fig.4-9).	 Average	 structures	 for	 the	 wildtype	 complexes	 are	 shown	 with	 RMSF	 values	normalized	to	crystallographic	B-factors	in	the	solved	complex	structure	described	in	this	paper.	Interestingly,	FabB2	had	increased	RMSF	values	overall	compared	to	FabB1,	consistent	with	 the	 elevated	 B-factor	 values	 seen	 in	 FabB2	 of	 the	 crystallographic	 structure,	strengthening	 the	 argument	 that	 MD	 and	 crystallographic	 data	 are	 able	 to	 structurally	describe	the	FabB	homodimer	in	two	discrete	states.	RMSF	values	for	every	simulation	were	
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plotted	for	the	FabB	homodimer	(Fig.	4-10),	and	both	carrier	proteins	(Fig.	4-11).	Difference	plots	were	generated	to	compare	the	D38A,	R62A	and	R124A	variants	to	wild-type	for	the	FabB	homodimer	(Fig.	4-12),	and	both	carrier	proteins	(Fig.	4-13).	
The D38A and R62A variants had much higher fluctuations compared to wild-type 
highlighting the sensitive protein-protein interactions. Interestingly, in all 24 simulations, FabB2 
had consistently higher fluctuations in RMSF values compared to FabB1 suggesting the 
homodimer is occupying two discrete states. The wildtype profile is relatively consistent amongst 
all loaded states, and the D38A, R62A and R124A variants showed a markedly decrease in 
consistency amongst states as a result of the disruption of key protein-protein interactions (Fig. 4-
11). R124A showed the greatest increase in RMSFs. Comparisons between the variant and wild-
type profiles reveal the D38A variant on AcpP to result in much higher RMSF values across both 
monomers (Fig. 4-12). Surprisingly, when a product is bound to either/both AcpPs there is no 
change, or a reduction in RMSFs for D38A, R62A, and R124A. This result implies the possibility 
that the specific salt bridges lose their importance after product turnover. R62A and R124A display 
the greatest change in RMSF on the AcpPs, as a decrease in specific protein-protein interactions 
between the pairs of proteins leads to an increase of atomic fluctuations on the relatively smaller 
AcpPs (Fig. 4-13).	
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Figure	4-10.		Root	Mean	Square	Fluctuations	(RMSF)	per	residue	for	the	FabB	homodimer	were	 generated	 for	 wildtype,	 AcpP:D38A,	 FabB:R62A,	 and	 FabB:R124A	 over	 all	 24	simulations.		
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Figure	 4-11.	 	 Root	Mean	 Square	 Fluctuations	 (RMSF)	 per	 residue	 for	 both	 AcpPs	were	generated	for	wildtype,	AcpP:D38A,	FabB:R62A,	and	FabB:R124A	over	all	24	simulations.	The	grey	highlighted	portions	in	the	background	represent	helical	regions	in	AcpP.		
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Figure	4-12.		Comparisons	between	the	variant	and	wild-type	RMSF	profiles	for	both	FabB	monomers.	
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Figure	4-13.		Comparisons	between	the	variant	and	wild-type	RMSF	profiles	for	both	AcpPs.	
	
4.3.4	Free	energy	calculations	MM-PBSA	calculations	were	performed	to	measure	the	∆G	of	protein	binding	surface	affinity	for	every	AcpP	present	in	the	24	simulations,	for	a	total	of	48	calculations	(Fig.	4-14).	These	calculations	were	only	performed	using	the	frames	from	140	to	150	ns,	which	were	also	the	final	set	of	frames	for	the	variant	simulations.	When	the	AcpPs	are	in	the	apo	state,	the	R62A	and	R124A	variants	had	much	lower	binding	affinity	compared	to	wildtype,	and	slightly	lower	in	the	holo	state	compared	to	wildtype.	Comparison	of	the	∆∆G	values	of	the	
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D38A,	R62A	and	R124A	variants	to	the	wildtype	show	a	decrease	in	binding	affinity	for	the	R124A	 variant	 in	 the	 apo	 and	 holo	 states,	 with	 the	measurements	 performed	 in	 the	 C8-substrate	and	C8-product	states	to	be	qualitatively	decreased	or	equivalent	(Fig.	4-15).	The	results	of	these	calculations	imply	that	the	importance	of	the	salt	bridge	interactions	might	only	be	important	during	recognition	and	initialization	of	the	complex,	and	less	important	once	the	substrate	is	released	via	the	switchblade	mechanism	into	the	active	site.		
Table 4-1. Results of MM-PBSA calculations. 	 apo	 holo	
	 Average	 Std.	Dev	 ∆∆G	vs	wt	 Average	 Std.	Dev	 ∆∆G	vs	wt	
WT1	 -32.182	 11.019	 -	 -49.021	 10.807	 -	
WT2	 -19.290	 14.346	 -	 -39.767	 9.926	 -	
D38A1	 -24.642	 7.331	 7.541	 -52.019	 9.556	 -2.998	
D38A2	 -15.312	 8.677	 3.977	 -37.382	 9.188	 2.384	
R62A1	 8.554	 8.893	 4.554	 -22.507	 8.070	 26.514	
R62A2	 4.571	 8.440	 23.861	 0.834	 12.978	 40.600	
R124A1	 -3.964	 9.956	 28.218	 -14.524	 9.443	 34.496	
R124A2	 22.046	 7.550	 41.335	 -1.124	 8.311	 38.643	
	 substrate	 product	
	 Average	 Std.	Dev	 ∆∆G	vs	wt	 Average	 Std.	Dev	 ∆∆G	vs	wt	
WT1	 -54.494	 10.444	 -	 -48.191	 14.006	 -	
WT2	 -26.413	 16.917	 -	 -41.704	 10.805	 -	
WT3	 -36.733	 15.971	 -	 -31.107	 10.921	 -	
WT4	 -49.100	 10.304	 -	 -41.527	 8.969	 -	
D38A1	 -41.622	 11.849	 12.872	 -48.634	 16.302	 -0.442	
D38A2	 -66.496	 12.045	 -40.082	 -34.786	 14.437	 6.918	
D38A3	 -43.459	 10.838	 -6.726	 -38.814	 14.122	 -7.706	
D38A4	 -52.578	 14.110	 -3.478	 -47.527	 11.605	 -6.000	
R62A1	 -28.240	 11.098	 26.253	 -27.971	 12.310	 20.221	
R62A2	 -44.623	 10.575	 -18.210	 -28.068	 13.985	 13.636	
R62A3	 -42.327	 10.661	 -5.593	 -21.964	 10.759	 9.143	
R62A4	 -40.060	 12.611	 9.041	 -24.986	 11.383	 16.542	
R124A1	 -6.837	 14.934	 47.657	 -10.614	 9.363	 37.578	
R124A2	 -27.210	 12.313	 -0.797	 -9.296	 11.265	 32.408	
R124A3	 -14.090	 7.598	 22.643	 -11.118	 11.191	 19.989	
R124A4	 -14.809	 9.986	 34.292	 -43.781	 11.650	 -2.254		
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Figure	 4-14.	 	 Protein	 binding	 surface	 affinity	 calculations.	 A	 total	 of	 48	 Molecular	Mechanics-Protein	Binding	Surface	Affinity	(MM-PBSA)	calculations	were	performed	on	the	wild-type	(wt),	and	three	variants	(D38A,	R62A,	and	R124A)	systems	analyzing	the	∆G	of	the	second	binding	event	between	the	carrier	protein	and	the	FabB	homodimer.	The	complex	encompassed	 both	 AcpPs	 and	 the	 FabB	 homodimer,	 with	 the	 ligand	 classified	 as	 an	individual	AcpP,	and	the	remaining	AcpP	and	FabB	homodimer	treated	as	the	receptor.	Two	calculations	were	performed	on	each	of	the	24	simulations,	measuring	the	∆G	of	binding	for	both	AcpPs	in	the	complex.	AcpPs	were	modeled	in	apo,	holo,	C8-substrate	and	C8-product	forms.	The	wildtype,	D38A,	R62A	and	R124A	values	are	colored	in	black,	purple,	blue	and	red,	 respectively.	 The	 first	 and	 third	 calculations	 in	 each	 set	 is	measuring	 the	 the	 ∆G	 of	binding	for	AcpP1,	and	the	second	and	fourth	calculations	in	each	set	are	measuring	the	the	∆G	 of	 binding	 for	 AcpP2.	 For	 the	 first	 and	 second	 calculations	 in	 each	 set	 both	 carrier	proteins	 are	 in	 identical	 states.	 To	 investigate	 cases	 of	 asymmetrical	 loaded	 states,	 both	AcpPs	were	loaded	with	C8-substrate	and	C8-product	for	the	third	and	fourth	calculations.		
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Figure	 4-15.	 	 Protein	 binding	 surface	 affinity	 ∆∆G	 of	 variants	 compared	 to	 wildtype.	Comparisons	of	∆G	values	of	the	D38A,	R62A	and	R124A	variants	with	wildtype	∆G	values	is	shown	above,	with	 the	D38A,	 R62A	and	R124A	variants	 colored	 in	purple,	blue	and	 red,	respectively.	The	first	and	third	calculations	in	each	set	is	measuring	the	the	∆G	of	binding	for	AcpP1,	and	the	second	and	fourth	calculations	in	each	set	are	measuring	the	the	∆G	of	binding	for	AcpP2.	For	the	first	and	second	calculations	in	each	set	both	carrier	proteins	are	in	identical	states.	To	investigate	cases	of	asymmetrical	loaded	states,	the	AcpPs	were	loaded	with	C8-substrate	and	C8-product	for	the	third	and	fourth	calculations.	R124A	has	reduced	binding	affinity	compared	to	wildtype	for	all	states	as	shown	by	the	increase	in	∆G	of	binding.	D38A,	R62A	and	R124A	have	an	observed	reduction	in	binding	affinity	compared	to	wildtype	for	the	apo	state,	suggesting	that	these	specific	residues	involved	in	salt	bridge	formation	are	important	for	recognition.	 	
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4.3.5	FabB	mutagenesis	and	lipid	profile	modulation	in	E.	coli	
	 A	 previous	 study	 showed	 the	 fatty	 acid	 product	 profile	 in	 vitro	 is	 subject	 to	 the	relative	 concentration	 of	 FabB.22	 The	 specific	 parameters	 that	 the	 FabB	 concentration	controls	is	chain	length	and	level	of	saturation	present	in	the	fatty	acids.	As	FabB	is	uniquely	suited	to	extend	10-carbon	cis-unsaturated	fatty	acids,	it	was	initially	hypothesized	that	a	decrease	in	FabB	will	result	in	a	decrease	in	the	production	of	unsaturated	fatty	acids.	FabF,	another	ketosynthase	involved	in	fatty	acid	biosynthesis	is	unable	to	process	unsaturated	10-carbon	substrates.	Surface	variants	were	generated,	and	quite	unexpectedly	we	did	not	observe	a	decrease	in	saturation	as	would	have	been	initially	predicted	(Fig.	4-16).	Counter-intuitively,	the	majority	of	the	variants	actually	increased	unsaturation	when	FabB	was	overexpressed	in	respect	to	the	native	system.	R124A	saw	a	marked	increase	in	C18:1	product,	and	even	generated	C16:1	product,	which	is	not	observed	in	wild-type.	A	new	model	is	proposed	which	would	support	the	above	results,	and	that	is	a	decrease	in	binding	affinity	as	a	result	of	the	surface	mutations,	actually	increases	the	turn-over	rate	between	FabB	and	AcpP.	Further	kinetic	studies	would	need	to	be	performed	to	evaluate	if	the	rate	limiting	 step	 is	 actually	 in	 fact	 the	dissociation	 step	and	enzyme	 turnover,	 instead	of	 the	previously	assumed	protein-association	step.				
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Figure	4-16.	Product	profile	of	the	E.	coli	type	II	FAS	bearing	FabB	surface	mutations.	The	products	are	denoted	by	chain	length	and	unsaturation	level.	All	experiments	were	run	in	triplicate.			
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4.4	Materials	and	methods	
4.4.1	Protein	expression	and	purification	pET28b	6x	His-tagged	constructs	containing	the	genes	for	E.	coli	AcpP	and	FabB	were	separately	transformed	into	E.	coli	BL21	(DE3)	cells	by	heat	shocking	at	42	°C	for	45	seconds	and	 plated	 onto	 LB	 agar	 plates	 supplemented	with	 50	 µg/mL	 kanamycin.	 Colonies	were	transferred	 to	 a	 10	mL	 LB	starter	 culture	 supplemented	with	 50	 µg/mL	 kanamycin	 and	shaken	 overnight	 at	 37	 °C.	 The	 starter	 culture	 was	 then	 transferred	 to	 1	 L	 of	 LB	supplemented	with	50	µg/mL	kanamycin	and	shaken	at	37	°C.	Once	the	OD600	reached	0.6,	expression	was	induced	by	addition	of	1	mM	IPTG,	and	the	cells	were	shaken	overnight	at	18	°C.	Cells	were	harvested	by	centrifugation,	resuspended	in	lysis	buffer	(50	mM	Tris	pH	7.5,	300	mM	NaCl,	10	mM	imidazole,	10	%	glycerol),	and	flash	frozen	in	liquid	nitrogen	for	storage	at	-80	°C.										 The	resuspended	cells	were	 lysed	by	sonication,	and	the	 lysate	was	centrifuged	at	21,000	rcf	for	60	minutes	to	remove	cellular	debris.	The	lysate	was	then	incubated	with	5	mL	of	Ni-NTA	resin	(ThermoFisher	Scientific)	for	1	hour,	and	the	resin	was	washed	with	lysis	buffer	 to	remove	unbound	protein.	The	proteins	of	 interest	were	eluted	 in	 fractions	using	 an	 imidazole	 gradient.	 SDS-PAGE	was	 used	 to	 analyze	 the	 fractions,	 and	 fractions	containing	the	protein	of	interest	were	combined	and	dialyzed	into	a	storage	buffer	(25	mM	Tris	pH	7.5,	100	mM	NaCl,	1	mM	DTT,	5%	glycerol).	AcpP	was	further	purified	using	a	HiTrap	Q	FF	anion	exchange	column	(GE	Healthcare	Lifesciences).	
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4.4.2	Crosslinking,	complex	purification,	and	crystallization	The	 phosphopantetheine	 (PPT)	 prosthetic	 group	 was	 removed	 from	 AcpP	 by	incubation	 with	 MBP-tagged	 AcpH,	 including	 12.5	 mM	MgCl2	 and	 2.5	mM	MnCl2.	 After	removing	 the	 AcpH	 with	 amylose	 resin	 (New	 England	 Biolabs),	 apo-AcpP	 was	chemoenzymatically	 loaded	with	 the	 chloroacryl-pantetheine	 crosslinker	 to	 form	crypto-AcpP	using	recombinant	CoaA,	CoaD,	CoaE,	Sfp,	200	mM	ATP,	10	mM	MgCl,	and	a	1.5x	molar	excess	 of	 the	 crosslinker.17	 The	 loading	 was	 confirmed	 using	 MALDI-TOF	 mass	spectrometry.	AcpP	was	purified	away	from	the	loading	enzymes	using	a	second	HiTrap	Q	FF	column.	100	µM	FabB	was	incubated	with	200	µM	crypto	AcpP	in	25	mM	Tris	pH	7.5,	100	mM	NaCl,	5	mM	DTT,	and	5%	glycerol	overnight	at	37	°C.	The	complex	was	then	purified	using	a	Superdex	200	(GE	Healthcare	Lifesciences)	size	exclusion	column,	concentrated	to	6	mg/mL,	and	flash	frozen	for	storage.	The	complex	was	crystallized	in	0.1	M	sodium	acetate	pH	5.4,	0.2	M	ammonium	acetate,	and	20%	PEG	4000	using	the	sitting	drop	vapor	diffusion	method.	The	crystals	were	flash	frozen	in	liquid	nitrogen	for	storage.	Diffraction	data	were	measured	using	beamline	8.2.1	at	the	Advanced	Light	Source	synchrotron	facility	and	processed	using	Mosflm.23	The	structure	was	solved	by	molecular	replacement	using	a	FabB	structure	(PDB	code:	2VB9)	as	a	search	model	and	refined	using	the	Phenix	suite	of	programs.24	
	
4.4.3	NMR	titration	studies	Isotopically	labeled	wt	and	D38A	AcpP	for	NMR	studies	was	prepared	as	previously	reported.15,	17	In	brief,	BL21	(DE3)	E.	coli	cells	bearing	the	appropriate	construct	were	first	deuterium	acclimated	then	grown	at	1	L	scale	in	13C,	15N,	and	2H	M9	minimal	media.	A	5	
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mL	culture	of	M9	minimal	media	prepared	with	25%	D2O	and	75%	H2O	was	inoculated	and	grown	overnight	at	37	°C.	100	µL	of	this	dense	culture	was	used	to	inoculate	a	5	mL	culture	prepared	with	50%	D2O	and	50%	H2O,	which	was	grown	overnight	at	37	°C.	In	turn,	100	µL	of	this	dense	culture	was	used	to	inoculate	a	5	mL	culture	prepared	with	75%	D2O	and	25%	H2O,	which	was	grown	overnight	at	37	°C.	Finally,	100	µL	of	this	dense	culture	was	used	to	inoculate	a	5	mL	culture	prepared	with	100%	D2O	and	grown	overnight	at	37	°C.	This	was	used	to	inoculate	a	1	L	flask	of	M9	minimal	media	prepared	with	1	L	D2O,	1	g	15NH4Cl,	and	4	g	13C	glucose.	The	culture	was	grown	(37	°C,	120	RPM	shaking,	baffled	flask)	to	an	OD600	of	0.8.	Expression	was	induced	with	the	addition	of	1	mL	of	1M	IPTG	(in	D2O,	0.22	µM	sterile	filtered),	and	carried	out	for	4	hours	at	37	°C.	Cells	were	harvested	by	centrifugation	at	600	rcf,	30	min,	6	°C.		 Cells	were	resuspended	in	40	mL	of	lysis	buffer	(25	mM	HEPES	pH	7.4,	250	mM	NaCl,	and	 10%	glycerol).	 They	were	 lysed	 by	 French	 pressure	 cell	 at	~25,000	PSI,	 over	 three	presses,	with	DNAse	and	RNAse.	Lysate	was	clarified	by	centrifugation	at	12,000	rcf,	45	min,	6	 °C	and	subjected	 to	Ni-NTA	 (ThermoFisher	Scientific)	purification.	Clarified	 lysate	was	tumbled	with	loose	resin	at	4	°C	for	30	minutes,	then	washed	with	25	mL	wash	buffer	(25	mM	HEPES	pH	7.4,	250	mM	NaCl,	and	10%	glycerol,	25	mM	Imidazole	pH	7.4)	to	remove	nonspecific	binding.	AcpP	was	eluted	with	10	mL	elution	buffer	(25	mM	HEPES	pH	7.4,	250	mM	NaCl,	 and	 10%	 glycerol,	 250	mM	 Imidazole	 pH	 7.4)	 then	 desalted	 (PD-10	 desalting	column,	GE	Healthcare)	into	25	mM	HEPES	pH	7.4,	250	mM	NaCl,	and	10%	glycerol.			 NMR	 experiments	 were	 carried	 out	 in	 the	 Biomolecular	 NMR	 Facility	 at	 UCSD,	managed	by	Dr.	Xuemei	Huang.	Titration	experiments	were	performed	on	a	600	MHz	Bruker	Avance	III	system	equipped	with	a	cryoprobe	at	37	°C.	Each	1H-15N	HSQC	was	acquired	with	
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uniform	sampling,	2048	(R+I)	points	in	the	direct	dimension,	256	(R+I)	points	in	the	15N	dimension,	24	scans,	and	a	1.5	s	recycle	delay.	Samples	were	prepared	at	100	uM	AcpP	in	50	mM	 potassium	 phosphate	 pH	 7.4,	 0.01%	 sodium	 azide,	 2.5	 mM	 tris(2-carboxyethyl)phosphine,	and	10%	D2O.	Data	was	processed	using	nmrPipe5	and	NMRFAM-SPARKY.25	Backbone	assignment	of	the	D38A	variant	was	achieved	by	comparison	with	the	known	 wt	 AcpP	 and	 confirmation	 using	 an	 HNCACB.	 Titration	 increment	 points	 were	achieved	by	preparing	a	0.0	molar	equivalent	and	2.0	molar	equivalent	sample,	acquiring	the	 first	 and	 last	 points	 of	 the	 titration,	 then	 incrementally	 mixing	 them	 to	 achieve	intermediate	ratios.	This	approach	was	found	to	yield	more	accurate	ratios	and	limit	protein	loss.	 Chemical	 Shift	 Perturbations	 (CSPs)	 were	 calculated	 using	 the	 formula:	 CSP	 =	[0.5*((ΔẟN/5)^2+(ΔẟH)^2)]^(½)	using	the	0.0	and	2.0	molar	equivalent	titration	points.26	
	
4.4.4	Molecular	dynamics	(MD)	simulations	The	 AcpP-FabB	 complex	 were	 modeled	 using	 the	 mechanism-based	 crosslinked	structure	described	 in	this	paper.	Using	 the	 software	UCSF	Chimera,	 crystal	waters	were	removed	and	hydrogens	added	using	the	Dock	Prep	tool,	and	the	chloroacrylyl-based	probe	covalently	 linked	 to	 S36	was	 converted	 in	 silico	 into	 holo,	 C8-substrate	 and	 C8-product	representations.27-28	The	phosphopantetheinyl	serine	residues	were	extracted	and	capped	with	 N-methyl	 (NME)	 and	 acetyl	 (ACE)	 fragments	 to	 generate	 dipeptides	 for	 force	 field	preparation	and	restricted	electrostatic	potential	(RESP)	charge	fitting.	Gaussian	09	Rev	C	was	used	for	geometry	optimization	and	electrostatic	potential	calculations	using	MP2/6-31G(d,p)//MP2/6-31G(d,p).	 RESP	 charges	 were	 calculated	 with	 intramolecular	 charge	restraints	and	an	overall	charge	of	-1	for	each	non-standard	residue	and	fit	using	the	R.E.D.	
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Server.29	 When	 possible,	 bond	 parameters	 were	 assigned	 using	 the	 main	 parameter	databases	 in	 the	 Amber	 ff14SB	 force	 field.	 Missing	 parameters	 were	 adopted	 from	 the	general	AMBER	force	field	(GAFF).	Six	simulation	types	were	setup	by	configuring	S36	on	chains	 C	 and	D	 of	 the	 carrier	 proteins	 as:	 C0D0	 (apo:apo),	 C1D1	 (holo:holo),	 C2D2	 (C8-substrate:C8-substrate),	C2D3	(C8-substrate:C8-product),	C3D2	(C8-product:C8-substrate),	and	C3D3	(C8-product:C8-product).	The	crystal	structure	served	as	the	basis	of	the	initial	structure	for	all	simulations.	LEaP	was	used	to	neutralize	the	apo	systems	by	adding	52	Na+	ions,	and	the	non-apo	systems	by	adding	54	Na+	ions	and	solvating	the	enzyme	complexes	in	 12-Å	 water	 buffer	 TIP3P	 truncated	 octahedron	 boxes.	 The	 fully	 solvated	 systems	contained	between	82,554	and	83,278	atoms.	MD	was	carried	out	using	AMBER	16.30	Minimization	was	carried	out	in	two	stages	using	SANDER	from	AmberTools	16.	The	initial	stage	was	carried	out	over	2,500	steps	for	the	solvent,	ions,	and	post-translationally	modified	S36	residues	of	the	carrier	proteins,	with	the	remaining	residues	of	the	proteins	restrained	by	a	force	constant	of	500	kcal/mol/Å2,	followed	by	a	second	stage	carried	out	over	5,000	steps	of	the	entire	system.	Heating	was	performed	using	SANDER	over	100-ps	allowing	the	system	to	heat	up	to	a	temperature	of	300K	using	the	Langevin	temperature	equilibration	scheme.	During	heating	the	same	set	of	atoms	as	the	initial	stage	of	minimization	was	restrained,	but	with	a	lower	force	constant	of	10	kcal/mol/Å2.	PME	was	used	to	compute	the	electrostatic	interactions	with	a	real	space	cutoff	of	10	Å,	which	was	also	used	for	the	van	der	Waals	interactions.	Time	steps	were	set	to	 2	 fs,	with	 hydrogen	 atoms	 constrained	 using	 the	 SHAKE	 algorithm.	 Equilibration	was	carried	out	using	SANDER	for	10	ns	on	all	simulations.	The	MD	production	simulations	were	carried	out	using	PMEMD.CUDA.	The	6	wildtype	complex	system	simulations	were	run	over	
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1	µs	(500,000,000	time	steps),	and	the	18	variant	complex	system	simulations	were	run	over	150	ns	(75,000,000	time	steps)	for	a	total	of	8.7	µs	for	all	24	simulations.	Simulation	speeds	of	45	ns/day	were	observed.		
4.4.5	Free	energy	calculations	The	Molecular	Mechanics	–	Protein	Binding	Surface	Affinity	(MM-PBSA)	calculations	were	performed	using	MMPBSA.py	in	Amber	16	to	measure	the	∆G	of	the	second	binding	event	 between	 the	 carrier	 protein	 and	 the	 FabB	 homodimer	 with	 one	 carrier	 protein	attached	in	either	the	apo,	holo,	substrate	or	product	states.31	The	total	non-polar	solvation	free	energy	was	modeled	as	a	single	term,	which	was	linear	and	proportional	to	the	solvent	accessible	surface	area.	The	 ionic	strength	was	set	at	0.1	mM	for	 the	PB	equation.	Atom-type/charge-based	radii	as	described	by	Tan	and	Luo	were	used	for	the	standard	atom	types,	and	 radii	 from	 the	 parameter-topology	 files	were	 used	 for	 the	 general	 amber	 force	 field	(GAFF)	atom	types.32	The	calculations	were	performed	twice	on	each	of	the	24	simulations,	treating	 the	 ligand	 as	 either	 AcpP1	 or	 AcpP2,	 and	 the	 remaining	 FabB	 homodimer	 and	opposite	AcpP	as	the	receptor	for	the	complexes.	The	wildtype,	and	three	R38A,	R62A	and	R124A	variants	were	the	four	complex	systems	analyzed.		A	total	of	four	calculation	types	were	performed	for	each	of	the	four	states	possible	for	each	complex	system,	with	the	first	type	measuring	the	∆G	of	binding	in	AcpP1	in	the	represented	state,	to	its	respective	FabB	homodimer	 complex	with	AcpP2	already	bound.	The	 second	 type	measured	 the	opposite	carrier	protein	AcpP2	in	its	represented	state,	 to	its	respective	FabB	homodimer	complex	with	 AcpP1	 already	 bound.	 The	 third	 type	 for	 each	 system	were	 calculations	 performed	when	AcpP1	was	 in	a	 substrate	state	or	product	 state,	 and	 it’s	opposing	AcpP	was	 in	 the	
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opposite	substrate	or	product	state.	The	fourth	type	was	carried	out	like	the	3rd	type,	but	for	AcpP2.	The	calculations	were	performed	using	the	frames	corresponding	to	140	to	150	ns	of	each	MD	simulation,	and	included	a	total	of	1,000	evenly	spaced	frames.	Convergence	was	measured	(Fig.4-13)	by	assessing	the	cumulative	average	over	the	1,000	frames.		
4.4.6	Principal	component	analysis	(PCA)	Principle	component	analysis	was	performed	using	CPPTRAJ.21,	33-34	A	total	of	160	ns	of	simulation	data	was	used	for	each	PCA	calculation,	for	a	total	of	16000	frames.	Prior	to	performing	PCA	computations	 for	each	simulation,	 all	 frames	were	superimposed	on	 the	first	frame,	and	water	molecules	and	sodium	ions	were	stripped.	The	coordinate	covariance	matrix	 used	 each	 residue’s	 heavy	 atoms,	 for	 a	 total	 of	 3,848	 atoms	 and	 a	 coordinate	covariance	 matrix	 size	 of	 11,544	 x	 11,544	 describing	 the	 Cartesian	 coordinates	 of	 each	frame.	 The	 projection	 along	 these	 eigenvectors	 of	 each	 coordinate	 frame	 from	 the	 first	simulation	trajectory	was	calculated.	
	
4.5	Conclusions		Combined	with	our	previous	studies	on	the	AcpP-FabA	interaction,	the	AcpP-FabB	structure	 provides	 foundational	 progress	 towards	 understanding	 unsaturated	 fatty	 acid	production	in	E.	coli.	Furthermore,	the	in	vitro,	in	silico,	and	in	vivo	results	together	highlight	the	 importance	of	AcpP	helix	 II	 for	anchoring,	 and	AcpP	helix	 III	 for	 chain	 translocation.	Chain	 flipping	 may	 be	 required	 for	 the	 productive	 outcome	 of	 these	 protein-protein	interactions,	but	 this	does	not	address	 the	subtle	differences	 in	each	 interaction	 that	 are	critical	to	pathway	regulation,	processivity,	and	cargo	communication.	The	differences	in	the	
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AcpP-FabA	and	AcpP-FabB	interactions	reveal	the	different	interaction	networks	that	can	act	on	the	AcpP.		Moving	forward,	these	subtle	interactions	must	be	thoroughly	understood	to	inform	future	drug	discovery	and	pathway	engineering	efforts.	
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CHAPTER	5	
Identification	of	a	Possible	Allosterically	Regulating	Histidine	pH	sensor	
in	a	Type	III	Polyketide	Synthase	Benzalacetone	Synthase	
5.1	Summary	Type	III	polyketide	synthases	are	stand-alone	homodimers	capable	of	carrying	out	multiple	decarboxylative	condensation	reactions	to	generate	complex	polyketide	products.	In	these	systems,	the	acetate	units	are	incorporated	in	the	growing	polyketide	chain	using	malonyl-CoA	extender	units	and	a	coumaroyl-CoA	starter	unit.	The	benzalacetone	synthase	RpBAS	conducts	a	one-step	decarboxylative	condensation	reaction	to	generate	the	diketide	
p-hydroxybenzalacetone	 (BA)	 as	 the	 dominant	 prouct	 at	 pH	 >	 7,	 or	 it	 conducts	 two	decarboxylative	condensation	reactions	to	generate	the	triketide	bis-noryangonin	(BNY)	as	the	dominant	product	at	pH	<	7.	While	several	structural	and	mutagenesis	studies	have	been	performed	on	RpBAS	and	its	homologs,	the	precise	mechanism	of	how	pH	affects	the	product	outcome	 remains	 a	 mystery.	 In	 this	 chapter,	 using	 molecular	 dynamic	 simulations,	 we	propose	a	framework	that	explains	the	pH	dependence	of	product	outcome	via	an	allosteric	regulation	mechanism	in	type	III	polyketide	synthases,	involving	a	solvent	exposed	histidine	on	 the	 surface	 of	 RpBAS.	 This	 in	 silico	 model	 resulted	 from	 the	 investigation	 of	conformational	dynamics	and	pKa	calculations	of	titratable	residues	using	MD	simulations.	The	 model	 was	 then	 explored	 experimentally	 via	 mutagenesis	 studies	 and	 biochemical	assays.	 The	 MD-based	 mutagenesis	 successfully	 led	 to	 a	 change	 of	 product	 outcome	 at	different	pHs.	The	above	result	represents	the	first	plausible	model	for	pH	dependence	of	type	III	PKS	product	outcome,	and	it	paves	the	foundation	for	future	engineering	efforts	of	type	III	PKSs	with	a	general	approach	towards	harnessing	pH	for	product	specificity.		
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5.2	Introduction	The	model	enzyme	of	enzymology	for	type	III	polyketide	synthases	(PKSs)	is	chalcone	synthase	(CHS)	from	alfalfa	(Medicago	sativa),	specifically	MsCHS2,	which	is	responsible	for	the	generation	of	a	tetraketide-derived	naringenin	chalcone	(NAR),	a	precursor	involved	in	the	biosynthesis	of	flavonoid	phytoalexins	and	anthocyanin	pigments.1	Crystal	structures	of	MsCHS2	 include	 an	 apo	 form,	 a	 CHS-CoA	 complex,	 a	 CHS-malonyl-CoA	 complex,	 CHS-hexanoyl-CoA	complex,	CHS-naringenin	complex,	and	a	CHS-resveratrol	complex	(PDB	IDs:	1BI5,	 1BQ6,	 1CML,	 1CHW,	 1CGK,	 and	 1CGZ,	 respectively).2	 This	 initial	 structural	 study	provided	important	information	about	the	three-dimensional	structure	of	type	III	PKSs,	as	well	as	 the	substrate	binding	pockets	and	key	residues	 for	binding	and	catalysis.	Another	enzyme	 from	 the	 type	 III	 PKS	 family,	 Benzalacetone	 synthase	 (RpBAS),	 generates	 only	 a	diketide-derived	product,	though	its	sequence	similarity	is	70%	with	MsCHS2.	RpBAS	was	originally	 characterized	 by	 Abe	 et	 al.,	 who	 revealed	 that	 it	 produces	 diketide-derived	 p-hydroxybenzalacetone	 by	 a	 one-step	 decarboxylative	 condensation	 of	 4-coumaroyl-CoA	with	 one	 malonyl-CoA.3	 It	 is	 thought	 that	 p-hydroxybenzalacetone	 is	 important	 for	 the	biosynthesis	of	phenylbutanoids.4	Curiously,	RpBAS	biosynthesizes	a	diketide	at	pH	8,	but	it	biosynthesizes	a	triketide	at	pH	6	(Fig.	5-1).	It	remains	a	mystery	how	pH	affects	the	product	outcome	of	RpBAS.	We	decided	to	undertake	the	task	of	exploring	conformational	dynamics	of	RpBAS	at	different	pHs.	It	is	the	goal	of	this	chapter	to	elucidate	the	structural	basis	of	pH	effects	on	the	product	outcome	of	RpBAS,	thus	providing	increased	detail	in	how	dynamics	and	pH	when	coupled	can	regulate	product	generation	in	type	III	polyketide	synthases.		
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Figure	5-1.	 RpBAS	 is	 responsible	 for	generation	 of	 the	 diketide	p-hydroxybenzalacetone	(BA)	at	an	optimum	pH	of	8.0,	which	is	provided	to	downstream	enzymes	responsible	for	generating	 phenylbutanoids.	However,	 at	 lower	 pHs,	 RpBAS	 is	 capable	 of	 generating	 the	triketide	shunt	product,	bis-noryangonin	(BNY).	MsCHS	is	responsible	for	the	generation	of	naringenin	 chalcone	 (NAR),	 a	 precursor	 involved	 in	 the	 biosynthesis	 of	 flavonoid	phytoalexins	 and	 anthocyanin	 pigments.	 Previous	mutagenesis	 studies	have	 restored	 the	NAR-forming	behavior	in	RpBAS.		
To	investigate	protein	structures	at	a	range	of	pHs	structurally	is	challenging.	X-ray	crystallography	is	severely	limited	due	to	its	difficulty	in	obtaining	a	structure	at	a	specific	pH,	let	alone	obtaining	structures	at	two	or	multiple	pH	values.	Protein	NMR	is	a	technique	that	can	investigate	the	pH	effects	on	protein	structure	and	dynamics,	though	is	limited	in	the	range	of	time	scales	it	is	capable	of	sampling.	In	this	chapter,	in	the	absence	of	a	suitable	experimental	 technique	 we	 utilize	 molecular	 dynamic	 simulations	 to	 understand	 how	different	pH	affects	the	product	outcome	of	RpBAS.	
OH
O
Diketide Intermediate
EnzS
O
CoAS
O
OH
O
Malonyl-CoA CO2
OH
O
Triketide Intermediate
O
EnzS
O
CoAS
O
OH
O
Malonyl-CoA CO2
H2O
CO2
pH
 >
 7
.5
O
OH
p-hydroxybenzalacetone
O
OO
O
O
OH
HO
HO
HO
OH
OH
Phenylbutanoids
OH
O
Tetraketide Intermediate
O
O
SEnzO
acidic pH conditions
bis-Noryangonin
(BNY) OH
O
OH
O
H2O
CO2
pH
 <
 7
.5
basic pH conditions
OH
OOH
HO OH
naringenin chalcone
Rp
BA
S
I2
14
L/
L2
15
F H2O
CO2
O
A B
C
Flavonoids
 146	
Theories	 had	 been	 abundant	 for	 the	 observed	 pH	 effects	 of	 RpBAS.	 For	 example,	lysines	 and	 arginines	 are	 often	 involved	 in	 electrostatic	 stabilization	 of	 reaction	intermediates.5	The	ionization	state	of	lysine	and	arginine,	either	in	the	active	site	or	on	the	surface,	 is	 important	 for	 the	 function	and	structure	of	 a	protein.	Nonpolar	environments,	such	 as	 those	 found	 in	 the	 active	 site	 of	 RpBAS,	 result	 in	 an	 increase	 of	 pKas	 for	 acidic	residues,	and	a	decrease	of	pKas	for	basic	residues.	A	driving	force	for	ionization	of	charged	residues	in	the	active	site	is	the	formation	of	salt	bridges.6	Electrostatic	interactions	are	also	known	 to	 be	 an	 important	 factor	 controlling	 pKa	 in	 ionizable	 amino	 acids	 that	 serve	 a	catalytic	role,	such	as	Cys150	in	RpBAS.	The	pKa	of	the	active	site	cysteine	was	measured	at	5.5	 +/-	 0.1.7	 pH,	 along	 with	 conjugation	 and	 complexation	 is	 also	 important	 in	 setting	pigment	color	in	plants.1	All	of	the	above	may	be	important	for	the	observed	pH	effects	on	product	outcome	of	RpBAS.	Noel	 proposed	 that	 Cys197,	 a	 second	 cysteine	 present	 in	 the	 active	 site	 of	 RpBAS	might	play	a	role	in	the	decarboxylation	reaction	of	the	diketide	intermediate,	releasing	p-hydroxybenzalcetone.7	However,	Abe	et	al	showed	that	variants	C197T	and	C197G	resulted	in	no	change	in	the	product	outcome,	thus	falsifying	the	initial	Noel	hypothesis.8	Interestingly,	this	 same	 study	 revealed	 a	 2-fold	 decrease	 in	 product	 formation	 in	 G256L,	 and	 a	 2-fold	increase	 in	S338V	 (both	G256	and	G338	are	 located	 in	 the	active	 site),	but	both	variants	produced	the	triketide	pyrone	bis-noryangonin	(BNY)	product	at	pH	8,	a	reverse	of	the	pH	dependence.	 Another	 structural	 investigation	 on	 RpBAS	 was	 by	 Shimokawa	 et	 al,	 who	investigated	 the	 role	 of	 Leu132	 of	 RpBAS	 at	 the	 entrance	 of	 the	 coumaroyl-CoA	binding	pocket.	This	is	because	in	MsCHS,	Leu132	is	replaced	by	Thr132,	and	he	hypothesized	that	this	difference	may	affect	the	product	outcome.9	Nine	L132	variants	of	RpBAS	were	screened,	
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and	the	MsCHS-mimic,	L132T,	indeed	resulted	in	the	production	of	chalcone	by	this	variant	RpBAS.	Going	further,	the	132A,	L132S,	and	L132C	variants	expanded	their	product	outcome	and	 were	 capable	 of	 biosynthesizing	 the	 tetraketide	 4-coumaroyltriacetic	 acid	 lactone	(CTAL).	Homology	modeling	suggested	that	the	expansion	of	product	size	in	the	variants	was	the	result	of	restoration	of	the	‘coumaroyl	binding	pocket’	in	the	active	site	cavity	of	variant	RpBAS.	 Another	 mutagenesis	 study	 was	 performed	 and	 found	 that	 the	 double	 variant	I214L/L215F	 of	 RPBAS	predominantly	 produced	BNY,	 but	 also	 produced	 the	 tetraketide	products	naringenin	chalcone	(NAR)	and	CTAL.4	The	above	structural	and	functional	results	are	summarized	in	previous	reviews,	and	are	interesting;	however,	there	remains	a	need	to	elucidate	the	molecular	basis	of	pH	effect	on	the	product	outcome	of	RpBAS.10-11		 Here,	we	present	the	first	MD	simulation	studies	of	a	type	III	PKS,	which	elucidates	how	 the	 product	 outcome	of	 RpBAS	 is	 affected	 by	 pH.	 Based	 on	 the	MD	 simulations,	we	further	generated	RpBAS	variants	 that	switched	the	product	outcome.	Our	results	pave	a	foundation	for	future	protein	engineering	efforts	of	type	III	PKS	to	produce	medically	useful	“unnatural”	natural	products.	
	 	
5.3	Results	and	discussions	The	initial	hypothesis	was	that	BNY,	the	triketide	product	formed	at	low	pHs	was	due	to	a	conformational	change	 in	the	active	site,	which	would	not	have	been	revealed	 in	the	crystal	 structures	 from	 the	 previously	 published	 work.	 It	 is	 also	 common	 in	 type	 III	polyketide	 synthases	 to	 have	 ‘hidden’	 tunnels,	 which	 can	 be	 activated	 or	 deactivated	depending	on	certain	conditions,	and	that	active	site	volume	size	can	control	chain-length	specificity.12	
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5.3.1	pH-dependent	homology	modeling	and	traditional	MD	simulations	Initial	 homology	models	were	 generated	with	 the	 diketide	 intermediate	manually	modeled	in	using	Chimera.13-14	The	pH	dependence	of	homology	models	in	the	range	of	4,	5,	6,	7,	8,	9,	10,	and	11	was	developed	using	the	H++	server	to	obtain	predicted	pKa	values	and	protonation	state	of	titratable	residues.	The	Asp	and	Glu	residues	have	predicted	pKa	values	near,	but	less	than	4.122	and	4.822,	respectively.	Therefore,	all	aspartic	and	glutamic	acid	residues	were	 set	 to	deprotonated	 states	above	pH	6.	Many	histidine,	 cystine,	 lysine	and	tyrosine	residues	have	predicted	pKa	values	between	4	and	11,	and	we	applied	the	predicted	values	to	assign	the	initial	protonation	states	for	all	homology	models.	Shown	below	in	Table	5-1	are	the	predicted	pKa	values	from	the	H++	servers,	with	calculations	performed	at	each	pH,	and	their	average	value	shown.	Residues	with	pKa	values	below	2.5	and	above	11.5	are	not	shown	in	the	interest	of	brevity.	The	predicted	pKa	values	from	the	H++	server	uses	an	approach	grounded	in	classical	continuum	 electrostatics	 with	 statistical	 mechanics	 principles.	 The	 calculations	 did	 use	several	approximations	to	render	them	computationally	feasible.	The	predicted	pKa	values	of	 Lys	 residues	 are	 all	 relatively	 high,	 and	 Lys321	has	 the	 estimated	 pKa	 value	 of	 9.255.	Therefore,	all	six	of	the	homology	models	generated	at	pH	4,	5,	6,	7,	8,	and	9	had	lysines	in	the	charged	form.	MD	simulations	were	performed	for	all	homology	models,	with	an	RMSD	of	1.56	Å	observed	between	the	pH	4	and	pH	11	models.	No	major	conformational	changes	were	observed	over	the	500	ns	simulations.	
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Table	5-1.	pKa	predictions	from	the	H++	server	Res	No.	 Average	pKa	 Std	Dev	 	 Res	No.	 Average	pKa	 Std	Dev	CYS	164	 10.840	 0.031	 	 LYS	55	 9.727	 0.010	
CYS	197	 9.714	 0.023	 	 LYS	57	 10.286	 0.011		 	 	 	 LYS	78	 11.130	 0.008	HIS	48	 6.377	 0.006	 	 LYS	96	 10.453	 0.011	
HIS	71	 5.014	 0.008	 	 LYS	100	 10.965	 0.006	HIS	95	 6.439	 0.006	 	 LYS	107	 11.098	 0.009	HIS	126	 4.629	 0.009	 	 LYS	115	 10.741	 0.009	
HIS	161	 2.963	 0.011	 	 LYS	123	 11.064	 0.007	HIS	205	 5.979	 0.013	 	 LYS	146	 11.167	 0.012	HIS	251	 6.661	 0.009	 	 LYS	155	 10.551	 0.007	
HIS	257	 6.371	 0.016	 	 LYS	182	 10.634	 0.012	
HIS	266	 4.819	 0.009	 	 LYS	269	 10.465	 0.009		 	 	 	 LYS	280	 9.706	 0.008	TYR	32	 11.179	 0.013	 	 LYS	316	 10.518	 0.006	TYR	142	 9.999	 0.010	 	 LYS	321	 9.255	 0.010	
TYR	268	 11.389	 0.011	 	 LYS	325	 10.056	 0.017		 	 	 	 LYS	352	 11.376	 0.010			 		
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Figure	5-2.	Traditional	MD	simulations	were	performed	on	the	homology	RpBAS	models	at	pHs	4,	5,	6,	7,	8,	9,	10	and	11.	Shown	above	is	the	initial	crystal	structure	(shown	in	grey),	compared	to	the	average	structures	generated	at	pH	4	(red)	and	pH	11	(blue).		
	
5.3.2	Constant	pH	simulations		Using	the	ends	of	previous	trajectories	from	the	initial	MD	simulations,	constant	pH	simulations	were	performed	on	the	diketide	bound	intermediate	to	calculate	the	pKa	values	for	residues	near	the	active	site.	During	constant	pH	simulations	that	were	implemented	in	AMBER,	every	100	steps,	a	residue	was	randomly	selected,	and	a	change	of	protonation	state	was	attempted.	The	constant	pH	molecular	dynamics	(CpHMD)	method	is	limited	to	a	total	of	50	titratable	residues,	and	RpBAS	contains	98	such	residues	in	total.	In	order	to	achieve	consistent	sampling,	only	10	residues	were	selected	to	be	titratable,	and	we	allowed	these	
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residues	to	protonate/deprotonate	over	the	course	of	the	simulations	(Fig.	5-3).	Residues	were	selected	based	on	their	relative	proximity	to	the	active	site,	and	predicted	pKa	values	from	the	H++	server.	 In	order	to	determine	 important	regions	 in	 the	active	site,	CoA	was	placed	in	the	active	site	of	RpBAS,	using	the	CoA-bound	cocrystal	structure	of	MsCHS	(PDB	ID:	1BQ6).	A	total	of	22	residues	were	within	8.00	Å	of	the	monoketide	intermediate	and	CoA	(Table	S5-1).	Of	the	22	residues,	10	were	selected	that	had	predicted	pKas	between	5	and	11,	which	 per	 the	 H++	 server	 was	 classified	 as	 titratable.	 These	 10	 residues	 included	 five	histidines	(H57,	H147,	H243,	H252,	and	H289),	three	lysines	(K41,	K43,	K255),	one	tyrosine	(Y254),	 and	one	 cysteine	 (C183).	No	 aspartic	or	 glutamic	 acid	 residues	were	 selected	 as	protonation	 of	 these	 residues	 occurs	 at	 a	 much	 lower	 pH	 range.	 Analysis	 shows	 the	simulations	 were	 relatively	 stable,	 though	 the	 pH	 10	 simulation	 had	 an	 issue	 with	 the	diketide	bound	intermediate	that	disrupted	the	lid	region	of	the	receptor.		RMSF	calculations	were	performed	for	the	final	50	ns	of	each	constant	pH	simulation,	and	 the	 more	 acidic	 pH	 simulations	 had	 greater	 fluctuations	 compared	 to	 the	 basic	 pH	simulations	(Fig.	5-5).	Residues	240	to	270	represent	the	flexible	beta-hairpin	region	that	contains	His257	and	His266.		
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Figure	 5-3.	 Ten	 residues	 were	 selected	 as	 titratable	 residues	 during	 the	 constant	 pH	molecular	dynamics	simulations	and	include:	K55,	K57,	H71,	H161,	C197,	H257,	H266,	Y268,	K269,	H303.	All	residues	are	within	7.5	Å	of	the	monoketide	bound	intermediate	(C164)	and	Coenzyme	A.			 	
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Figure	5-4.	RMSD	 fluctuations	over	500	ns	of	 constant	pH	simulations,	showing	 that	 the	results	were	relatively	stable,	with	all	simulations	(except	pH	10)	maintaining	RMSD	values	below	3.5.				
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Figure	 5-5.	 RMSF	 calculations	 were	 performed	 on	 the	 final	 50	 ns	 of	 each	 constant	 pH	simulation.			 	
5.3.3	pKa	calculations	The	 protonation	 states	 of	 sidechains	 are	 influenced	 primarily	 by	 electrostatic	contributions	of	 protein-solvent	 and	 intra-protein	 interactions.15	Using	 the	 results	 of	 the	constant	pH	simulations,	we	obtained	the	ratio	between	protonated	and	deprotonated	states	in	the	constant	pH	simulations	(Fig.	5-6).	The	second	active	site	cysteine,	Cys197,	which	had	previously	been	predicted	to	be	catalytic,	showed	a	pKa	shifted	upfield,	further	falsifying	the	Noel	 hypothesis	 about	 the	 its	 catalytic	 role	 in	 the	 deprotonated	 form.	 Further,	 careful	attention	was	given	to	Cys197,	because	another	plausible	model	for	diketide	and	triketide	selection	 at	 different	 pHs	 could	 be	 the	 deprotonation	 of	 the	 phenol	 group	 of	 the	 bound	
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intermediate	 (Fig.	 S5-1),	 which	 may	 be	 facilitated	 by	 Cys197,	 although	 this	 is	 doubtful,	because	 our	 calculations	 shows	 that	 Cys197	 stays	 protonated	 between	 pH	 6-8	 of	 the	simulations.		Significantly,	the	expected	pKa	values	of	two	solvent-exposed	residues,	His257	and	His266,	were	shifted	upfield	with	pKas	calculated	at	6.81,	and	7.29,	respectively.	At	pH	6,	His257	is	70	%	deprotonated,	and	at	pH	9	it	is	almost	100%	in	the	neutral	protonated	form.	Similarly,	at	pH	6,	His266	is	90	%	deprotonated	and	charged,	and	at	pH	9	it	is	almost	100	%	in	 the	 neutral	 protonated	 form.	 Thus	 the	 pH	 dependence	 of	 RpBAS	 may	 reflect	 the	protonation	states	of	His257	and	His266.	
	
Figure	5-6.	pKa	calculations	of	titratable	sidechains	from	constant	pH	MD	simulations.		
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The	 above	 result	 is	 in	 stark	 contrast	 to	 the	 catalytic	 residue,	 His303,	 which	 is	downshifted	to	a	pKa	value	of	4.85	in	the	active	site	as	a	result	of	its	interaction	with	Cys157.	H++	server	predicted	that	the	pKa	of	His303	was	below	1.5.	Therefore,	the	pH	dependence	of	RpBAS	is	unlikely	linked	to	the	active	site	His303.	In	the	original	crystal	structure	of	RpBAS,	His266	is	bound	in	two	different	binding	motifs	in	monomers	A	and	B	(Fig.	5-7)	(PDB	ID:	5AQR).16	Phe265	is	known	as	the	gatekeeper	residue	 that	 is	 important	 for	 guiding	 the	 growing	 intermediate	 chain	 (hence	 selecting	diketide	versus	triketide	production).	These	structural	observations,	coupled	with	the	above	pKa	 calculations,	 suggest	 that	 His266	 is	 responsible	 for	 orienting	 Phe265	 during	 chain	elongation,	and	this	structural	effect	between	His266	and	Phe265	may	be	accomplished	by	hydrophilic	interactions	with	His257.	This	explains	how	a	change	in	the	protonation	states	of	His257	and	His266	may	disrupt	this	delicate	balance	of	electrostatics.		
	
Figure	5-7.	A	comparison	of	active	sites	in	RpBAS	between	chain	A	(magenta)	and	chain	B	(green)	from	the	previously	solved	crystal	structure.	Cys157	is	loaded	with	the	monoketide	intermediate,	and	Phe265	stabilizes	the	phenol	moiety	during	chain	elongation.			
5.3.8	Structural	Bioinformatics	To	further	investigate	the	role	of	His257	and	His266	as	possible	pH	sensors	in	RpBAS,	bioinformatics	analysis	was	performed.	His	257	and	His	266	are	highly	conserved	in	RpBAS	
Phe265
Phe265
Phe265
His	266 6.6	Å
His	257His	257His	266 4.1	Å His	266
His	257
Cys157 Cys157 Cys157
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and	three	other	chalcone	synthases	(FhCHS1,	OsCHS,	and	MsCHS2)	(Fig.	5-8).	In	comparison,	His257	 is	 replaced	by	 leucine	 in	AhSTS	and	 lysine	 in	PsSTS,	while	His266	 is	 replaced	by	tyrosine	in	AhSTS	and	glutamine	in	GhPYS	and	PsSTS.	It	is	known	that	pH	also	has	an	effect	on	the	product	outcome	of	chalcone	synthases;	 therefore,	similar	 to	 the	above	analysis	of	RpBAS,	the	surface-exposed	histidines	of	chalcone	synthases	(aligned	to	His257	and	His266)	may	play	a	similar	role	in	regulating	the	conformation	of	active	site	Phe265,	which	has	been	shown	to	be	important	for	guiding	the	growing	substrate	in	the	active	site	cavity.	The	above	analysis	 explains	 how	 pH,	 or	 protonation	 states	 of	 surface	 His,	 may	 affect	 the	 product	outcome	of	type	III	PKS.	To	the	best	of	our	knowledge,	such	an	observation	has	never	been	noted	before.	
	
Figure	5-8.	A	multiple	sequence	alignment	between	RpBAS	(PDB	ID:	3A5Q)	and	homologs:	FhCHS1,	OsCHS,	MsCHS2,	AhSTS,	GhPYS,	ErAQS,	 and	PsSTS	 (PDB	 IDs:	4WUM,	4YJY,	1BI5,	1Z1E,	 1QLV,	 5WX4,	 1XES,	 respectively).	 H257	 and	 H266	 (red	 triangles)	 are	 relatively	conserved	 among	 homologs,	 and	 were	 set	 as	 titratable	 residues	 in	 the	 constant	 pH	simulations.	.	F265	is	known	to	be	important	for	stabilizing	the	growing	intermediate	(purple	star).	Y268	and	K269	(blue	arrows)	are	also	shown	and	were	set	as	titratable	residues	in	the	constant	pH	molecular	dynamics	simulations.	H303	(green	diamond)	is	known	to	function	as	one	of	the	three	catalytic	residues	of	the	catalytic	triad.			
5.3.9	Experimental	investigations		 In	order	to	investigate	the	effect	of	protonation	on	His257	and	His266,	mutagenesis	studies	were	performed.	Several	variants	were	generated,	as	well	as	the	knockout	mutations	of	active	site	Cys197	as	the	negative	control.	Assays	were	performed	at	pH	6,	7,	8	and	9.	The	product	 formation	 was	 measured	 as	 total	 ion	 count	 in	 the	 LC-MS	 elution	 spectra,	 with	products	reported	as	ratios	between	the	diketide	versus	triketide	products.	 Interestingly,	
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H257A	had	shown	nearly	no	production	of	diketide	p-hydroxybenzalacetone,	while	it	was	able	to	biosynthesize	the	triketide	bis-noryangonin	at	all	pH	values	tested.	The	variants	only	have	 a	 small	 decrease	 in	 enzyme	 turnover	 as	 compared	 to	 the	 wildtype.	 These	 results	support	 our	 hypothesis,	 that	 His257	 is	 important	 for	 orienting	 Phe265	 in	 the	 beta-loop	region	near	the	active	site,	such	that	the	alanine	mutation	of	His257	completely	switched	the	product	outcome	of	RpBAS.	To	the	best	of	our	knowledge,	this	is	the	first	mutation	of	type	III	PKS	that	shows	such	a	drastic	switch	of	pH	dependence	for	its	product	outcome.	The	above	result	supports	that	RpBAS	has	the	ability	to	sense	its	external	pH	environment,	and	thereby	allosterically	modulate	its	substrate	pocket	size	so	that	it	can	control	the	product	outcome	at	different	pHs.			
5.4	Materials	and	methods	
5.4.1	Protein	expression	and	purification	The	pET28B(+)	vector	encoding	the	wild	type,	full-length	RpBAS	with	an	N-terminal	His6x-tag	(Genewiz)	and	variants	were	expressed	in	Top10	Competent	Cells	(ThermoFisher).	After	 confirmation	 of	 DNA	 sequences,	 the	 expression	 plasmids	 were	 transformed	 and	expressed	in	BL21	(DE3)	E.	coli	cells	(Novagen).	Cells	transformed	with	the	RpBAS	plasmid	were	grown	to	OD600	=	0.8	at	310	K	in	LB	media	containing	50	µg/mL	kanamycin.	The	cell	cultures	were	cooled	to	291	K	and	protein	expression	was	induced	using	100.0	 M	of	IPTG.	The	 cell	 cultures	were	 incubated	 for	 an	 additional	 16	 hours	 at	 291	K	 and	 harvested	 by	centrifugation	at	5,000g	for	30	minutes.	The	cell	pellets	were	resuspended	in	50	mM	tris-HCl	pH	8.0,	5	%(v/v)	glycerol,	7	mM	imidazole,	and	200	mM	NaCl.	Resuspended	cells	were	flash	frozen	in	liquid	nitrogen	and	stored	at	-80	°C	for	24	hours.	Resuspended	cells	were	thawed	
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on	ice	for	30	min	and	the	cells	were	disrupted	using	sonication.	The	cell	debris	was	cleared	by	centrifugation	at	14,100g	for	1	hour.	The	supernatant	was	collected,	and	batch	bound	to	HisPurTM	Cobalt	Resin	(Thermo	Scientific)	for	30	minutes	at	4°C.	His-tag	was	cleaved	using	1	unit	thrombin	/	2	mg	RpBAS	protein	over	4	hours	at	16	C.	Successful	cleavage	measured	by	LC-MS	at	1,	2	and	4	hour	timepoints	to	ensure	complete	clevage.	Pre-histag	cleavage	mass	was	44,390.00	Da,	and	post-histag	cleavage	mass	was	42,640.00,	with	no	presence	of	his-tagged	 protein	 in	 mixture.	 	 	 of	 RpBAS	 was	 purified	 according	 to	 the	 manufacturer’s	instructions	 using	 an	 imidazole	 step-gradient.	 Fractions	 containing	 pure	 protein	 were	determined	 by	 SDS-PAGE	 and	 fractions	 containing	 RpBAS	 were	 combined	 and	 dialyzed	against	50mM	tris-HCl	pH	8.0,	5%(v/v)	glycerol,	and	2	mM	dithiothreitol	at	4	°C	for	12	hours.		Further	 purification	 of	 RpBAS	was	 conducted	 by	 anion	 exchange	 chromatography	 using	HiTrap	Q	FF	(GE	Healthcare)	according	to	the	manufacturer’s	instructions.	Purified	RpBAS	was	dialyzed	against	20	mM	HEPES-NaOH	pH	8.0,	100	mM	NaCL,	and	2	mM	dithiothreitol.	The	protein	solution	was	concentrated	to	20	mg/mL	and	filtered	by	0.22	µM	Ultrafree-MC	filter	(Millipore).		
5.4.2	Site-directed	mutagenesis	The	online	program	NEBaseChanger	(https://nebasechanger.neb.com/)	was	used	to	design	primers	for	all	the	RpBAS	variants	using	the	previously	described	cloned	pET28B(+)	w.t.	RpBAS	DNA	template.	The	following	primers	were	used	for	mutagenesis.	All	mutations	were	confirmed	though	automated	DNA	sequencing	(Genewiz/Retrogen).	Primer	Description												 Primer	Sequence	H71	(general	reverse)		 5’-	TTCTCAATACGGCTGTTC	
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H71A	(forward)		 									 5’-	GCGCTATTTAgccGTGACCGAGGAAATTC	H71F	(forward)		 									 5’-	GCGCTATTTAttcGTGACCGAGGAAATTC	H71I	(forward)		 									 5’-	GCGCTATTTAatcGTGACCGAGGAAATTC	H71K	(forward)		 									 5’-	GCGCTATTTAaagGTGACCGAGG	H71V	(forward)		 									 5’-	GCGCTATTTAgtcGTGACCGAGGAAATTC	H71W	(forward)		 									 5’-	GCGCTATTTAtggGTGACCGAGGAAATTC	H71Y	(forward)		 									 5’-	GCGCTATTTAtacGTGACCGAGG	H71Q	(special	reverse)	 5’-	TTCTCAATACGGCTGTTCTC	H71Q	(forward)	 	 5’-	GCGCTATTTAcaaGTGACCGAGG	C157	(reverse)	 	 5’-	TAGAACATGAAGCGCTTC	C157	(forward)	 	 5’-	TCATTTAGGTgctTATGCCGGCG	H161	(general	reverse)	 5’-	AAGCGCTTCACGCTCGGA	H161A	(forward)		 									 5’-	CATGTTCTATgccTTAGGTTGTTATGCCGGCGG	H161F	(forward)		 									 5’-	CATGTTCTATttcTTAGGTTGTTATGCCGGCGG	H161I	(forward)		 									 5’-	CATGTTCTATatcTTAGGTTGTTATGCCGGCGGTACAGTGC	H161K	(forward)		 									 5’-	CATGTTCTATaagTTAGGTTGTTATGCCGGC	H161Q	(forward)		 									 5’-	CATGTTCTATcagTTAGGTTGTTATGCCG	H161V	(forward)		 									 5’-	CATGTTCTATgtcTTAGGTTGTTATGCCGGCGG	H161W	(forward)		 									 5’-	CATGTTCTATtggTTAGGTTGTTATGCCGGCGG	H161Y	(forward)		 									 5’-	CATGTTCTATtacTTAGGTTGTTATGCCGG	H257	(general	reverse)	 5’-	GCGCCATGGCTTTCCGGA	H257A	(forward)		 									 5’-	CATTGAGGGTgccCTGTTAGAGAGCGGTTTAAGTTTTC	H257V	(forward)		 									 5’-	CATTGAGGGTgtcCTGTTAGAGAGCGGTTTAAGTTTTC	
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H257W	(forward)		 									 5’-	CATTGAGGGTtggCTGTTAGAGAGCGGTTTAAGTTTTC	H257Y	(forward)		 									 5’-	CATTGAGGGTtacCTGTTAGAGAGCGGTTTAAG	H266	(general	reverse)	 5’-	CCGCTCTCTAACAGATGAC	H266A	(forward)	 	 5’-	TTTAAGTTTTgcgTTATACAAGACCGTGCCGACAC					 "	H266V	(forward)		 									 5’-	TTTAAGTTTTgttTTATACAAGACCGTGCC	H266W	(forward)		 									 5’-	TTTAAGTTTTtggTTATACAAGACCGTGCCG	
	
5.4.3	Enzyme	Reaction	Reaction	mixtures	contained	27	µM	4-coumaroyl-CoA,	54	µM	malonyl-CoA,	20	µg	of	purified	enzyme	in	a	500	µL	volume	of	100	mM	potassium	phosphate	buffer,	and	1	mM	EDTA.	Reactions	were	performed	at	pHs	6.0,	7.0,	8.0	and	9.0.	Reaction	mixtures	were	incubated	for	30	minutes	and	at	30°C	and	were	quenched	by	 the	addition	of	50	µL	20%	HCl.	Reaction	products	were	extracted	with	600	µL	ethyl	acetate,	concentrated	via	Eppendorf	Vacufuge,	and	dissolved	in	200	µL	UPLC-MS	grade	acetonitrile.			
5.4.4	pH-dependent	Receptor	Modeling	Five	receptors	were	modeled,	including	apo	RpBAS,	and	RpBAS	bound	with	one	of	the	four	 intermediates	 (monoketide,	 diketide,	 triketide	 and	 tetraketide).	 The	 apo	 and	monoketide-bound	structures	were	obtained	from	the	crystal	structures	(PDB	code:	3A5Q	and	 3A5R).	 The	 diketide,	 triketide	 and	 tetraketide	 structures	 were	 modeled	 using	 the	monoketide	 crystal	 structure	 and	 docking	 the	 substrates	 in	 the	 active	 site.	 To	minimize	initial	 steric	 clashes,	 the	 diketide,	 triketide	 and	 tetraketide	 intermediates	were	 assigned	AM1-BCC	 charges	 and	 minimized	 using	 Chimera.	 The	 bound	 intermediates	 were	 then	
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excised	 and	 capped	 with	 acetyl	 and	 N-methyl	 caps,	 followed	 by	 geometry	 optimization,	frequency	 calculations,	 single	 point	 energy	 calculations,	 and	 electrostatic	 potential	 (ESP)	calculations	using	B3LYP/6-31G(d,p)//B3LYP/6-31G(d,p)	by	Gaussian	09	Rev	E.	Using	the	ESP	derived	from	Gaussian,	restricted	ESP	(RESP)	charges	were	fit	using	the	R.E.D.	server.	Initial	protonation	states	of	titratable	residues	were	set	using	the	H++	server	at	pHs:	4,	5,	6,	7,	8,	9,	10,	and	11.	The	topology	and	coordinate	files	generated	by	H++	were	converted	to	pdb	using	ambpdb	from	the	AMBER	suite.			
5.4.5	Ligand	Parameterization	and	Modeling	Six	 ligands	were	manually	constructed	using	Chimera,	which	 include	4-coumaroyl-CoA,	malonyl-CoA,	benzalacetone	 (BA),	bis-noryangonin	 (BNY),	4-coumaroyltriacetic	 acid	lactone	(CTAL),	and	naringenin	chalcone	(NAR).	Using	these	 initial	structures,	we	applied	Gaussian	 09	 Rev	 E	 B3LYP/6-31G(d,p)//B3LYP/6-31G(d,p)	 to	 calculate	 geometry	optimization,	 frequency	 calculations,	 single	 point	 energy	 calculations,	 and	 electrostatic	potential	(ESP).	Because	no	RpBAS	crystal	structure	in	the	PDB	contained	malonyl-CoA,	the	ligand	 was	 extracted	 from	 the	 malonyl-CoA	 bound	 MsCHS	 structure	 (PDB	 ID:	 1CML).	Coumaroyl-CoA	was	manually	modeled	using	the	CoA	moiety	from	malonyl-CoA,	because	no	type	III	PKSs	in	the	PDB	contain	coumaroyl-CoA.			
5.4.6	Constant	pH	Molecular	Dynamics	Simulations	Molecular	 dynamic	 simulations	 were	 carried	 out	 using	 Amber	 14.17	 The	 Amber	ff14SB	 force	 field	 with	 the	 constant	 pH	 library	 and	 constant	 pH	modifications	 file	were	used.18	K41,	K43,	H57,		H147	C183,	H243,	H252,	K255,	Y254,	and	H289	were	selected	to	be	
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titratable	residues,	and	were	allowed	to	change	protonation	states	during	constant	pH	MD	(cpHMD)	simulations.	LEaP	was	used	to	add	hydrogens	and	neutralize	the	system	by	adding	Na+	and	Cl-	ions	dependent	on	pH.	Systems	were	solvated	in	a	12	Å	water	buffer	TIP3P	box.		Energy	minimizations	using	SANDER	were	performed	in	two	stages	to	remove	any	steric	clashes	present	in	the	initial	crystal	structure.		The	initial	stage	was	carried	out	over	2500	steps	for	the	solvent	and	ions,	with	the	protein	and	ligand	restrained	by	a	force	constant	of	500	kcal/mol/Å2,	followed	by	a	second	stage	carried	out	over	5000	steps	of	the	entire	system.		A	short	100	ps	simulation	with	weak	restraints	(force	constant	of	10	kcal/mol/Å2	on	the	protein	and	cofactor)	was	used	to	heat	up	the	system	to	300	K	using	a	Langevin	temperature	equilibration	 scheme.	Periodic	boundary	 conditions	were	used,	 along	with	a	non-bonded	interaction	cutoff	of	10	Å.		For	the	simulations,	hydrogen	atoms	were	constrained	using	the	SHAKE	algorithm,	allowing	 for	a	2	 fs	 time	step.	 Initial	 simulations	were	 run	over	500	ns	(250,000,000	time	steps)	to	equilibrate	the	systems	prior	to	constant	pH	simulations.	During	constant	 pH	 simulations,	 the	 salt	 concentration	 was	 set	 to	 100	 mM,	 with	 100	 steps	 of	relaxation	dynamics,	and	100	steps	of	in-between	attempted	protonation	state	changes.	The	evaluation	of	protonation	attempts	was	performed	with	the	generalized	Born	model	(igb	=	2	in	AMBER),	with	a	total	of	2,500,000	attempted	protonation	state	changes.	Constant	pH	simulations	were	run	over	500	ns	(250,000,000	time	steps).			
5.4.7	Structural	Bioinformatics	Using	 the	 FASTA	 sequence	 from	 Rheum	 palmatum	 BAS	 (UniProtKB	 accession	number:	Q94FV7),	RpBAS	was	subjected	to	a	BLAST	search	using	Geneious	with	the	blastp	algorithm,	with	a	BLOSUM62	matrix.19		
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5.4.8	LC-MS	The	HPLC	system	utilized	was	a	Waters	Acquity	H	UPLC	Class	(Waters	Corporation,	Milford,	MA,	USA).	The	analytical	column	was	a	1.7	µm	x	2.1	mm	x	50	mm	Water	Acquity	UPLC	 BEH	 C18	 column	 (Waters	 Corporation,	 Milford,	 MA,	 USA).	 The	 mobile	 phase	 was	water:acetonitrile	 (v/v)	with	 0.1	%	 formic	 acid,	 and	was	 delivered	 at	 a	 flow	 rate	 of	 500	μL/min	over	five	minutes.	A	single	quadrupole	Waters	QDA	Detector	(Waters	Corporation,	Milford,	MA,	USA)		was	used	in	positive	polarity	ESI	mode.	Masses	were	detected	on	the	100-600	m/z	range.	Benzalacetone	had	a	retention	 factor	of	1.47	min,	with	the	m/z	of	parent	peak	of	163.0.	Nitrogen	was	used	as	a	source	gas	and	maintained	at	8885	psi.	Data	acquisition	and	processing	was	performed	using	Waters	MassLynx	4.0	(Waters	Corporation,	Milford,	MA,	USA).			
4.4.9	Synthesis	of	p-coumaroyl-CoA	p-coumaroyl-CoA	was	chemically	synthesized	as	previously	described	by	Stöckigt	et	
al.20	The	coumaroyl-ester	intermediate	was	verified	by	1H	NMR	and	mass	spec	(m/z:	284.2	(parent	peak,	M	+	Na+),	285.2,	279.4).	The	final	product,	p-coumaroyl-CoA	was	verified	by	1H	NMR	and	mass	spec	(m/z:	914.14	(parent	peak),	407.21,	476.69,	834.20,	768.0).			
4.5	Conclusions	
	 In	 this	 chapter,	 we	 analyzed	 the	 pH	 dependence	 of	 RpBAS	 using	 computational	biology	and	molecular	biology.	This	is	new	for	PKS,	but	we	had	found	precedents	for	enzymes	unrelated	with	natural	product	biosynthesis.	For	example,	the	β-amyloid	precursor	protease	(BACE1)	 has	 received	 much	 attention	 as	 a	 potential	 target	 against	 Alzheimer’s	 disease.	
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Butler	et	al.	developed	a	potent	BACE1	inhibitor,	which	unfortunately	had	equal	affinity	for	cathepsin	D	(CatD)	at	high	pH,	though	at	low	pH	it	preferred	to	bind	BACE1.21	In	order	to	investigate	 the	 effect	 of	 pH	 on	 inhibitor-BACE1	 binding	 affinity,	 Harris	 et	 al	 performed	constant	pH	simulations	similar	to	those	performed	in	this	chapter.22	They	also	identified	a	histidine	 residue,	 which	 is	 capable	 of	 allosterically	 modulating	 conformation	 changes	 in	BACE1.		They	combined	the	constant	pH	approach	with	free-energy	perturbation	(FEP)	to	predict	changes	in	binding	free	energy.	Binding	events	between	receptors	and	ligands	can	also	shift	pKas	upward	and	downward,	which	has	an	effect	on	binding	and	stabilization	at	certain	pH	values.	 In	BACE1,	His45	modulated	 the	 conformation	of	Phe105	 through	pi-pi	interactions	in	a	pH-dependent	manner.			 Another	study	was	performed	by	McDougal	et	al	using	1H	NMR	and	constant	pH	MD	simulations	 to	 determine	 pKa	 values	of	 histidine	 residues	 in	 α-Conotoxin	MII	peptides.23	NMR	titration	experiments	were	used	to	measure	the	pKa	values	experimentally,	and	were	in	consistent	agreement	with	calculated	pKa	values	from	constant	pH	calculations,	with	an	overall	median	absolute	deviation	(MAD)	of	0.3	Å.	We	learned	from	these	examples	about	the	insights	that	constant	pH	MD	simulations	can	offer	about	protein	dynamics	that	govern	the	observed	pKa	values	of	enzyme	residues.		In	this	Chapter,	we	found	that	His257	and	His266	of	RpBAS	regulate	the	stability	and	protein	dynamics	of	the	beta-hairpin	region.	The	protonation	states	of	His257	and	His266	help	orient	the	gatekeeper	residue,	Phe265,	which	in	term	affects	the	product	outcome	to	diketide	versus	triketide.	A	decrease	in	pH	increases	the	flexibility	in	this	region,	as	observed	from	 RMSF	 fluctuations,	 and	 thereby	 alters	 the	 product	 profile	 as	 observed	 in	 the	mutagenesis	 studies.	 In	 summary,	 this	work	paves	 the	 foundation	 for	 future	engineering	
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studies,	which	could	combine	the	pH	switching	mechanism	observed	 in	RpBAS	and	other	types	III	PKSs	with	their	ability	to	accept	un-natural	starter	units,	so	that	new	“unnatural”	natural	products	can	be	biosynthesized.		
	
4.7	Supplementary	Tables	and	Figures	
Table	S5-1.	Description	of	residue	function	from	previous	studies.		
	
	 	
Res	No. Res	Name Notes55 Lys Form	h-bonds	w/	phosphates	of	CoA58 Arg Form	h-bonds	w/	phosphates	of	CoA62 Asn Lys	in	MsCHS71 His Predicted	pKa	=	8.14131	-	140 Loop:	CLAGVDMPGA Flexibility	of	the	loop	structure	may	be	important	for	catalytic	activity
132 Leu
L132G,	L132A,	L132S,	L132C,	L132T,	L132F,	L132Y,	L132W,	L132P	mutants.	L132T	-	restored	chalcone-forming	activity	in	BAS.	L132A/S/C	produced	CTAL.	Homology	modeling	suggested	this	was	the	result	of	restoration	of	the	'coumaroyl	binding	pocket'	in	the	active-site	cavity.	Km	value	similar	to	double	mutant,	but	decrease	in	kcat.	this	suggests	no	change	in	binding,	but	in	catalysis.	Triple	mutant	(L132T/I214L/L215F)	showed	no	improvement	in	chalcone-forming	activity,	but	resulted	in	loss	of	activity.	L132T	active	site	is	large	enough	to	support	tetrakertide	as	was	tested	with	other	starter	units.133 Gly Ser	in	MsCHS137 Met cyclization	pocket.	4.0	Å	from	neighboring	chain	active	site	monoketide	intermediate161 His Predicted	pKa	=	6.43.164 Cys Conserved	in	all	CHS-like.	Defines	active	site.	(pKa	H++	:	10.8)197 Cys C197T,	C197G	-	no	change	in	product	pattern.	Known	Coumaroyl-CoA	binding	pocket.	Was	previously	suggested	to	be	a	possible	catalytic	residue.205 His on	outside,	but	highly	conserved	and	close	to	His257/His	266	(neighbors).	predicted	pKa	=	6.0214 Ile Critical	role	in	diketide	formation	reaction215 Leu Critical	role	in	diketide	formation	reaction
240-270 Beta	hairpin	VPESHGAIEGHLLESGLSFHLYKT MD	predicted	this	is	pretty	flexible.	No	trps	here,	but	one	proline	(P233)254 Ile cyclization	pocket	(conserved)
256 Gly cyclization	pocket	(conserved).	G256L	-	reduced	product	formation	by	half
257 His on	outside,	but	highly	conserved	and	close	to	His266.	predicted	pKa	=	6.81265 Phe cyclization	pocket	(conserved)266 His on	outside,	but	highly	conserved	and	close	to	His257.	predicted	pKa	=	7.29
303 His Catalytic	triad	in	CHS-like	enzymes.	His	303	most	likely	acts	as	a	general	base	during	the	generation	of	a	nucleophilic	thiolate	anion	from	Cys	164	(PTM).	Predicted	pKa	=	4.85.336 Asn Conserved	in	all	CHS-like.	Defines	active	site.	May	function	in	the	decarboxylation	reaction.338 Ser Critical	role	in	diketide	formation	reaction	(conserved).	S338V	-	increased	activity	2-fold.375 Pro cyclization	pocket	(conserved)
RpBAS
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Table	S5-2.	Table	for	residue	selection	
	
	
Figure	S5-1.	The	 second	active	 site	 cysteine	may	deprotonate	 the	diketide	 intermediate,	though	deprotonation	was	unobserved	during	constant	pH	simulations,	casting	doubt	on	this	alternative	model.				
Res No.
Distance	
from	
Cys157
H++
pKa
cpH
pKa
Expt.	
pKa Notes
* Cys 164 2.0	Å 10.8 * 5.5 The	pKa	of	the	catalytic	cysteine	in	BAS	must	shift	below	7.0	to	serve	as	an	effective	nucleophile.
1 Lys 269 2.0	Å 10.5 10.630 - K	in	seven	sequences:	RpBAS,	FHCHS1,	OsPKS,	MsCHS,	AsSTS,	CmQNS,	and	AsPCSGlu 192 3.0	Å 0.0 Conserved	in	all	10	sequences.	Present	in	Coumaroyl-CoA	binding	pocket.	Known	to	bind	Coumaroyl-CoAAsp 217 3.0	Å 0.0 Conserved	in	all	10	sequences
2 Cys 197 4.0	Å 9.7 >11.00 - C	in	RpBAS,	and	T	in	FhCHS1,	OsPKS,	MsCHS,	AsSTS,	CmQNS,	and	PsSTS.	Present	in	Coumaroyl-CoA	binding	pocket.	Known	to	bind	Coumaroyl-CoAAsp 207 4.0	Å 0.1 Conserved	in	first	9	sequencesGlu 255 4.0	Å 2.4 D	in	FhCHS1	and	MsCHS,	E	in	RpBAS	and	CmQNS.		6	different	residues	among	10	sequences
3 Tyr 268 4.0	Å 11.4 10.340 - T	in	RpBAS,	L	in	RhCHS1,	OsPKS,	and	MsCHS.	This	residue	does	not	appear	very	conserved.	7	different	residues.
4 Lys 55 5.0	Å 9.7 9.800 - Conserved	in	all	10	sequencesTyr 165 5.0	Å 12.0 F	in	FhCHS1,	OsPKS,	MsCHS,	AsSTS,	PsSTS,	OsCUS.	Y	in	RpBAS,	CmQNS,	AsPCS
5 His 257 5.0	Å 6.4 6.810 - Conserved	in	7	sequences.	L	in	AsSTS,	K	in	PsSTS,	and	R	in	OsCUS.	Interface	residue
6 His 266 5.0	Å 4.8 7.290 - H	in	RpBAS,	FhCHS1,	OsPKS,	MsCHS,	AsSTS,	and	CmQNS
7 His 303 6.0	Å 0.0 4.850 - Catalytic	Triad	Residue.	Conserved	in	all	10	sequencesAsp 311 6.0	Å 0.8 Conserved	in	all	10	sequencesCys 60 7.0	Å 12.0 Conserved	in	all	10	sequencesGlu 61 7.0	Å 3.5 E	in	RpBAS,	FhCHS1,	AsSTS,	CmQNS,	GhPYS,	PsSTS.	D	in	OsPKS	and	MsCHSTyr 69 7.0	Å 11.6 Y	in	8	sequences.	H	in	AsSTS	and	CmQNS
8 His 161 7.0	Å 3.0 6.430 - H	in	RpBAS	and	AsSTS.	Q	in	FhCHS1,	OsPKS,	MsCHS,	CmQNS,	GhPYS,	and	PsSTS.	AsSTS	and	PsSTS	appear	to	have	a	HQ	and	QH	flip	at	residues	154	&	155Cys 131 7.2	Å 12.0 C	in	RpBAS.	T	in	FhCHS1,	OsPKS,	MsCHS,	AsSTS,	CmQNS,	GhPYS
9 His 71 7.6	Å 5.0 8.140 - H	in	RpBAS	and	OsPKS.	Y	in	FhCHS1	and	MsCHS
10 Lys	 57 7.75	Å 10.3 10.110 - K	in	7	sequences	including	RpBAS.	Q	in	MsCHSTyr 334 7.9	Å 12.0 Conserved	in	all	10	sequencesHis 205 8.0	Å 6.0 Conserved	in	8	sequences	(D	in	AsSTS,	C	in	OsCUS)Cys 190 8.75	Å disulfide disulfideCys 130 8.8	Å disulfide disulfideLys 53 9.0	Å 12.0 Conserved	in	all	10	sequencesTyr 160 10.0	Å 12.0 Conserved	in	8	sequences.	F	in	PsSTS,	and	H	in	OsCUSGlu 380 10.7	Å 0.0 Conserved	in	first	9	sequencesTyr 86 10.8Å 12.0 Conserved	in	7	sequences	(F	in	GhPYS	and	PsSTS,	deleted	in	OsCUS)
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CHAPTER	6	
Conclusions	and	Future	Directions	
6.1	Conclusions		 Enzymes	in	the	acetate	and	non-ribosomal	peptide	pathways	biosynthesize	valuable	natural	products	in	an	assembly	line	fashion.	These	natural	products	are	difficult	to	access	through	 organic	 synthesis	 because	 of	 their	 chemical	 complexity,	 innate	 reactivity,	 and	multiple	stereocenters.	Current	and	future	engineering	efforts	have	focused	on	the	ability	to	add,	delete	or	switch	out	starter	and	extender	units	in	these	pathways	with	minimal	success.	Genomics	 and	 bioinformatics	 have	 provided	 us	 with	 tools	 that	 can	 predict	 the	 product	outcome	of	megasynthases,	though	we	are	still	 in	the	dark	about	the	driving	force	for	the	protein-protein	and	protein-substrate	interactions	in	these	systems.	Such	a	knowledge	gap	has	hampered	protein	engineering	efforts	of	megasynthases.1		In	order	to	address	this	gap	in	knowledge,	I	have	developed	a	molecular	mechanics	force	field	for	simulating	enzymes	in	the	 acetate	 and	 non-ribosomal	 peptide	 pathways	 in	 which	 their	 intermediate	 products,	often	highly	reactive,	are	chauffeured	between	the	catalytic	domains	via	carrier	proteins.	The	 force	 field,	when	 implemented	using	MD,	can	perform	simulations	of	megasynthases	with	atomic	details,	generate	models	of	transient	interactions	in	these	megasynthases,	and	provide	crucial	information	to	engineers.			 In	 Chapter	 2,	 the	 methodology	 and	 validation	 of	 the	 pantetheine	 force	 field	 was	described	in	detail.	Primary	force	fields	are	limited	to	modeling	standard	monomeric	units	in	macromolecules,	such	as	amino	acids,	nucleic	acids,	sugars,	as	well	as	small	molecules.2-3	Specialized	force	fields,	which	are	capable	of	modeling	special	cases,	are	available	for	NCAAs,	phosphorylated	 amino	 acids,	 and	 more	 common	 PTMs.4-8	 The	 force	 field	 that	 I	 have	
	 171	
developed	is	capable	of	modelling	FASs,	PKSs,	and	NRPSs	in	which	starter	units,	extender	units	and	intermediates	are	linked	to	a	phosphopantetheine	prosthetic	group.	Previously,	in	order	 to	 perform	 simulations	 on	 these	 megasynthases,	 intensive	 electronic	 structure	calculations	and	optimizing	parameters	are	needed.	This	new	force	field	therefore	provides	accessibility	to	performing	MD	simulations	of	megasynthases,	with	the	additional	benefit	of	providing	 end-users	 with	 reproducible	 parameters.	 The	 force	 field	 was	 compared	 to	experimental	structural	data	published	in	the	literature	and	showed	high	consistency	with	experimental	data.			 In	Chapter	3,	the	force	field	was	applied	to	the	NRPS	reductase	domain	(MxaR)	from	the	slime	bacteria	Stigmatella	aurantiaca.	MxaR	performs	a	four-electron	reduction	using	two	 NADPH	 molecules	 to	 generate	 a	 hybrid	 polyketide-nonribosomal	 peptide	 product.	Myxalamids	serve	as	 inhibitors	of	 the	electronic	 transport	chain,	with	the	potential	 to	be	used	as	an	anti-cancer	 therapeutic,	 or	as	a	biofuel	 additive.9	MD	based	models	 identified	residues	 important	 for	 protein-substrate	 interactions	 in	 the	 R	 domain.	 Biochemical	engineering	efforts,	which	were	based	on	the	MD	models,	resulted	in	the	design	of	a	mutant	reductase	domain	capable	of	reducing	the	non-native	substrate	decanoyl-PCP	to	1-decanol,	a	 potential	 biofuel	 replacement.	 Specifically,	 a	 R1339A	 mutant	 accelerated	 the	 product	turnover	 of	 decanoyl-PCP	 and	 decanal	 compared	 to	 the	 wildtype.	 This	 study	 combined	crystallography,	 biochemistry	 and	 molecular	 dynamics,	 and	 it	 not	 only	 aided	 our	understanding	of	a	4-electron	reductase	domain,	but	also	provided	a	framework	for	future	engineering	efforts.			 In	Chapter	4,	the	interactions	between	the	E.	coli	acyl	carrier	protein	(AcpP)	and	β-ketoacyl-ACP-synthase	I	(FabB)	were	investigated	using	X-ray	crystallography,	NMR	and	MD	
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simulations.	 The	 combination	 of	 structural	 biology	 and	 molecular	 dynamic	 simulation	showed	how	the	extension	of	fatty	acid	acyl	chains	is	accomplished	in	the	bacterial	FASs,	with	 a	 focus	 on	 the	 role	 of	 protein-protein	 interactions	 in	 the	 regulation	 of	 fatty	 acid	composition.	This	study	built	upon	a	previous	study	where	our	group	successfully	cross-linked	AcpP	with	β-hydroxyacyl-AcpP	dehydratase	(FabA),	allowing	the	first	comparison	of	protein-protein	interactions	in	type	II	fatty	acid	biosynthesis.	AcpP	helix	II	is	shown	to	be	important	in	anchoring	the	CP	when	interacting	with	FabA	and	FabB.	NMR	and	MD	studies	revealed	helix	III	interactions	with	FabB	which	may	function	in	product	turnover	and	AcpP	release.		 In	Chapter	5,	pH	modulated	product	generation	in	a	type	III	polyketide	synthase	(the	benzalacetone	synthase,	RpBAS)	was	investigated	using	in	silico	models	and	validated	via	mutagenesis	 and	 biological	 assays.	 At	 low	 pH,	 RpBAS	 generates	 the	 triketide	 bis-noryangonin	 (BNY).	 In	 comparison,	 at	 high	 pH,	 RpBAS	 generates	 the	 diketide	 p-hydroxybenzalacetone	(BA).	A	previous	study	by	Shimokawa	et	al	revealed	that	by	reducing	active	 site	 occupancy	 through	 mutagenesis,	 additional	 chain	 extensions	 and	 additional	products	can	be	biosynthesized.10	Therefore,	initially,	it	was	assumed	that	differences	in	pH	probably	alter	 the	volume	of	 the	active	site,	hence	selecting	the	diketide	versus	triketide	product.	 Interestingly,	MD	 simulations	 performed	 at	 low	 and	 high	 pH	did	 not	 show	 any	drastic	conformational	changes	or	change	in	active	site	cavity	size.	Rather,	MD	simulations	shows	 that	 a	 surface-exposed	 histidine	 residue	 may	 function	 as	 a	 pH	 sensor,	 which	 is	capable	of	restraining	an	active	site	phenylalanine	that	stabilizes	the	growing	substrate	via	pi-pi	interactions	within	the	active	site.		
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6.2	Future	directions	
6.2.1	Force	field	optimization	and	improvements		 In	 Chapter	 2,	 the	 development	 of	 an	 initial	 phosphopantetheine	 force	 field	parameters	was	described	 in	detail.	 It	 is	 common	 in	 force	 field	development	 to	 improve	force	field	parameters	after	it	is	utilized	in	several	studies	through	parametrization.	Below	is	 an	example.	The	 initial	LIPID11	 framework	parameter	 set	was	primarily	based	on	the	General	Amber	Force	Field	(GAFF),	with	additional	parameters	adopted	from	the	Glycam	force	 field.3	 Here,	 the	 authors	 purposely	 changed	 the	 names	 of	 the	 atom	 types,	 so	 that	revisions	in	the	future	could	be	accomplished.	Dickson	et	al	would	later	optimize	the	original	LIPID11	 force	 field	 by	 updating	 the	 torsion	 parameters	 in	 the	 hydrocarbon	 tails	 using	electronic	structure	calculated	at	a	higher	level	with	the	cc-pVQZ	basis	set.2	Furthermore,	additional	 fitting	 to	 physical	 observables	 was	 performed	 by	 fitting	 the	 force	 field	 to	reproduce	the	heat	of	vaporization	for	methyl	acetate,	which	it	performed	poorly	with	the	previous	LIPID11	and	GAFF	parameters.	This	optimized	force	field	was	released	as	LIPID14.			 A	 major	 future	 improvement	 of	 my	 phosphopantetheine	 force	 field	 would	 be	 to	generate	an	all-inclusive	force	field,	where	extender	units,	starter	units	and	intermediates	could	be	generated	with	an	as-needed	basis.	NORINE,	a	database	of	non-ribosomal	peptide	extender	 units	 and	 non-ribosomal	 peptides	 is	 available	 online,	 which	 contains	 534	monomer	 units	 and	 1187	 peptides.	 In	 order	 to	 increase	 coverage,	 it	 is	 impractical	 to	generate	 force	 field	 parameters	 for	 every	n-mer,	 because	 this	would	 be	 computationally	infeasible.	However,	we	could	generate	the	force	field	of	molecules	on	demand	with	minimal	input	and	control	by	the	end-user.	This	could	be	accomplished	through	a	pipeline	encoded	in	a	software	package,	or	a	user-friendly	web	server.	However,	a	foreseeable	issue	with	such	
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an	approach	would	be	the	need	to	deal	with	unknown	parameters,	including	torsion	angles,	this	future	direction	is	still	worth	pursuing	if	we	wish	to	further	expand	the	user	coverage	for	the	phosphopantetheine	force	field.		
	
6.2.2	Domain	docking	engineering	through	free	energy	binding	studies		 A	major	engineering	goal	in	these	systems	is	 to	 control	 the	 incorporation	 of	 “unnatural”	building	 blocks	 through	 insertion,	 deletion	 or	swapping	of	the	modules.	This	is	regulated	in	the	assembly	line	through	docking	domains	between	modules.	 Vigorous	 efforts	 had	 been	 invested	towards	 this	 goal,	 but	 they	 had	 failed	 or	generated	the	desired	product	in	low	yield.	This	is	 most	 likely	 the	 result	 of	 our	 lack	 of	understanding	of	protein	dynamics	and	protein-protein	 interactions	 in	 these	 systems.	 In	addition,	more	structures	of	the	docking	domains	are	needed.	It	would	be	incredibly	useful	if	 computational	 techniques	 could	 identify	 and	 predict	 binding	 patterns	 in	 the	 docking	domains,	which	would	allow	docking	domains	to	be	swapped,	or	be	altered	to	adjust	their	binding	preference.	A	protocol	to	identify	sequence	motifs,	known	as	the	fingerprints,	was	described	by	Keatinge-Clay	and	used	to	define	the	regions	of	the	ketoreductase	domain	that	control	 the	 stereochemistry	 of	 the	 reduction	 product.11	Wood	 et	 al	 had	 recently	 used	 a	similar	 protocol	 on	 acyl	 carrier	 proteins	 (Figure	 6-1).	 He	 identified	 contact	 patterns	 in	
Figure	6-1.	Helix	II	and	helix	III	of	ACP	is	known	 to	 be	 important	 for	 binding	 and	interacting	 with	 its	 partner	 domains	once	loaded.	(PDB	ID:	1T8K)		
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different	families	of	acyl	carrier	proteins	through	sequence	and	cladogram-based	analysis	in	 the	 trans-AT	 systems.12	 Wood’s	 analysis	 on	 the	 co-evolution	 between	 ACP	 and	 its	downstream	 partner	 provides	 evidence	 that	 simply	 engineering	 a	 single	 domain	 is	 not	enough.	This	may	also	explain	why	previous	engineering	efforts	have	failed	in	these	systems,	and	that	a	coupled	approach	between	the	interacting	domains	needs	to	be	taken	into	account.	While	 sequence	 comparison	 studies	 have	 been	 done	 on	 the	 carrier	 proteins	 and	ketoreductase	 domains,	 none	 have	 been	 conducted	 on	 the	 docking	 domains,	 which	 is	probably	the	result	of	a	lack	of	structural	information	on	these	recently	discovered	domains.			 One	 way	 this	 could	 address	 the	 above	 knowledge	 gap	 is	 to	 perform	 isothermal	calorimetry	(ITC)	experiments	between	the	docking	domains	of	upstream	and	downstream	modules	 to	 generate	 a	 database	 of	 binding	 energies.	 Initial	 free	 energy	 calculations	performed	in	silico	on	the	same	systems	could	be	used	to	fit	the	existing	natural	products	force	 field	 to	better	 represent	 the	experimentally	derived	binding	 free	energies.	 Such	an	approach,	 if	setup	correctly	with	a	 test	set	and	validation	set,	could	provide	a	 force	 field	capable	of	binding	affinity	between	the	docking	domains	in	these	systems.		
	
6.2.3	Long-range	interactions	and	allostery	in	polyketide	synthases		 In	the	type	II	FAS,	it	appears	that	interdomain	communication	may	play	a	key	role	in	product	regulation.	In	Chapter	4,	when	FabB	is	bound	to	AcpP,	MD	simulations	showed	an	increase	in	movement	in	the	α6-α7	helix-turn-helix	(HTH)	motif	of	FabB,	which	is	in	close	proximity	to	interact	with	another	highly	flexible	helix	(α10)	of	the	same	monomer.	In	order	to	analyze	these	dynamic	regions	in	more	depth,	residue	interaction	network	(RIN)	analysis	could	be	performed	on	 these	systems.	RINs	 could	be	generated	 for	FabB	with	no	 carrier	
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protein,	or	with	one	carrier	protein	loaded	in	various	states.	Such	an	approach	could	be	used	to	 perturb	 FabB	 and	 cluster	 residues	 into	 communities.	 Furthermore,	 studies	 could	 be	performed	with	 carrier	proteins	present	on	both	FabB	monomers	 to	 further	probe	 long-range	interactions	of	FabB-AcpP	complex	so	that	we	can	better	understand	how	the	carrier	proteins	might	communicate	across	homodimers	of	FabB.		 In	addition	to	network	analysis	of	model	type	II	FAS	systems,	network	analysis	can	also	 be	 applied	 to	 long-range	 interactions	 that	 allosterically	 modulate	 active	 sites	 of	enzymes	in	the	acetate	and	non-ribosomal	peptide	pathways.	Specifically,	if	lids	are	present	in	enzymes	of	these	systems,	the	crystal	structures	are	often	obtained	in	the	open	or	closed	states.	 It	 is	known	that	 the	 lid	regions	can	control	preference	 for	substrate	selection	and	product	generation.	An	increased	knowledge	in	the	dynamics	of	these	hinge	movements,	or	other	conformational	changes,	would	provide	a	blueprint	for	protein	engineers	who	wish	to	modify	these	lid	regions.			
6.2.4	Molecular	dynamics	simulations	on	large	enzyme	complex	over	long	timescales		 The	past	five	years	have	seen	a	proliferation	of	megasynthase	structures,	including	the	 partner	 enzyme	 complexes	 described	 in	 Chapter	 4,	 FabA:AcpP	 and	 FabB:AcpP.	 Juan	Perilla	and	the	late	Klaus	Schulten	reported	an	MD	simulation	for	a	large	protein	complex	with	 64	million	 atoms	 over	 1	 µs	 to	 study	 the	 physical	 properties	 of	 the	 HIV-1	 capsid.13	Performing	molecular	 dynamics	 simulations	 on	 complexes	 of	 this	 size	 reveals	 emergent	properties	 that	cannot	be	observed	 in	simulations	on	a	smaller	scale.	Physical	properties	such	 as	 electrostatics,	 vibrational	 and	 acoustic	 properties,	 and	 solvent	 effects	 can	 be	elucidated	via	such	large-scale	simulations.	Principal	component	analysis	and	normal-mode	
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analysis	 can	 be	 used	 to	 analyze	 the	 collective	 motions	 of	 the	 viral	 capsid	 to	 study	 the	hydrodynamic	effects.	Similar	approaches	can	be	utilized	for	FAS,	PKS	and	NRPS.		 While	MD	simulations	have	been	performed	on	a	homology	model	of	hFAS,	none	have	been	performed	on	larger	systems	in	these	pathways.	The	computational	power	is	available	to	 perform	 all-atom	simulations	on	 system	 as	 large	 as	 the	 FAS	multi-enzyme	 complexes	found	in	fungi	and	bacteria	(Fig.	6-2).14	Anselmi	et	al	performed	a	simulation	on	fungal	FAS	using	 a	 coarse-grained	model,	 and	 showed	 that	 ACP	 shuttling	 is	 the	 result	 of	molecular	crowding	 effects.15	 All-atom	 simulations	 have	 the	 potential	 to	 explore	 long-standing	questions	in	the	field.	Specifically,	are	the	ACPs	coupled	and	able	to	see	each	other,	or	are	they	independent?	Because	FASs	from	bacteria	and	fungi	are	different	than	those	found	in	humans,	 they	are	vigorously-pursued	 targets	 for	drug	development.	Additional	details	of	protein	dynamics	 in	 these	systems	could	 lead	to	a	greater	understanding	of	 the	complex	interactions	in	these	megasynthases.		
 
Figure	6-2.	Crystal	structure	of	the	1.9	Mda	type	I	FAS	from	Mycobacterium	tuberculosis.14	The	structure	 is	similar	 to	 fungal	FAS	and	consists	of	 two	reaction	chambers	on	opposite	sides	of	an	internal	wheel.	(PDB	ID:	4V8W)		
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